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Abstract 
Glioblastoma (GBM) and Medulloblastoma (MB) are the most common brain 
tumours of adults and children respectively. These tumours are hypoxic as 
their oxygen levels are lower than the physiological 5-8% O2 found in the 
brain. Tumour hypoxia can promote tumour cell invasion, increase metastatic 
potential and leads to resistance to conventional cancer therapies. 
Chemotherapeutic agents and irradiation induce excessive DNA damage in 
order to overwhelm the DNA repair pathways and initiate apoptosis. This 
thesis aimed to examine the impact of hypoxia on DNA repair mechanisms in 
GBM and MB, which has not yet been reported. Hypoxic tumours are 
associated with poor patient outcome, in part due hypoxia-induced resistance 
to treatment. Work in this thesis showed that, in MB and GBM cells, chronic 
hypoxia was necessary to induced a resistance phenotype. Downregulation of 
critical components of the double strand break repair pathway was found to 
be responsible for treatment resistance in some, but not all hypoxic MB cells. 
Since hypoxia can directly influence transcription of DNA repair proteins, a 
NanoString assay was used to obtain a comprehensive assessment of DNA 
repair gene expression in multiple MB and GBM cell lines exposed to hypoxia. 
Moderate and severe hypoxic exposure had a variable impact on gene 
expression, with no clear-cut impact of different oxygen tensions. The level of 
transcripts of several DNA repair genes were downregulated across multiple 
GBM cell lines, especially LIGIV, which encodes DNA Ligase IV responsible for 
joining double strand breaks during DNA repair. A multiphoton laser 
microirradiation protocol was used to assess, in living cells, the functional 
impact of LIGIV downregulation. Reduced double strand break repair 
efficiency in hypoxia was observed, which may lead to genomic instability that 
drives tumour progression. Investigations into GBM and MB tumour cell 
biology, such as that described in this thesis, will aid in the development of 
new treatment methods, which are desperately needed.  
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1.1 Human cancers 
Cancer is a deadly disease where abnormal cells rapidly divide and invade 
healthy tissues. Cancer can arise in many areas of the body including the 
lungs, liver, stomach, brain, bones and skin, leading to organ malfunction and 
ultimately death. In 2015, 8.8 million people died from cancer globally making 
it the second leading cause of death. Cancer development is a multi-step 
process whereby pre-cancerous lesions undergo cellular changes resulting in 
the formation of a malignant tumour. Lifestyle choices such as poor diet, 
smoking and alcohol use, can significantly increase risk of developing cancer, 
yet genetic factors also play a role. Through advances in medical technology 
and scientific research, the survival rate for some cancers has improved in the 
last few decades. In the 1970s only four in ten women with breast cancer 
survived beyond ten years, yet this figure has increased to eight in ten due to 
enhancements of detection and improved treatment methods. The prevalence 
of cancer is increasing with an ageing population. Cancer in childhood is rare, 
and the survival rate is high compared to adults. However, detrimental side 
effects from treatment can arise (Murphy et al., 2013). For both adult and 
childhood cancer, the survival remains low, and further research is required to 
improve detection and treatment.   
Through a variety of mechanisms, the majority of cancers acquire a set of 
functional capabilities that enable the progression and development of cancer. 
These characteristics are known as the ‘Hallmarks of Cancer’, first described 
by Hanahan and Weinberg in 2000. Cancer cells can evade cell death 
(apoptosis), sustain blood vessel production (angiogenesis), generate growth 
signals, invade healthy tissue (metastasis) and have limitless ability to 
replicate (Hanahan and Weinberg, 2000). The identification of these classical 
properties of cancer has aided the development of targeted therapies and 
improved understanding of the disease as a whole (Figure 1.1). In 2011, the 
‘Hallmarks of Cancer’ was further updated to include evading the immune 
system, genetic instability and metabolism reprogramming (Hanahan and 
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Weinberg, 2011) (Figure 1.1). In part, these characteristics are mediated 
through interactions with the surrounding environment, known as the tumour 
microenvironment. The microenvironment can directly influence tumour 
progression and the response to treatment. Exploration of the implications of 
a low oxygen (hypoxic) tumour microenvironment on tumour cell biology will 
be a feature of this thesis.  
 
Figure 1.1: The Hallmarks of Cancer. General characteristics of cancer that 
contribute to tumorigenesis and cancer progression. Highlighted hallmarks 
are to be discussed in this thesis. Adapted from Hanahan and Weinberg, 
2011. 
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1.2 Brain tumours 
The primary site of tumour formation can directly influence patient outcome. 
Brain tumours, in particular, are linked to poor patient survival. Unlike other 
cancers such as breast cancer, the outcome of brain tumour has improved very 
little in the last few decades. Surgery is limited, as removing substantial 
proportions of healthy tissue can negatively affect patient health. Additionally, 
the blood-brain barrier restricts the diffusion of chemotherapeutic agents, 
limiting possible treatment options. These factors directly contribute to the 
poor outcome of brain tumour patients. Brain tumours are classified into 
benign low grade (grade I and II) or malignant high grade (grade III and grade 
IV), and are named based on the cell or region of origin (Louis et al., 2007, 
2016). High-grade tumours pose a significant threat to life. Further 
understanding of the cell biology of these tumours is required to improve the 
treatment and management of this complex disease.  
1.3 Adult glioblastoma 
Adult glioblastoma multiforme (GBM) is the most common malignant brain 
tumour, which arises in the cerebellum. 2,200 new cases are diagnosed in the 
United Kingdom each year. GBM is primarily found in older patients over 60 
with a median diagnosis age of 64 (Dolecek et al., 2012). Survival rates are 
poor with mean survival for England in 2007-2011 being 6.1 months and a five-
year survival rate of 3.4% (Brodbelt et al., 2015). Clinical presentation includes 
headaches, confusion, memory loss, seizures and changes in personality. Due 
to the unspecific nature of these symptoms, diagnosis of GBM is usually 
delayed resulting in detection when a tumour is well established. This, as well 
as the highly infiltrative and resistant nature of GBM, is responsible for the 
tragically low survival rates.  
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1.3.1 Pathology 
The WHO classification of central nervous system (CNS) tumours 
differentiates gliomas into four histology-based grades, segregated by the 
degree of aggressiveness, anaplasia and un-differentiation (Louis et al., 2007, 
2016). GBM is defined as a Grade IV astrocytoma (Figure 1.2) and accounts for 
82% of malignant gliomas (Dolecek et al., 2012). Vascularisation and level of 
necrosis differentiate grade IV (GBM) from grade III astrocytoma. Although 
GBM is primarily diagnosed using histology, recent advances in sequencing 
technologies have enabled the identification of molecular signatures of GBM.  
 
Figure 1.2: Classification of Gliomas. Gliomas fall into three subgroups. 
These are further categorised into grades based on aggressiveness, 
anaplasia, un-differentiation and vascularisation. G1 - G4 = WHO Grade I – 
Grade IV.  
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The Cancer Genome Atlas Consortium (TCGA) performed transcriptome 
profiling on over 600 GBM tumours, resulting in the identification of genetic 
mutations in TP53, EGFR, IDH1 and PTEN (for brevity abbreviations will be 
used for genes and proteins, for full names see appendix 1.1), as well as 
abnormalities in the p53, RB and receptor tyrosine kinase pathways 
(McLendon et al., 2008; Noushmehr et al., 2010; Verhaak et al., 2010; Brennan 
et al., 2013; Ceccarelli et al., 2016). This work enabled the molecular 
classification of GBM into four subtypes; Classical, mesenchymal, neural and 
proneural (Phillips et al., 2006; Verhaak et al., 2010). However, recent work by 
Wang et al. 2017 using single-cell transcriptomic analysis, suggest that only 
three subtypes exist as the neural subtype is likely due to contamination with 
other non-GBM neural tissue (Wang et al., 2017). Proneural GBM has the best 
outcome, whereas mesenchymal results in a low rate of survival (Phillips et al., 
2006). The classical characteristics of the three main GBM subtypes are 
detailed in Table 1.1. Primary and secondary GBM can frequently be 
distinguished by the Isocitrate dehydrogenase (IDH) status, with mutated IDH 
genes primarily found in secondary tumours (Ohgaki and Kleihues, 2013). 
Although histology is still the primary tool for GBM diagnosis, identification of 
GBM molecular signatures will enable a further understanding of tumour cell 
biology, which may lead to a personalised medical approach with targeted 
therapies.  
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Table 1.1: The common molecular characteristics of GBM subtypes. 
Information obtained from Veraak et al., 2010 
Subtype Characteristics 
Classical 
 EGFR amplification and 
increased expression 
 Chromosome 7 amplification 
 Chromosome 10 loss 
 No TP53 mutations  
Mesenchymal 
 Loss of NF1 gene or low 
expression 
 Expression of mesenchymal 
makers 
Proneural 
 Alterations of PDGFRA gene 
 Mutations in IDH1 
 TP53 mutations and loss of 
heterozygosity  
 
1.3.2 Cellular origin of GBM 
The specific cell of origin for GBM is unknown, yet the development of GBM 
mouse models has aided the identification of potential GBM-initiating cell 
types. Within an adult brain, two neurogenic regions (areas where 
neurogenesis occurs) are present, the subventricular zone (SVZ) and the 
subgranular zone (SGZ). Within the SVZ and SGV, neural stem cells (NSC) 
reside. NSC can self-renew and give rise to progenitor cells (Eriksson et al., 
1998; Sanai et al., 2005). Specifically, the SVZ contains glial progenitors, which 
have limited self-renewal capabilities and commit to specific cell types. Adult 
NSC, as well as progenitor cells, express nestin (Lendahl et al., 1990; 
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Zimmerman et al., 1994). Injection of Cre-recombinase adenovirus, under the 
control of the nestin promoter, into the SVZ of mice with conditional tumour 
suppressor alleles, Nf1, Trp53, Pten, enabled the specific targeting of NSC, 
resulting in the formation of high-grade astrocytoma (Llaguno et al., 2010). 
Additionally, using a similar Cre-recombinase system targeting adult lineage-
restricted progenitor cells, mice formed both grade III and grade IV 
astrocytomas (Alcantara Llaguno et al., 2015). Whether fully differentiated 
CNS cells are involved in GBM formation is controversial and has not been 
fully explored. Taken together, mutations in both NSC and lineage-restricted 
progenitor cells can give rise to GBM; therefore, different origins could 
contribute to the heterogeneity of GBM.  
1.3.3 Treatment 
Current treatment methods of GBM show limited success. Standard protocols 
involve initial resection of the tumour mass followed by radiotherapy (RT) and 
chemotherapy. Surgical resection of GBM is challenging, due to the highly 
infiltrative nature of these tumours, making it difficult to define the exact 
tumour border. Therefore, RT and chemotherapy are essential. Typically, RT is 
given as 30 fractions with a 60 Gy dose (Omuro and DeAngelis, 2013). A 
randomised trial using an escalated irradiation dose found no significant 
improvement in survival with irradiation doses above 60 Gy (Chang et al., 
1983). The alkylating agent temozolomide (TMZ) is used as an adjuvant with 
RT. This combination results in an increase in mean survival rate compared to 
RT alone (Athanassiou et al., 2005). However, the effectiveness of TMZ is 
limited due to the requirement methylguanine methyltransferase (MGMT) 
gene silencing in order to induce DNA damage leading to apoptosis (Brada et 
al., 1999; Glassner et al., 1999; Esteller et al., 2000; Hegi. et al., 2005). 
Investigations into alternative treatment protocols are underway to improve 
survival rates, particularly in non-silenced MGMT patients. For example, 
Olaparib, a PARP inhibitor used for ovarian cancer, is currently undergoing a 
phase I trial for GBM. Inhibiting the DNA damage response pathway by 
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reducing PARP activity may increase the sensitivity of GBM to ionising 
radiation and temozolomide (Cheng et al., 2005). Additionally, vaccine 
development is a potentially promising therapeutic option. These vaccines are 
composed of dendritic cells pulsed with tumour lysate or synthetic peptides, 
resulting in the initiation of an anti-tumour immune response (Zhang et al., 
2004). Initial results from a recent phase III trial found that the vaccine is safe 
and may extend survival, yet data from this study is only in the preliminary 
stages of analysis (Liau et al., 2018). Although attempts to improve GBM 
treatment have been made, survival over five years remains close to zero, 
highlighting the need for further understanding of the complex biology of 
these tumours.  
1.4 Paediatric medulloblastoma 
Medulloblastoma (MB) is a primitive neuroectodermal tumour (PNET) 
(Grade IV) that arises in the posterior fossa. It is the most common paediatric 
malignant tumour of the CNS accounting for 15-20% of neoplasms (Hargrave 
and Zacharoulis, 2007). The peak incidence for MB is 4-7 years with increased 
prevalence in males, yet MB has been identified in a small proportion of 
teenage individuals (Pizer and Clifford, 2008). In comparison to GBM, the 
prognosis of MB is better; however current treatment protocols can have a 
negative impact on the developing brain of a child.  
1.4.1 Pathology 
Previously, classification of MB was primarily based on histopathology. 
However, advances in sequencing technologies have enabled a molecular-
based approach (Louis et al., 2007). Recent classification defines MB into four 
subgroups: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Group 4.  
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1.4.1.1 WNT – 10% of MB 
The WNT subgroup of MB is based on activation of WNT signalling through 
genetic mutations in the Wingless signalling cascade. Commonly, mutations 
in the CTNNB1 gene are found which results in stabilisation of β-catenin, 
leading to aberrant activation of the WNT pathway (Yokota et al., 2002; 
Ellison et al., 2005; Northcott et al., 2017). Other mutated genes found in 
WNT MB include APC, DDX3X, SMARCA4, AXIN1 and CREBBP (Dahmen et 
al., 2001; Yokota et al., 2002; Jones et al., 2012; Pugh et al., 2012; Robinson et 
al., 2012; Northcott et al., 2017). Chromosomal aberrations such as loss of 
chromosome 6 has also been observed (Clifford et al., 2006). From a survival 
perspective, patients with WNT MB have the best prognosis, as these tumours 
respond well to chemotherapy (Cho et al., 2011; Northcott et al., 2011; Kool et 
al., 2012; Taylor et al., 2012). Diagnosis of WNT is often by detection of 
monosomy 6 or CTNNB1 mutations, yet these are not always present 
suggesting that some WNT tumours will be missed (Northcott et al., 2017). 
1.4.1.2 SSH – 30% of MB 
SHH tumours display aberrant activation of the Sonic Hedgehog pathway. 
This is commonly due to germline or somatic mutations in components of the 
SHH pathway, for example, PATCHED1 and SUFU (Robinson et al., 2012). 
Additionally, these tumours tend to have MYCN and GLI2 amplification (Jones 
et al., 2012; Pugh et al., 2012; Robinson et al., 2012). In a third of SHH 
tumours, TP53 mutations have been identified which are thought to be 
germline mutations resulting in a worse patient outcome (Zhukova et al., 
2013).  
1.4.1.3 Group 3 – 25% of MB 
Group 3 MB are undoubtedly the most aggressive MB tumours, as they are 
highly metastatic, with tumour dissemination normally observed at initial 
diagnosis (Kool et al., 2012). Unlike the other MB subtypes, Group 3 has the 
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fewest recurrent mutations (Jones et al., 2012; Northcott et al., 2012, 2017; 
Pugh et al., 2012; Robinson et al., 2012), however in 20% of Group 3 MB, MYC 
amplification is found in combination with PVT1 amplification (Kool et al., 
2012; Northcott et al., 2012, 2017). Additionally, TGF-β and NOTCH signalling 
pathways may be activated (Kool et al., 2012; Northcott et al., 2017). In 40% of 
patients, 17p loss and 17q gain has been identified (Kool et al., 2012; Shih et al., 
2014). Mutation in TP53 are rare in Group 3 MB (Zhukova et al., 2013).  
1.4.1.4 Group 4 – 35% of MB 
Group 4 is currently the least understood of the MB tumour subtypes in part 
due to the current lack of animal models. Group 3 and Group 4 MB present 
with a high level of molecular similarity, however recent work by Cavalli et al. 
determined they are molecularly distinct (Cavalli et al., 2017). Similar to 
Group 3, Group 4 MB has amplification of MYC, simultaneous loss of 17p and 
gain of 17q, and TP53 mutations are rare (Kool et al., 2012; Zhukova et al., 
2013; Northcott et al., 2017), Duplication of the SNCAIP gene has also been 
identified. At the time of diagnosis of Group 4 MB, metastatic dissemination is 
often observed (Kool et al., 2012), however, prognosis is moderately better 
than Group 3 MB.  
A detailed summary of age distribution, sex distribution, metastatic potential, 
recurrence and prognosis for each subgroup can be found in Table 1.2.  
1.4.1.5 Further Subtyping of MB 
Although the four subtypes are the MB classification accepted by the World 
Health Organisation (WHO), recent work suggests there may be up to 12 
subtypes: two WNT, four SHH, three Group 3 and three Group 4. Using 
genome-wide methylation and expression analysis of MB tumours, Cavalli et 
al. were able to identify cytogenetically and clinically distinct subsets of the 
four main MB subgroups (Cavalli et al., 2017). Whether these 12 subtypes will 
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be assimilated into the classification of MB, and will play a role in clinical 
management remains to be seen.  
Table 1.2 Comparison of characteristics of medulloblastoma. Infant = 0 – 3 
years. Child = 3 – 16 years. Information from Skowron et al., 2015; Taylor et 
al., 2012.  
 
WNT SHH Group 3 Group 4 
Gender 
distribution 
50% M 
50% F 
50% M 
50% F 
75% M 
25% F 
75% M 
25% F 
Age 
distribution 
100% Child 
50% Infant 
50% Child 
25% Infant 
75% Child 
10% Infant 
90% Child 
Rate of 
Metastasis 
Rare Low High High 
Recurrence None Local Metastatic Metastatic 
Prognosis Excellent Good Poor Good 
 
1.4.2 Cellular origin of MB  
Understanding the cellular origin of MB has been challenging due to the high 
level of tumour heterogeneity. Each subgroup of MB arises within different 
regions of the brain, therefore, are likely to arise from a different tumour 
initiating cells. Work by Gibson et al. determined that the WNT subtype 
originated from progenitor cells in the dorsal brainstem (Gibson et al., 2011), 
whereas SSH MB arises from granule neurone precursors cells in the cerebellar 
hemispheres (Schüller et al., 2008; Yang et al., 2008; Gibson et al., 2011; 
Perreault et al., 2014). The origins of Group 3 and Group 4 is less clear, yet 
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evidence suggests that Group 3 may arise from granule neuron precursors, 
ventricular zone stem cells or other progenitors (Kawauchi et al., 2012; Pei et 
al., 2012). Whereas, Group 4 MB may originate from deep nuclei precursors in 
the upper rhombic lip (Lin et al., 2016). Further exploration of the genetic 
drivers of the MB subgroups will allow for the development of MB mouse 
models that will give insight into MB origins.  
1.4.3 Treatment 
Similar to GBM, surgical resection followed by radiotherapy and 
chemotherapy is the general treatment protocol for MB. Total resection of the 
tumour may be possible if the tumour has not extensively invaded the 
brainstem or cerebellum (De Braganca and Packer, 2013). Removal of the 
whole tumour mass was initially viewed as ideal, however, damage to healthy 
tissue leads to cognitive defects and issues with motor function (Leland et al., 
1996). Recent work determined that there was no observed benefit to 
progression-free survival when comparing gross total resection and near-total 
resection for WNT, SHH and Group 3 MB. Therefore, total resection may not 
be required, and limited resection could reduce unwanted side effects of 
excessive resection (Thompson et al., 2016). 
Chemotherapy is used post-surgery, with cisplatin, cyclophosphamide and 
vincristine being favoured (Packer et al., 2006; Jakacki et al., 2012). 
Exploration of other useful chemotherapeutic agents is currently underway. 
For example, evidence suggests that TMZ in conjunction with radiotherapy is 
tolerable in paediatric MB patients (Nicholson et al., 2007; Malbari et al., 
2012), yet whether this improved survival requires further exploration. Post-
surgery RT is specifically directed at the entire craniospinal axis (whole brain 
and spinal column) due to the dissemination pattern of the tumour (Gold et 
al., 1999). There is no significant difference in the toxicity of irradiation when 
using hyper-fractionated (several daily doses) over standard RT (single daily 
dose) (Câmara-Costa et al., 2015). Alternative RT techniques are under 
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investigation for MB treatment to reduce the off-target effects and toxicity of 
standard protocols. Proton beam therapy, has been shown to have a similar 
positive outcome as standard RT, with acceptable levels of toxicity (Yock et al., 
2016). Also, intensity modulated radiotherapy (IMRT) reduces unwanted 
ototoxicity (toxicity to the ear) compared to standard RT (Huang et al., 2002; 
Bao et al., 2009; Polkinghorn et al., 2011). The use of RT in infants is 
unfavourable due to the developmental defects likely to occur. Therefore, in 
young patients (< 3 years old), chemotherapy alone is preferable post-
resection, with radiotherapy introduced when the child is at least three years 
old (Rutkowski et al., 2008). Molecular classification has enabled a more 
personalised approach to MB treatment. For example, WNT tumours, which 
have the best prognosis, may require less RT and chemotherapy for successful 
treatment. Current trials are underway to understand whether it would be 
possible to reduce the dose of RT and chemotherapy used for WNT MB 
(ClinicalTrials.gov Identifier: NCT02724579).  
In the era of molecular classification of MB, the development of targeted 
therapies has begun. In SHH tumours, which present with amplification of GLI 
genes, inhibiting the transcription factor GL12 presents as a valuable 
therapeutic option. Arsenic trioxide (ATO) can inhibit the activity of GLI as 
well as decrease protein expression and stability. In a murine model, daily 
treatment with ATO inhibited the growth of  SHH MB (Kim et al., 2010, 2013). 
ATO is currently undergoing phase II clinical trials for the treatment of SHH 
MB. Also, a modified measles virus, can selectively kill MB cells presenting 
CD46 markers on the tumour cell membrane (Studebaker 2012, 2010), and is 
currently in a clinical trial to treat recurrent MB (ClinicalTrials.gov Identifier: 
NCT02962167). The development of future treatment options for MB may 
help reduce the unwanted developmental defects caused by current methods. 
This will be driven, in part, by further understanding of the molecular 
signature of MB.  
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1.5 Tumour microenvironment 
The environment in which a solid tumour resides is a complex milieu of both 
malignant and non-malignant cells each playing a significant role in tumour 
promotion or suppression. Many cell types have been identified within the 
tumour microenvironment (TME), such as immune cells, fibroblasts, 
pericytes, tumour vasculature and lymphatics (Balkwill et al., 2012). For 
example, T lymphocytes, such as CD8+ T memory cells, which have cancer-
killing properties, can be present (Schietinger et al., 2010). Natural killer cells 
may also be within the surrounding stroma. Tumour-associated macrophages 
(TAM) are abundant in most cancers and have pro-tumorigenic properties. 
For example, TAMs can produce epidermal growth factors (EGFs) which 
promotes tumour cell migration (Wyckoff et al., 2004). Additionally, 
transcriptional profiling of TAMs shows enrichment for compounds than are 
pro-angiogenic (Ojalvo et al., 2009). Overall, TAMs play a significant role 
within the TME and can result in pro-cancer outcomes. Although cells within 
the TME can influence tumour progression and metastasis, environmental 
characteristics can influence tumour cell biology. Specifically, variations in 
oxygen availability can result in pro-tumorigenic phenotypes.  
1.6 Tumour hypoxia 
The simplistic definition of hypoxia is the point at which the demand for 
oxygen outweighs the supply. Within the TME, hypoxia can directly influence 
tumour cell biology. Tumour hypoxia is caused by 1) reduced blood perfusion 
due to poor vasculature formation, which is prone to bursts and leaks. 2) 
Increased diffusion distances (>70 µm) between cells and blood vessels caused 
by increased cell proliferation (Vaupel et al., 1989; Vaupel and Harrison, 
2004). These features of the tumour vasculature results in spatial and 
temporal heterogeneity in oxygen supply (Figure 1.3).  
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Figure 1.3: Aberrant vasculature contributes to tumour hypoxia. Within a 
tumour, long diffusion distances, blocked vessels and bursts cause tumour 
regions to become hypoxic.   
 
The oxygen level in healthy tissue is defined as physioxia, which is highly 
dependent on proximity to oxygen providing blood vessels. In the brain, 
oxygen levels are around 5-8%, yet in brain tumours such as MB and GBM, 
cells are exposed to 0.5% to 3% O2 (Rampling et al., 1994) (Table 1.3). This 
leads to cellular adaptions such as the switch to glycolytic metabolism, 
increased red blood cell production (erythropoiesis) and the development of 
new blood vessels (angiogenesis) to restore oxygen homeostasis.  
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Table 1.3: Median oxygen tension in organs, as well as primary tumours. 
Re-drawn from Muz et al. 2015.  
 
1.7 Consequences of tumour hypoxia 
Tumour hypoxia causes cellular adaptations that can lead to pro-tumorigenic 
benefits, enabling cancer growth, metastasis and protection from anti-cancer 
therapy. These changes include increased angiogenesis, increased invasive and 
metastatic potential, and resistance to chemo- and radiotherapy.  
1.7.1 Increased angiogenesis 
For tumours to grow, the creation of new blood vessels is required 
(angiogenesis). However, vessels in solid tumours have an aberrant structure, 
prone to bursts and leaks, which directly contributes to the hypoxic 
phenotype. Hypoxia stimulates the production of new blood vessels, through 
Tissue/Organ 
Physoxia 
(Median % O2) 
Cancer 
Hypoxia 
(Median % O2) 
Brain 4.6 Brain Tumour 1.7 
Breast 8.5 Breast Cancer 1.5 
Cervix 5.5 Cervical Cancer 1,2 
Kidney Cortex 9.5 Renal Cancer 1.3 
Liver 4.0-7.3 Liver Cancer 0.8 
Lung 5.6 Non-small Cell 
Lung Cancer 
2.2 
Pancreas 7.5 Pancreatic 
Tumour 
0.3 
Rectal Mucosa 3.9 Rectal Carcinoma 1.8 
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stimulation of pro-angiogenic factors such as VEGF, EPO, PDGF, FGF 
(Semenza and Wang, 1992; Krock et al., 2011). Also, hypoxic tumour cells 
secrete matrix metalloproteases (MMPs) that can degrade the surrounding 
matrix, aiding the invasion of sprouting vessels into tissue (Yamanaka and 
Ishikawa, 2000; Ben-Yosef et al., 2002; Choi et al., 2011). This newly formed 
vasculature within the hypoxic environment is contorted and irregular causing 
altered blood flow further exacerbating the hypoxic environment.  
In an attempt to halt tumour angiogenesis and reduce tumour growth, an 
anti-VEGF monoclonal antibody, bevacizumab, was developed, which had 
anti-vascular effects (Willett et al., 2004). This was a promising treatment 
option for highly vascularised tumours such as GBM. Phase III clinical trials 
showed that adding bevacizumab treatment to standard GBM therapy (RT and 
TMZ), resulted in progression-free survival to 10.6 months compared to 6.2 
months in the placebo group, although there was no difference in the overall 
survival rate (Chinot et al., 2014). In contrast, clinical trials for recurrent GBM, 
investigating treatment with bevacizumab and various chemotherapeutics 
(TMZ, carboplatin, irinotecan) indicated little patient benefit over standard 
protocols (Verhoeff et al., 2010; Desjardins et al., 2012; Reardon et al., 2012; 
Field et al., 2015). Despite these disappointing results, bevacizumab became 
an FDA approved treatment for recurrent GBM in 2009 (Cohen et al., 2009). 
Anti-VEGF therapy can successfully reduce angiogenesis, however increased 
tumour cell invasion has been observed, attributed in part, to the hypoxic 
environment created as a result of reduced blood supply (Keunen et al., 2011). 
The invasive side effect of bevacizumab may be reversed by integrins 
inhibition. Ishida et al. determined that treatment of cells with and the 
integrin inhibitor, celingitide, reduced cell invasion caused by bevacizumab 
(Ishida et al., 2014), yet the immediate clinical applications are not clear. 
Overall, the use of angiogenesis inhibitors can be beneficial in combating the 
pro-angiogenic phenotype of hypoxic tumours, yet the added consequence of 
increased invasion will likely reduce the positive anti-cancer implications.   
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1.7.2 Increased invasive and metastatic potential 
Hypoxia increases tumour cell propensity to invade and metastasise. 
Pro-angiogenic properties of hypoxic tumours, such as the increased 
production of MMPs, can enable tumour cell invasion to local tissue 
(Yamanaka and Ishikawa, 2000; Ben-Yosef et al., 2002; Choi et al., 2011). In 
gliomas, activation of TGF-β2 signalling upregulated the expression of MMP -
1, -2, -9 leading to increased tissue invasion (Wick 2011). Also, these highly 
invasive hypoxic cells have increased ability to form a secondary metastasis. In 
a chick embryo model of neuroblastoma, cells pre-cultured in hypoxia were 
able to metastasise to chick organs, yet normoxic cells could not (Herrmann et 
al., 2015). Also, hypoxic myeloma cells injected into mice spread to new bone 
marrow faster than normoxic cells (Azab et al., 2011). This increased 
metastatic potential is in part due to epithelial-mesenchymal transition (EMT) 
induced by hypoxia, whereby tumour cells acquire mesenchymal 
characteristics. For example, hypoxic myeloid cells have decreased expression 
of E-cadherin and increased CXCR4 levels, classical mesenchymal attributes 
(Barbara Muz et al., 2015). Additionally, the driver of EMT, TGF-β, is 
upregulated in hypoxic cells (Falanga et al., 1991). Other hypoxia-induced 
changes promoting EMT include the stabilisation of Snail, and upregulation of 
N-cadherin, Vimentin and SMA (B. Muz et al., 2015; Choi et al., 2017). 
Exposure of MB cells to intermittent hypoxia induced EMT, highlighted by an 
increase in N-cadherin, Snail and Vimentin, resulting in increased invasive 
properties (Gupta et al., 2011). GBM cells cultured in hypoxia have been found 
to have a mesenchymal phenotype with increased invasive properties as well 
as increased CDXC4 and VEGF expression (Zagzag et al., 2006; Joseph et al., 
2015). Therefore, hypoxia may contribute to the highly infiltrative and invasive 
characteristics of GBM. Overall, tumour hypoxia can promote the spread of 
cancer, which is a direct cause of cancer-induced death.  
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1.7.3 Chemo- and radioresistance 
Tumour hypoxia strongly correlates with poor patient survival (Wilson and 
Hay, 2011), partly due to the chemo- and radioresistance phenotype of hypoxic 
cells. Hypoxia-induced resistance has been recognised since the 1950’s 
(Deschner and Gray, 1959), yet the molecular mechanisms have only been 
identified in the last few decades. Hypoxia-induced resistance occurs primarily 
as a result of the following situations; cell cycle arrest of hypoxic cells, 
inhibition of apoptosis, induction of autophagy, impaired drug delivery and 
reduced drug efficacy in a low oxygen environment. 
1.7.3.1 Hypoxia-induced cell cycle arrest 
Severe hypoxia can induce cell cycle arrest through the upregulation of p21 
and p27 (Amellem and Pettersen, 1991; Gardner et al., 2001; Goda et al., 2003). 
Many anti-cancer therapies require cycling cells to induce sufficient cell death. 
For example, at the end of S and G2 phase, cells are less sensitive to irradiation 
compared to the G2/M phase (Pawlik and Keyomarsi, 2004). Also, cells need 
to be actively synthesising DNA in order to induce lethal double strand breaks, 
after DNA base damage from TMZ treatment (Zhang et al., 2012). Therefore, 
cell cycle arrest can lead to indirect resistance to irradiation and TMZ. 
However, the level of hypoxia required to induce cell cycle arrest may vary. 
Studies that identified the hypoxia-induced arrest utilised severe hypoxia, with 
close to anoxic values, however more pathologically relevant levels (1 – 0.1%) 
fail to induce significant cell cycle arrest in GBM and MB cells (Fan, 2014; 
Richards et al., 2016). Therefore, the contribution of cell cycle arrest to 
treatment resistance in GBM and MB is likely to be limited.  
1.7.3.2 Inhibition of apoptosis  
Hypoxia can downregulate apoptosis signalling, leading to treatment 
resistance. Reports suggest that Bid and Bax, key pro-apoptotic proteins are 
downregulated by hypoxia. In human colon carcinoma cells, hypoxia reduced 
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Bid and Bax expression (Erler et al., 2004). Also, hypoxia-induced 
phosphorylation of Bax by Pim-1 inhibits apoptosis (J. Chen et al., 2009). MB 
cells exposed to intermittent hypoxia had reduced expression of pro-apoptotic 
genes (Bax and Bad) as well as induced expression of anti-apoptotic genes 
(Gupta et al., 2011). The Bcl-2 protein is directly responsible for regulation of 
apoptosis, through binding with Bax and inhibiting its activity. Hypoxia can 
result in upregulation of Bcl-2 in gastric cancer cells contributing to hypoxia-
induced chemoresistance (Liu et al., 2008). Overall, alterations of pro-
apoptotic systems in hypoxic tumour cells can protect against treatment-
induced apoptosis. In contrast, some studies suggest that hypoxia alone can 
trigger apoptosis and p53 activity (Graeber et al., 1994; Hammond et al., 2002; 
Hammond, Dorie, et al., 2003). However, these studies used severe hypoxic 
exposure (<0.2%), whereas moderate hypoxia elicits a protective anti-
apoptotic phenotype.  
1.7.3.3 Induction of autophagy 
Autophagy is an evolutionarily conserved phenomenon triggered when cells 
are exposed to stressors such as nutrient deprivation or metabolic stress. 
Autophagy enables the production of ATP and anabolic or catabolic 
precursors from internal sources to avoid necrosis or apoptosis (Lum et al., 
2005). Therefore, cells no longer rely on external oxygen for energy 
production. Hypoxia can directly induce autophagy, which can protect cells 
from death (Bellot et al., 2009). Inhibition of autophagy has been shown to 
increase sensitivity to chemotherapeutic agents (Li et al., 2010; Liu et al., 2011). 
Recent work suggests that resistance to therapeutic agents is in part, due to 
hypoxia-induced activation of autophagy (Liu et al., 2010). For example, in 
glioblastoma hypoxia-induced autophagy promotes tumour cell survival as 
well as resistance to the anti-angiogenic therapy bevacizumab (Hu et al., 
2009). Hypoxic induced autophagy is a protective adaptation, which prevents 
treatment-induced apoptosis. 
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1.7.3.4 Impaired drug delivery and reduced drug efficacy  
The tortuous vasculature of hypoxic tumours results in altered blood flow to 
regions of the tumour. Therefore, the delivery of chemotherapeutic agents 
through the bloodstream is hindered. Also, efflux proteins, such as 
p-glycoproteins, can remove substrates from the intracellular region to the 
extracellular space, reducing the internal drug dose. Increased expression of 
p-glycoproteins (multi-drug resistance proteins, MDR) can cause drug 
resistance in cancer (Abraham et al., 2015). Hypoxia can indeed upregulate the 
expression of multi-drug resistance 1 (MDR-1) and multi-drug resistance 
protein 1 (MPR-1) resulting in chemoresistance (Comerford et al., 2002; 
Wartenbert et al., 2003; Lv et al., 2015). In glioma cells, hypoxia upregulated 
MPR-1 gene expression results in reduced sensitivity to etoposide and 
doxorubicin (Chou et al., 2012). Alterations of MDR expression in hypoxia can 
directly alter the response to chemotherapy, yet increased MDR by hypoxia is 
not found in all cell types (Fan, 2014).  
A low oxygen environment can directly reduce drug efficacy. Compounds such 
as alkylating agents (e.g. Melphalan) require molecular oxygen for the 
mechanism of action, therefore are less active in hypoxia (Teicher et al., 1987). 
Additionally, irradiation in a normoxic environment results in the reaction of 
oxygen with the end of broken DNA, making repair more challenging. This 
phenomenon, known as the oxygen enhancement effect, is lost in low levels of 
oxygen, making radiotherapy less effective against hypoxic tumours (Chapman 
et al., 1973). 
Overall, hypoxia can result in reduced drug load both extracellularly and 
intracellularly, as well as causing reduced treatment activity. These 
characteristics of hypoxic tumours play a significant role in hypoxia-induced 
tumour resistance.  
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1.8 HIF – the master regulator of the hypoxic response  
The hypoxia-inducible factor (HIF) is responsible for mediating the response 
to a low oxygen environment by initiating processes such as angiogenesis, 
erythropoiesis and energy production. Transcriptional activation by HIF was 
first demonstrated through investigations into the expression of the 
haematopoietic growth factor, erythropoietin (EPO) (Semenza and Wang, 
1992). Since then, HIF has been directly implicated in transcriptional 
activation of hundreds of genes involved in various cellular processes. HIF is a 
basic helix loop helix protein, comprising of an oxygen sensitive α subunit and 
constitutively expressed β subunit. There are three known isoforms, HIF-1, 
HIF-2 and HIF-3, with HIF-1 being the most studied (Wenger, 2002). The 
structure of HIF-1α includes a bHLH domain, PAS domain (PER-ARNT-SIM), 
oxygen-dependent domain (ODD), amino-terminal transcriptional activation 
domain (NTAD) and carboxy-terminal transcriptional activation domain 
(CTAD) (Wang et al., 1995) (Figure 1.4). The bHLH domain is essential for 
DNA binding, and the PAS domain is required for dimerisation with HIF-1β 
(Wang et al., 1995).  
 
Figure 1.4: Structure of HIF-1α. HIF-1α is a basic helix-loop-helix protein, 
826 amino acids in length. bHLH = basic helix-loop-helix, PAS = PER-
ARNT-SIM. ODD = oxygen dependent domain, N-TAD = amino-terminal 
transcriptional activation domain, CTAD = carboxy-terminal 
transcriptional activation domain, Pro = proline, Asn = asparagine. The key 
hydroxylation sites are indicated.  
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HIF-α is constitutively expressed yet the levels are tightly regulated through 
the activity of prolyl-4-hydroxylase domain proteins (PHD1, 2 and 3). PHDs 
utilise oxygen as a co-factor in hydroxylation of proline residues in the ODD of 
HIF-α (Bruick and McKnight, 2001; Epstein et al., 2001). The von Hippel-
Lindau protein (pVHL), recognises and polyubiquitinates hydroxylated HIF-α 
targeting it for destruction by the 26S proteasome (Tanimoto and Makino, 
2000; Ivan et al., 2001). Factor inhibiting HIF (FIH), an asparaginyl 
hydroxylase, can also regulate HIF through hydroxylation of an asparagine 
residue, preventing interaction with its transcriptional co-activator p300 
(Hewitson et al., 2002; Lando et al., 2002; McNeill et al., 2002). The 
regulatory mechanisms of PHDs and FIHs act together to prevent 
transcriptional activation of HIF target genes in normoxia. In a hypoxic 
environment, the activity of both PHDs and FIHs decreases, thus their ability 
to inhibit HIF is diminished (Bruick and McKnight, 2001; Lando et al., 2002). 
This enables the HIF-α protein to accumulate in the nucleus where the α and 
β subunits form a heterodimer (Wenger, 2002), which can interact with co-
activators such as p300 (Arany and Huang, 1996). Gene expression is induced 
through binding to the hypoxia response element (HRE) comprising of a core 
sequence, 5’-[A/G]CGTG-3’, within the promoter of hypoxia-responsive genes 
(Wenger et al., 2005) (Figure 1.5).  
Tight regulation of HIF activity is critical to prevent unwanted transcriptional 
activation. However, in many cancers, HIF-1α and HIF-2α levels are high 
(Talks et al., 2000), and significantly contribute to pro-tumorigenic 
adaptations in hypoxic tumours. Specifically, HIF-1α is upregulated in MB in 
comparison to the healthy cerebellum (Cruzeiro et al., 2017). Also, mutations 
in the IDH1 gene, similar to those found in secondary GBM, can result in the 
accumulation of HIF-1α (Guerra et al., 2009). Oxygen-independent HIF 
accumulation in gliomas has been observed, primarily due to activation of 
EGFR and loss of the tumour suppressors p53 and PTEN. EGFR amplification 
or overexpression is often found in GBM, which correlates with poor prognosis 
(Frederick et al., 2000). Overactivation of EGFR signalling leads to initiation 
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of the P13K/AKT/mTOR pathway (Clarke et al., 2001), causing the 
accumulation of HIF-1α. Additionally, loss or mutation of PTEN, the primary 
inhibitor of the PI3K/AKT pathway, results in the accumulation of HIF and 
increased vascularization (Zundel et al., 2000). p53 may play a role in HIF 
regulation, through MDM2-mediated ubiquitination and degradation of HIF. 
Therefore in TP53 mutated tumours, HIF may accumulate (Ravi et al., 2000). 
The accumulation of HIF, through genetic alterations or a hypoxic TME, can 
lead to the activation of cellular processes, which drive tumour progression 
contributing to the poor prognosis of hypoxic tumours.   
 
Figure 1.5: Regulation of HIF α in normoxia and hypoxia. In an oxygenated 
environment, HIF α. Protein levels are tightly regulated through the activity 
of PHDs and VHL, which target HIF α for destruction. In hypoxia, HIF α 
accumulates and dimerises with HIF β in the nucleus. HIF activates gene 
expression through binding at the hypoxia-inducible element (HRE).   
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1.9 DNA damage response and cancer therapy 
It is essential for cells to protect the integrity of their genome and prevent 
unwanted mutations. However, this is a challenging task, as cellular DNA is 
constantly under attack from both endogenous and exogenous sources, which 
actively damage DNA. For example, UV rays from the sun can cause 1 x 105 
DNA lesions per day (Hoeijmakers, 2009). Also, ionising radiation from both 
cosmic rays and the sun can result in breakage of the DNA, causing single 
strand and double strand breaks (SSB, DSB). Internal cellular mechanisms 
cause DNA damage, such as metabolism, which results in the formation of 
reactive oxygen species (ROS) that can oxidise DNA and cause SSB. Also, 
errors in DNA replication can result in mismatched DNA bases which lead to 
mutations if not repaired (Ciccia and Elledge, 2010). Cellular DNA is being 
attacked from all angles. However, networks of complex DNA repair 
mechanisms can repair these DNA lesions and maintain genome integrity. 
Collectively these mechanisms are known as the DNA damage response 
(DDR). Although, the repair mechanism employed is specific to the damage 
type, each of the repair pathways follows a similar set of events, recognition of 
damage, recruitment of repair proteins, and mechanical repair of the DNA 
damage (Figure 1.6). If DNA damage cannot be repaired, due to defects in 
repair mechanism or the overwhelming quantity of DNA damage, activation of 
apoptosis, through p53 stabilisation, is triggered. This key feature of the 
cellular response to DNA damage is exploited in cancer therapy. For several 
decades, radiotherapy has been the primary line of treatment against cancer. 
RT creates complex DNA damage (SSB, oxidative bases, DSB etc.), which is 
challenging for cells to repair, therefore cell death is initiated. Additionally, 
some chemotherapeutic agents directly or indirectly damage DNA. These 
agents include alkylating agents, crosslinking agents, and inhibitors that trap 
enzymes at DNA (e.g. topoisomerase inhibitors). 
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Figure 1.6: The DNA damage response. Stages of the DNA damage response, 
with examples of the protein complexes involved in each step.  
 
1.9.1 Alkylating agents 
The first documented use of alkylating agents as a cancer therapeutic was in 
the 1940s when Goodman and colleagues trialled the use of nitrogen mustard 
to treat lymphoma and leukaemia (Goodman et al., 1946). Since then, 
derivatives of nitrogen mustard have been created, which feature prominently 
in anti-cancer therapies. Alkylating agents affect DNA by adding alkyl or 
methyl groups to DNA bases. This results in a bulky adduct which stalls 
replication, leading to replication fork collapse and the formation of DNA 
breaks (Roos and Kaina, 2006) (Figure 1.7). Common alkylating agents used 
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clinically include temozolomide, cyclophosphamide, and melphalan. 
Temozolomide is the primary chemotherapeutic agent used in GBM treatment 
(Athanassiou et al., 2005). However, the success of TMZ as a therapeutic 
agent is highly dependent on the MGMT status of a tumour. MGMT can 
directly remove the O6methyl guanine induced by TMZ (Brada et al., 1999; 
Glassner et al., 1999; Esteller et al., 2000). The presence of alkylated or 
methylated bases leads to the activation of base excision repair (BER), as well 
as double strand break repair pathways if the damage is not corrected before 
replication (Figure 1.7).  
1.9.2 Crosslinking agents  
Several alkylating agents, including nitrogen mustard, can cause crosslinking 
of opposite strands of the DNA double helix, known as an interstrand 
crosslink (ICL). These are thought to be more lethal compared to alkylation 
alone (Kohn et al., 1966; Wiltshaw, 1979). In the 1960’s the discovery of 
platinum-containing compound, cisplatin, dramatically altered the survival 
prospect for cancer patients. Cisplatin (Cis-diamminedichloroplatinum(II)) 
was discovered when a magnetic field generated by platinum electrodes was 
shown to block E.coli cell division (Rosenberg et al., 1965). In the 1970s, 
cisplatin was slowly adopted as a chemotherapeutic agent, yet with some 
hesitation (Wiltshaw, 1979). However, since initial testing in the 1970’s, the 
patient survival rate for testicular cancer has dramatically improved, 
attributed mainly to the adoption of cisplatin as a primary therapeutic strategy 
(Ansell and Shamash, 2008). Further platinum based compounds have since 
been developed, including carboplatin and oxaliplatin, which are actively used 
in the clinic for cancer treatment (Wheate et al., 2010). Cellular repair 
mechanisms activated to repair ICLs induced by platinum-based compounds 
include the Fanconi anaemia pathway, homologous recombination repair and 
non-homologous end joining (Figure 1.7).  
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1.9.3 Enzyme trapping  
DNA-protein complexes form during many cellular processes including 
transcription, DNA repair and DNA replication. Therefore, trapping these 
proteins onto the DNA poses a potential option for halting cellular processes. 
For example, topoisomerases enzymes are responsible for relieving the strain 
on the supercoiled DNA double helix. The DNA is nicked by the 
topoisomerase which releases the tension within the helix (Berger et al., 1996). 
Several inhibitors or ‘poisons’ of topoisomerases have been developed which 
trap the enzyme at the DNA, blocking replication and causing the formation 
of single and double strand breaks (Binaschi et al., 1995; Burden and Osheroff, 
1998) (Figure 1.7). Common topoisomerase inhibitors used clinically include 
etoposide, camptothecin and doxorubicin. Etoposide inhibits 
topoisomerase II, and is used to treat MB, testicular cancer, lymphoma and 
lung cancer for example (Wozniak and Ross, 1983). DNA damage induced by 
topoisomerase inhibitors is repaired by single-strand break repair, 
homologous recombination repair and non-homologous end joining 
(Figure 1.7). 
 
Figure 1.7: Types of DNA damaging agents, the damage they induce, and the 
repair pathways initiated.  
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1.10 Repair of DNA damage 
Once anti-cancer agents inflict DNA damage, repair mechanisms are 
activated. Specific mechanisms are employed to repair different types of DNA 
damage, with crosstalk between some pathways. Three key repair mechanisms 
are homologous recombination repair, non-homologous end joining and base 
excision repair (Figure 1.8).  
 
Figure 1.8: Repair steps of HRR, NHEJ and BER. Simplified depictions of the 
critical steps of homologous recombination repair (HRR), non-homologous 
end-joining (NHEJ), base excision repair (BER) and the essential protein 
complexes involved.  
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1.10.1 Homologous recombination repair  
Homologous recombination repair (HRR) is responsible for the repair of DSB 
as well as other lesions which can cause replication arrest (Lundin et al., 
2002). For HRR to occur, the presence of homologous DNA is required, found 
in G2 and S phase of the cell cycle. In summary, the repair process involves 
recognition of the break, processing of DNA ends followed by DNA strand 
invasion, DNA synthesis and resolution of complex structures.  
Initially, the MRN complex, composed of MRE11, RAD50 and NBN, recognises 
the DSB. MRE11 is primarily responsible for end-resection of DNA due to its 
endonuclease activity (Paull and Gellert, 1998), and both MRE11 and RAD50 
can tether DNA ends (De Jager et al., 2001). Upon recruitment to the damage 
site, NBN is phosphorylated and acts as a beacon for other DNA repair 
proteins initiating further protein recruitment to the broken DNA (Desai-
mehta et al., 2001).  
After initial end processing by MRE11, exposed single-stranded DNA (ssDNA) 
is bound by RPA, followed by the binding of RAD51 forming a nucleoprotein 
filament. RAD51 is responsible for catalysing the search for homology as well 
as strand invasion (Pâques and Haber, 1999; Sung, 1994). The RAD51 
paralogues (RAD51 B, RAD51 C, RAD51 D, XRCC2, XRCC3) and RAD52 also 
play a role in these search processes (Kawabata et al., 2005). Both BRCA1 and 
BRCA2 can interact with RAD51 and play a fundamental role in controlling 
HRR (Sharan et al., 1997; Wong et al., 1997; Moynahan et al., 1999). Once 
invasion of the homologous strand has occurred, a D-loop forms, which 
initiates the synthesis of DNA utilising the homologous DNA as a template. 
This leads to the formation of a Holliday junction which is resolved by Top3 
and BLM (Petr et al., 2012), resulting in ligated DNA strands (Ranjha et al., 
2018). Overall, HRR is a complex multistep process involving many essential 
protein complexes required for efficient repair of the double strand break.  
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1.10.2 Non-homologous end joining 
During the cell cycle, in G0 and G1, HRR is not available due to the lack of 
homologous DNA stands being present. Therefore non-homologous end 
joining (NHEJ) is required for DSB repair. NHEJ is a highly error-prone process 
due to the lack of a homologous DNA template for copying the 
complementary sequence during DNA synthesis. Initial steps of NHEJ involve 
the formation of a complex of DNA-PK and Ku (Ku70/Ku80) at the DSB, 
responsible for recognition of the break (Gottlieb and Jackson, 1993; Kurimasa 
et al., 1999). Ku is composed of two subunits, Ku70 and Ku80, which form a 
protein complex with a DNA binding core (Walker et al., 2001). Subsequently, 
DNA-PKcs is recruited resulting in a geometrical change to the protein 
complex enabling Ku to translocate along the DNA (Yoo, 1999), this allows the 
recruitment of further DNA repair proteins to the ends of the DNA for 
processing.  
DNA end processing requires various enzymes including Artemis, PNK, WRN 
and DNA polymerases (Mahaney et al., 2009). These proteins are responsible 
for preparing the DNA ends for re-joining. A heterodimer of DNA Ligase IV 
and XRCC4 is the final complex to be recruited to the damage site. The 
presence of Ku is essential for this recruitment (Nick McElhinny et al., 2000; 
Mari et al., 2006). Also, recruitment can be triggered by the interaction of XLF 
and XRCC4 (Yano et al., 2009). DNA Ligase IV is directly responsible for 
ligating the two DNA strands together, the final step of NHEJ. Little is known 
regarding the signals involved in the dissociation of the DNA repair protein 
complexes from the repaired DNA however in the case of DNA-PKcs, auto-
phosphorylation results in its disassociation from DNA (Chan and Less-Miller, 
1996; Merkle et al., 2002; Uematsu et al., 2007). Although NHEJ is the primary 
repair mechanism employed for the repair of DSB, it is a highly error-prone 
and can result in chromosomal rearrangements and translocation.  
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1.10.3 Base excision repair 
Base excision repair (BER) is responsible for the removal of aberrant bases 
from DNA, arising from methylation, oxidation or deamination. The causes of 
these base changes include spontaneous decay of DNA or as a result of an 
attack from exogenous sources such as chemicals or radiation (Lindahl, 1993). 
Initiation of BER involves damage recognition by a specific DNA glycosylase 
which removes the aberrant base creating an abasic site (Stivers and Jiang, 
2003; Friedman and Stivers, 2010). AP-endonucleases (e.g. APE1 or APE2) 
create a nick in the DNA phosphodiester backbone at the abasic site (Demple 
et al., 1991), which is further processed by DNA polymerase, resulting in a 
nucleotide-free gap (Sobol et al., 1996). At this stage, the DNA can be 
processed through short-patch BER pathway or long-patch BER. Pathway 
choice is poorly understood however ATP levels, type of DNA intermediate 
produced after AP-endonuclease action or even the cell cycle stage, can 
influence this decision (reviewed in Fortini and Dogliotti, 2007).  
Short-patch BER involves the addition of a single nucleotide to the nucleotide-
free gap by pol β or pol λ (Braithwaite et al., 2005). However, long patch BER 
involves flap displacement synthesis by either pol δ or pol ε, whereby 2-12 
nucleotides are replaced by the polymerase resulting in the displacement of 
part of the DNA strand (Fortini et al., 1996). This ‘flap’ structure is recognised 
and removed by FEN1 (Harrington and Lieber, 1994). To seal the nicked DNA, 
DNA Ligase I aided by PCNA or DNA Ligase III complexed with XRCC1 is 
required (Caldecott et al., 1994; Hubscher et al., 1998). Additionally, PARP-1 
has been shown to have a role in BER by protecting repair intermediates from 
deterioration as well as preventing the formation of excessive single-strand 
breaks (Parsons et al., 2005). Overall, BER is a highly efficient method of 
removal of individual damaged bases.  
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1.11 Failure of DNA repair mechanisms  
When large amounts of DNA damage is induced by anti-cancer treatments, 
the cell is unable to repair the DNA lesions. This leads to the induction of 
apoptosis, the primary aim of chemo- and radiotherapy. Apoptosis is initiated 
through the activities of p53, the ‘guardian of the genome’. For example, after 
the induction of SSB and DSB by ionising radiation, damage recognition 
complexes recruit ATM and ATR, which phosphorylate further downstream 
signalling proteins such as Chk1 and Chk2 (Guo et al., 2000; Liu et al., 2000; 
Matsuoka et al., 2000). This leads to the phosphorylation of p53, which 
inhibits MDM2 binding and thus prevents p53 degradation (Shieh et al., 1997). 
p53 is then able to activate pro-apoptotic genes such as Bid and Bax, to trigger 
apoptosis (Banin et al., 1998; Canman et al., 1998; Epstein et al., 2001; Turenne 
et al., 2001; Saito et al., 2002). This is a desirable outcome for cancer therapy, 
as it results in tumour cell death and a decrease in tumour volume. Somatic 
mutations in TP53, the gene encoding p53, are found in cancer, with TP53 
mutations in ~25% of brain tumours (Olivier et al., 2010). These mutations 
can directly affect p53 functionality and alter the response to anti-cancer 
therapy. In many tumours, TP53 mutations are associated with poor prognosis 
(Robles and Harris, 2009). For MB, TP53 mutations are enriched in the SHH 
sub-group and are associated with poor patient outcome in part due to 
treatment failure (Zhukova et al., 2013). However, the impact of the TP53 
mutation on GBM prognosis is less clear, with conflicting views (Shiraishi et 
al., 2002; Wang et al., 2014). Overall, alterations to the DDR and p53 can have 
a negative impact from a treatment perspective. Defective repair mechanism 
can also have pro-tumorigenic benefits, creating mutations, which drives 
tumour progression.  
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1.12 Mismatch repair and pro-tumorigenic benefits  
During DNA replication, incorrect nucleotides can be incorporated into DNA 
resulting in a mismatch. These mismatched errors need to be repaired 
successfully to prevent a mutation. The repair mechanism responsible for 
correcting these mistakes is mismatch repair (MMR) (Figure 1.9). Cells with 
non-functional MMR have an increased rate of spontaneous mutation (Tiraby 
and Fox, 1973), and are often less sensitive to alkylating agents such as 
temozolomide and the interstrand crosslinking agent cisplatin (Fink et al., 
1998). 
 
Figure 1.9: Repair steps of MMR. Simplified depictions of the critical steps of 
mismatch repair (MMR) and the essential protein complexes involved.  
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The repair protocol for incorrectly inserted nucleotides involves the initial 
formation of the MutSα protein complex composed of MSH2 and MSH6 
(Gradia et al., 1997). MutSα undergoes a conformational change in an ATP 
dependent manner resulting in the formation of a sliding clamp, which can 
translocate along DNA (Blackwell et al., 1999; Gradia et al., 1999; Iaccarino et 
al., 2000). This sliding clamp protein-DNA complex is bound by a second 
heterodimer, MutLα (MLH1/PMS2), again in an ATP dependent manner (Li 
and Modrich, 1995), and this large protein complex can translocate bi-
directionally along the DNA strands in search of discontinuity in the DNA. 
EXO1 is responsible for the 5’ to 3’ excision of nucleotides in stretches of DNA 
which include the detected mismatch (Zhang et al., 2005). The missing 
nucleotides are replaced with the correct nucleotide sequence by DNA 
polymerase δ, and DNA Ligase I repairs nicks (Longley et al., 1997; Zhang et 
al., 2005). Additionally, PCNA and RFC1 locate to the mismatch site to aid in 
the synthesis of the corrected nucleotides (Longley et al., 1997; Dzantiev et al., 
2004). Correction of the mismatched base is essential as this can lead to point 
mutations, which can directly contribute to cancer progression. Therefore, 
deficiencies within MMR will aid tumorigenesis.  
 
1.13 Hypoxia and the DNA damage response 
The tumour microenvironment can have a direct impact on the efficiency of 
DNA repair mechanisms. Specifically, hypoxia can regulate DNA repair 
through epigenetic modifications, regulation of transcription, translation and 
post-translational modifications, resulting in changes to DNA repair proteins.  
1.13.1 Epigenetic modifications 
Hypoxia can result in direct modification of chromatin causing modulation of 
gene transcription, which can persist long after normoxia is restored. For 
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example, under severe hypoxia (<0.01%) an increase in H2K4me3 and 
decrease in H3K27me3 leads to widespread repression of total RNA and 
mRNA synthesis (Johnson et al., 2008). Also, HIF-1 can directly induce 
expression of JMJD1A, a histone demethylase gene, which reduces histone 
H3K9 methylation at the adrenomedullin (ADM) and growth and 
differentiation factor 15 (GDF15) gene promoters, increasing their expression 
and promoting tumour growth (Krieg et al., 2010). Therefore, alterations of 
the chromatin signature can directly affect cancer progression. The DNA 
repair genes, BRCA1 and RAD51 are regulated in hypoxia through chromatin 
modifications. H3K4 demethylation, H3K9 methylation and H3K9 
deacetylation at the BRCA1 promoter induced by hypoxia results in reduced 
expression of BRCA1. A similar epigenetic signature was also found for RAD51 
(Lu et al., 2011). Alterations in BRCA1 and RAD51 transcription could directly 
affect the functionality of HRR. Hypoxia-induced silencing of the MLH1 gene, 
involved in MMR, arises due to decreased H3K4 methylation induced by the 
H3K4 demethylases, LSD1 and PLU-1 (Lu et al., 2014). Taken together, 
hypoxia-induced chromatin modifications can directly regulate the expression 
of DNA repair genes, which may result in lasting changes.  
1.13.2 Regulation of transcription  
Adaptation to a hypoxic environment is mediated through alteration of 
transcription. Many gene expression changes are HIF-dependant. The 
expression of DNA repair proteins in hypoxia has been well studied, with most 
publications suggesting a decrease in gene expression under a hypoxic 
environment. For example, several publications by the Glazer group found 
that hypoxia-induced downregulation of HRR components leading to reduced 
HRR capacity (Bindra et al., 2004, 2005, 2007; Meng et al., 2005; Bindra and 
Glazer, 2007; Chan et al., 2008). Specifically, RAD51 and BRCA1 expression is 
downregulated in hypoxia due to binding of the repressive E2F4/p130 complex 
to E2F sites in proximal promotors (Bindra et al., 2005; Bindra and Glazer, 
2007). Also, NBN, a key component involved in DSB recognition, is 
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downregulated in hypoxia as HIF-1α displaces MYC at the NBN promotor (To 
et al., 2006). The impact of hypoxia on DNA repair gene expression will be 
discussed further in Chapter 4.  
1.13.3 Regulation of translation 
Hypoxia can directly influence protein translation. The translation initiation 
factor elF2α is phosphorylated in hypoxia (0-0.2%) resulting in reduced 
activity and an overall downregulation in mRNA translation (Koritzinsky et al., 
2007). Additionally, disruption of the mRNA cap-binding complex eIF4F leads 
to alterations in translation efficiency in hypoxia (Hernández-Jiménez et al., 
2012), Chan et al. observed that chronic hypoxia (72 h 0.2%) resulted in 
reduced BRCA2, RAD54, XRCC3, RAD51. RAD51B and RAD51C protein levels, 
yet there was no change to mRNA levels. Exploring BRCA2 and RAD51 further, 
it was determined that there were fewer ribosomes attached to BRCA2 and 
RAD50 mRNA in hypoxia in comparison to normoxia. These changes led to a 
3-fold reduction in HRR capacity (Chan et al., 2008). Hypoxia can also reduce 
the translation of BER proteins leading to reduced BER activity and increased 
sensitivity to DNA damaging agents (Chan et al., 2014). In addition to reduced 
translation efficiency, microRNAs, small non-coding RNAs, can reduce the 
expression of specific proteins. Several microRNAs are induced by hypoxia, 
creating the ‘microRNA signature’ of hypoxia. These microRNAs play a role in 
tumour formation, apoptosis, invasion and proliferation (Kulshreshtha et al., 
2007). Hypoxia-induced upregulation of miR-201 and miR-373 in a HIF-
dependant manner resulted in downregulation of RAD52 (HRR) and RAD23B 
(NER), suggesting that microRNAs may play a fundamental role in the 
regulation of DNA repair pathways in hypoxia (Crosby et al., 2010). Overall, 
evidence suggests that hypoxia can lead to translational regulation of DNA 
repair proteins through reduced translation initiation and the induction of 
microRNAs, which can alter the functionality of DNA repair mechanisms. 
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1.13.4 Regulation of post-translational modifications 
Post-translational modifications of proteins enable rapid control of protein 
functionality, allowing fast reaction and adaptation to cellular changes or 
stresses. Protein modifications include phosphorylation, sumoylation, 
ubiquitination, and acetylation, which can alter protein function, levels and 
localisation. Under severe hypoxia (0.02%), phosphorylation of ATM and ATR 
has been observed independent of DNA damage, thought to be triggered by 
hypoxia-induced replication arrest (Hammond et al., 2003; Hammond et al., 
2002; Bencokova et al., 2009). This results in rapid phosphorylation of ATR 
and ATM targets, including Chk1 and Chk2, leading to phosphorylation of 
H2AX, 53BP1 and p53. Hypoxia-induced ATR-dependent phosphorylation of 
p53 could lead to apoptosis in hypoxia (Hammond et al., 2002). Also, 
activation of the Fanconi anaemia pathway in an ATR-dependant manner may 
protect from DNA damage induction through stabilisation of the replication 
forks (Scanlon and Glazer, 2014). Overall, the post-translational modifications 
of DNA repair proteins in hypoxia are thought to act as a protective 
mechanism against hypoxia-induced DNA damage. However, for these 
modifications to occur severe hypoxic stress is required, whether moderate 
hypoxia is sufficient for these changes needs further investigation.  
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1.14 Project aims and hypothesis  
Brain tumours are complex and challenging diseases. Glioblastoma has a poor 
patient outcome due to the highly infiltrative nature of GBM and resistance to 
standard therapies. In contrast, treatment of medulloblastoma is somewhat 
successful, but high dose chemo- and radiotherapy can lead to developmental 
difficulties in young patients. To improve treatment protocols for GBM and 
MB, further understanding of tumour cell biology is imperative. These 
tumours are hypoxic, resulting in cellular adaptions that can lead to increased 
invasion and metastasis as well as resistance to conventional cancer therapy. 
The majority of treatment protocols for GBM and MB aim to create high levels 
of DNA damage to induce apoptosis. However, hypoxia can have a direct 
impact on DNA repair mechanisms. To date, there are no publications that 
examine the impact of hypoxia on DNA repair mechanisms in hypoxic GBM 
and MB cells, therefore this was the primary aim of the thesis. Previous 
scientific research focusing on DNA repair and hypoxia has resulted in 
significant discrepancies between findings, in part due to variations in cell line 
and hypoxic exposure, with the majority of research being conducted in severe 
hypoxia (<0.1%). Here, pathophysiological hypoxia (0.1 – 1%) was investigated 
to give an overall view of the impact of hypoxia on DNA repair in the tumour 
as a whole. Initially, examination of the double strand break recognition 
machinery in hypoxic MB cells was undertaken to determine whether hypoxia-
induced changes could contribute to treatment resistance (Chapter 3). Next, a 
focused transcriptomic approach was adopted to gain a global overview of the 
expression of common DNA repair genes, under hypoxia (Chapter 4). Finally, 
the functional impact of the observed gene expression changes was 
investigated (Chapter 5).  
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2.1 Chemicals and reagents 
All tissue culture reagents were purchased from Gibco. Chemicals and drugs 
were from Sigma-Aldrich, unless otherwise stated. Custom designed oligo 
primers were purchased from Sigma-Aldrich. 
 2.2 Cell culture  
Glioblastoma (Table 2.1), medulloblastoma (Table 2.2), neuroblastoma and 
HeLa cell (Table 2.3) were maintained at 37oC, 21% O2 and 5% CO2 in the 
appropriate culture medium.  
Table 2.1: Summary of glioblastoma cell lines, their p53 status and source.  
 
 
 
Cell Line Culture Medium p53 Status Source 
U87-MG 
 
EMEM, 10% (v/v) 
FCS, 1% (v/v) NaPyr 
Wild Type ATCC-HTB-14 
D566-MG EMEM, 10% (v/v) 
FCS, 1% (v/v) NEAA, 
1% (v/v) NaPyr 
Mutated Provided by Professor 
DD Bigner (Duke 
University Medical 
Centre, USA) 
U251-MG 
 
EMEM, 10% (v/v) 
FCS, 1% (v/v) NEAA, 
1% (v/v) NaPyr 
Mutated CLS (Eppelheim, 
Germany) 
T98G EMEM, 10% (v/v) 
FCS, 1% (v/v) NaPyr 
Mutated  ATCC-CRL-1690  
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Table 2.2: Summary of medulloblastoma cell lines, their p53 status and 
source. 
 
Table 2.3: Summary of other cell lines used.  
 
2.2.1 Cell passaging 
Cells were passaged when 80-90% confluent. For adherent cells the culture 
medium was removed, cells were washed with PBS and incubated for 5 min at 
37oC with 1 ml 1 x Trypsin/EDTA. Detached cells were re-suspended in culture 
medium. For cells grown in suspension, the cells were transferred to a 50 ml 
falcon tube and centrifuged at 100 g for 5 min. The culture medium was 
removed and the cells re-suspended in fresh culture medium. Cells were 
counted using a Bio-Rad TC20 cell counter. Cells were seeded into a T75 flask 
to maintain the cells (See Table 2.4 for seeding density) or an appropriate 
vessel for experimentation. 
Cell Line Culture Medium p53 Status Source 
D283-MED EMEM, 10% (v/v) 
FCS, 1% (v/v) 
NEAA, 1% (v/v) 
NaPyr 
Wild Type ATCC-HTB-185 
MEB-Med8A DMEM, 10% (v/v) 
FCS,  
Mutated Provided by Prof T. 
Pietsh 
Cell Line Culture Medium Source 
HeLa 
(Cervical carcinoma) 
EMEM, 10% (v/v) FCS, 
1% (v/v) NEAA 
ECACC no: 93021013  
 
SK-N-AS 
(Neuroblastoma) 
EMEM, 10% (v/v) FCS, 
1% (v/v) NaPyr 
ECACC no: 95011817 
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Table 2.4: Seeding densities for cells in 75 cm2 flasks 
 
 
 
 
 
 
2.2.2 Hypoxic Incubation 
Hypoxic culture at 1% O2 was conducted in a Don Whitley H35 Hypoxystation 
and at 0.1% O2 in a New Brunswick Galaxy 48R incubator. The oxygen tension 
of hypoxic chambers was regularly tested using a Microx 4 fibre Optic Oxygen 
Meter (PreSens). Additionally, cells incubated in hypoxia were checked when 
possible for hypoxic markers (GLUT1, VEGF), by RT-PCR, to ensure a hypoxic 
response was present. 1 day and 5 day hypoxic exposure was used to represent 
chronic and acute hypoxia. Fan 2014 had previously demonstrated that at 
these time points, there was a differential impact on HIF levels, drug 
sensitivity and DNA repair gene expression. Additionally, up to 5 days 
exposure had little impact on cell proliferation and viability of the chosen cell 
lines as shown by Fan 2014, Richards et al 2016 and experimental observations 
in this thesis.  
 
Cell Line Number of cells seeded per 75 cm2 flask 
U87-MG 2 – 1 x 106 
D566-MG 1 x 106 
U251-MG 1 x 106 
T98G 2 – 1 x 106 
D283-MED 10 x 106 
MEB-Med8A 4 x 106 
HeLa 1 x 106 
SK-N-AS 2 – 1 x 106 
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2.3 Drug treatment 
For survival assays, cells were pre-incubated in the specified O2 concentration 
prior to drug application. Etoposide, temozolomide and cisplatin were applied 
to cells maintained in their designated O2 condition (with the exception of 
0.1% O2), yet treatment with phleomycin occurred only in 21% O2. Drug doses 
and treatment duration were chosen based on preliminary experimental data 
as well as literature evidence. Dimethyloxalylglycine (DMOG) was utilised as a 
hypoxia mimetic and applied to cells in normoxic conditions to a final 
concentration of 0.5 mM. Acriflavin (AF) was applied to cells, which were 
placed directly in the designated O2 condition for 24 h. Cells were treated with 
digoxin for 8 h prior to placing into hypoxia for 24 h.  
2.4 X-ray irradiation 
Cells were seeded onto 35 mm dishes 24 h prior to irradiation. Cells were 
cooled on ice before irradiating in a CellRad Faxitron (130-150 kV, 5 mA) at 
room temperature, 21% O2. Post-irradiation, cells were again cooled on ice 
before trypsinization. Cells were counted and seeded in a 96-well plate, before 
returning the cells to 21% or 1% O2 for 48 h before assaying for survival. 
2.5 MTS assay 
The MTS assay (Promega) is a quantitative colorimetric method for 
determining viable cells in culture. It relies upon the reduction of a 
tetrazolium compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, by metabolically 
active cells to a coloured formazan product (Berridge and Tan, 1993). Cells 
were incubated with 20 µL of MTS reagent in 100 µL of culture medium for 
2-4 h before determining absorbance at 492 nm. The absorbance values were 
proportional to the number of metabolically active cells. Background 
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subtraction was done using absorbance from wells containing medium only. 
Absorbance values were normalised to control wells.  
2.6 Proliferation assays 
Cells were seeded in 24 well plates 24 h before drug treatment. Etoposide was 
applied at a specified concentration for 24 h, before washing the cells and 
adding fresh medium. Cells were left to grow for 5 days post-treatment. Cells 
were then washed with PBS, and stained with a crystal violet solution (0.5% 
(w/v) in EtOH) for 10 min at room temperature. The crystal violet stain was 
removed and excess stain washed with H2O. Plates were left to dry completely, 
before adding 10% SDS and incubating at 37oC for 1 h. Absorbance at 590 nm 
was determined which was proportional to the number of crystal violet 
stained cells. Absorbance values were normalised to the untreated control. 
2.7 Transient transfection 
Transient transfection was conducted 24-48 h prior to experimental use. 
Various transfection reagents were used for differing cell lines as described 
Table 2.5. All transfections were conducted following manufacturers 
guidelines. 
Table 2.5: Details of specific transfection reagents for each cell line. 
 
 
 
 
Table 2.5 Details of specific transfection reagents for each cell line.  Cell line Transfection 
reagent 
Ratio of DNA to 
reagent 
Mass DNA per 
3.5 cm2 dish (µg) 
U87-MG Viromer 1:0.4 2 
D566-MG JetPrime 1:2 1.5 
HeLa Polyethyleneimine 1:2 1 
Materials and methods 
47 
 
2.8 RNA extraction and reverse transcription 
Cells were seeded into 60 mm dishes and incubated in the specified O2 
conditions for the indicated time points. Adherent cells were washed with 
PBS, lysed in 400 µl of lysis buffer (Roche), and scraped with a cell scraper to 
detach the cells. For non-adherent cells the cell suspension was centrifuged at 
100 g for 5 min, and the cell pellet washed with PBS before a final 
centrifugation. The cells were re-suspended in 400-500 µl of lysis buffer. Cell 
lysate was stored at -80oC until use. RNA extraction was performed using High 
Pure RNA Extraction Kit (Roche) following the manufacturers protocol. RNA 
purity and concentration was determined using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific). 1-2 µg of RNA was utilised for reverse 
transcription using Superscript Vilo reverse transcription master mix 
(Invitrogen), following the manufacturers protocol. cDNA was diluted 1:20 
with RNase/DNase free H2O and stored at -20oC before use in RT-PCR. 
2.9 Quantitative real-time PCR (RT-PCR) 
RT-PCR was performed in a LightCycler480. White 96-wells plates (Roche) 
were used with the standard well component mix of 10 µl SYBER Green PCR 
Mix (Roche), 1 µl of 5 mM forward primer, 1 µl of 5 mM reverse primer (Table 
2.7), 2 µl cDNA (or H2O for no template control) and 6 µl H2O. 3x technical 
replicates were included for each condition. Cycling parameters are described 
in Table 2.6. Data analysis was performed using the LightCycler480 SW 1.8 
software, utilising a relative quantification method with respect to the 
housekeeping gene CYCLOA. Fold change was determined relative to 
normoxic controls. 
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Table 2.6: General cycling parameters for RT-PCR 
 
 
 
 
 
 
 
 
Step Temperature (oC) Time (s) Number of Cycles 
Pre-incubation 
50 
95 
120 
600 
1 
Amplification 
95 
60 
72 
10 
15 
15 
40 
Melt Curve 
95 
65 
97 
5 
60 
Continuous 
1 
Cooling 40 10 1 
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Table 2.7: RT-PCR Primer Sequences 
 
 
 
 
 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
ABL 1 TGGGGCATGTCCTTTCCATC GATGTCGGCAGTGACAGTGA 
CYCLOA GCTTTGGGTCCAGGAATGG GTTGTCCACAGTCAGCAATGGT 
ERCC4 CTCCCTCGCCGTGTAACAAA ACACCAAGATGCCAGTAATTAAATC 
FEN1 GTTCCTGATTGCTGTTCGCC ATGCGAATGGTGCGGTAGAA 
GLUT1 GAACTCTTCAGCCAGGGTCC ACCACACAGTTGCTCCACAT 
LIG IV TCCCGTTTTTGACTCCCTGG GGCAAGCTCCGTTACCTCTG 
MRE11 AGTCCAGCAGTGGGAATTTCT TCAGTCAAGCTCCTCTGGGA 
MSH5 GTTTGCGAAGGTGTTGCGAA GTCTGAGACCTCCTTGCCAC 
NBN AGAATGGCTTTTCCCGAACT CAAGAAGAGCATGCAACCA 
PARP1 GCCCTAAAGGCTCAGAACGA CTACTCGGTCCAAGATCGCC 
PMS2 AGCACTGCGGTAAAGGAGTT CAACCTGAGTTAGGTCGGCA 
RAD50 TGCTTGTTGAACAGGGTCGT TCACTGAATGGTCCACGCTC 
UBE2T ATGTTAGCCACAGAGCCACC ACCTAATATTTGAGCTCGCAGGT 
VEGF CTCCACCATGCCAAGTGGTC GCAGTAGCTGCGCTGATAGA 
WRN TCACGCTCATTGCTGTGGAT CAACGATTGGAACCATTGGCA 
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2.10 Western blotting 
2.10.1 Protein extraction 
Adherent cells were washed with PBS before adding 150-500 µl of lysis buffer 
(50 mM pH 7.5 Tris-HCL, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na3VO4, 1% (v/v) 
Triton X-100, 50 mM Sodium flouride, 5 mM Sodium pyrophosphate, 10 mM 
Sodium B-glycerophosphate, 0.1 mM PMSF, 1 in 100 protease cocktail 
inhibitor) and scraped with a cell scraper. Suspension cells were centrifuged at 
100 g for 5 min, washed with PBS and the centrifugation step repeated to 
remove the PBS. The cell pellets were re-suspended in 100-200 µl lysis buffer. 
Cell lysates were frozen at -20oC. Lysates were defrosted at 4oC on a rotary 
wheel for 1 h, then centrifuged at 13000 g for 15 min. The supernatant was 
transferred to a fresh 1.5 ml tube on ice. Protein quantification was conducted 
using Pierce BCA Protein Assay Kit (ThermoFisher) following the 
manufacturers protocol.   
2.10.2 Sample preparation 
Protein samples were mixed with 5 x laemmli buffer (250 mM pH 6.8 Tris 
HCL, 10% (w/v) SDS, 30% (v/v) Glycerol, 5% (v/v) β-mercaptoethanol, 0.02% 
(w/v) Bromophenol blue), and boiled at 95oC for 5 min. Samples were cooled 
on ice and centrifuged briefly before loading onto SDS-PAGE gel. 
2.10.3 SDS-PAGE for protein separation 
20-40 µg of protein was loaded into wells of a 4% stacking gel (0.4 M Tris base 
pH 6.8, 4% (v/v) Acrylamide, 0.65 ng/µl APS and 0.325% (v/v) TEMED) with a 
6% or 10% resolving gel (0.4 M  pH 8.8 Tris base, 0.1% (w/v) SDS, 6-10% (v/v) 
Acrylamide, 0.25 ng/µl APS and 0.125% (v/v) TEMED) cast with Mini-
PROTEAN 3 system (Bio-Rad). 10 µl of protein ladder (Precision Plus Protein All 
Blue Standards, Bio-Rad) was also loaded into the stacking gel. The SDS-PAGE 
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was run at 100-130 V for up to 1.5 h in running buffer (25mM Tris base, 
192 mM Glycine, 1% (w/v) SDS).  
2.10.4 Protein transfer 
Protein was transferred onto nitrocellulose membrane (0.2 µm, Bio-Rad), in a 
Bio-Rad tank with transfer buffer (25 mM Tris, 192 mM Glycine, 20% (v/v) 
ethanol). Transfer was run at 4oC for 1.5 h (300 mA) or overnight (50 mA). 
2.10.5 Antibody incubation 
Membranes were blocked in 5% (w/v) skimmed milk for 1 h then washed in 
TBS-T (20 mM Tris, 140 mM NaCl, adjusted to pH 7.6, 0.1% (v/v) Tween-20). 
Membranes were incubated in primary antibody diluted in 5% (w/v) BSA in 
TBS-T overnight at 4oC. After primary antibody incubation, the membranes 
were washed three times in TBS-T and incubated with the secondary antibody, 
diluted in 5% (w/v) BSA in TBS-T, for 1 h at room temperature. See Table 2.8 
for details of antibodies and dilutions.  
2.10.6 Developing and analysis 
Protein was visualised using Amersham ECL western blotting detection kit 
(GE Healthcare). Membranes were incubated with 1 ml developer solution and 
captured with a Syngene gel imaging G-box using GeneSnap image acquisition 
software. Densitometry analysis of images was conducted using Fiji 
(Schindelin et al., 2012).  
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Table 2.8: Antibodies used for western blotting  
 
2.11 Immunocytochemistry (ICC) 
Cells were seeded onto glass coverslips in 12 well plates 24 h prior to fixing 
with 4% (w/v) paraformaldehyde at room temperature for 10 min. After 
fixation cells were washed 3 x with PBS then blocked for 20 min at room 
temperature in blocking buffer (1% (w/v) BSA, 0.1% (v/v) Triton X-100, and 
Antibody Source Reference Species Dilution 
Anti-Mouse-HRP Abcam ab6808 Sheep 1 in 5000 
Anti-Rabbit-HRP Cell Signalling 7074S Goat 1 in 3000 
ATM Abcam ab32420 Rabbit 1 in 5000 
ATM Ser1981 Abcam ab81292 Rabbit 1 in 2000 
β-Actin Abcam  ab8226 Mouse 1 in 6000 
Cyclophillin A Cell Signalling 2175 Rabbit 1 in 1000 
HIF-1α Bethyl 20960-1-AP Rabbit 1 in 500 
HIF-2α Bethyl A700-003 Rabbit 1 in 1000 
Histone2B Abcam ab1790 Rabbit 1 in 1000 
MLH1 Abcam ab92312 Rabbit 1 in 1000 
MRE11 Abcam  ab214 Rabbit 1 in 1000 
NBN Abcam ab32074 Rabbit 1 in 500 
PARP1 Santa Cruz sc-53643 Mouse 1 in 2500 
PCNA Santa Cruz sc-9857 Mouse 1 in 1000 
PMS2 Abcam ab110638 Rabbit 1 in 1000 
Vinculin Abcam ab129002 Rabbit 1 in 10,000 
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0.4% (v/v) Tween 20 in PBS). The cells were incubated in primary antibody 
(diluted in blocking buffer) overnight at 4oC, then washed in blocking buffer 
before secondary antibody incubation for 1 h at room temperature (see Table 
2.9 for antibodies). Coverslips were incubated in To-pro-3 (1 in 1000) 
(ThermoFisher) for 30 min at room temperature then washed with PBS before 
mounting onto glass microscope slides with Dako Fluorescent Mounting 
Medium (Dako UK Ltd). Throughout the procedure, coverslips were protected 
from light using foil. Slides were imaged on a Zeiss axiovert Epifluorescence 
microscope using Zeiss 38 HE filter set (GFP) and Chroma 39007 filter set (To-
pro-3). Analysis of signal intensity was performed using Fiji (Schindelin et al., 
2012). Signal was background subtracted before normalisation to control 
samples. 
Table 2.9: Antibodies used in immunocytochemistry  
Antibody Source Reference Species Dilution 
Anti-Rabbit-
AlexaFluor488  
Invitrogen A-11008 Goat 1 in 500 
ɣH2AX Ser139 Cell Signalling 9718 Rabbit 1 in 200 
 
2.12 Luciferase assay 
Cells were transfected for 24 h with a plasmid containing the luciferase gene 
(Figure 2.1), before washing with PBS and applying 300 µl of lysis buffer 
(25 mM pH 7.5 Tris phosphate, 15% (v/v) glycerol, 1% (w/v) BSA, 8 mM MgCl2, 
0.1 mM EDTA, 0.03% (w/v) DTT, 1% (v/v) Triton X-100). 80 µl of lysed cells 
were combined with 200 µl of luciferin working solution (500 µM luciferin, 
2.5 mM ATP in lysis buffer), into a single well of a white 96 well plate, in 
triplicate. Endpoint luminometry measurements were taken using a BMG 
Labtech FLUOstar Omega plate reader.  
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Figure 2.1: Plasmid map of luciferase containing plasmid CMV-pGL4.16. A 
CMV promotor drives the expression of the luciferase gene. A HindIII 
restriction site lies directly between the promotor and start codon. Map was 
drawn using SnapGene (4.1.4). 
 
2.13 NanoString study 
NanoString experimentation was conducted using nCounter VantageTM RNA 
Panel for DNA Damage and Repair (LBL-10250-03), which contained probes 
for 192 genes (180 DNA repair genes and 12 housekeeping genes, for a full list 
of genes see appendix 1.2). For information on cell lines used see Chapter 4 
section 4.1.1.  
2.13.1 Sample preparation 
Cells grown in 60 mm dishes were incubated in either 21%, 1% or 0.1% O2, and 
5% CO2 at 37oC for 5 days before lysis. Cell lysing, RNA extraction and reverse 
transcription was conducted as described in section 2.9.  
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2.13.2 Test for hypoxic markers 
To ensure the cells had responded to the hypoxic environments, cDNA was 
utilised in quantitative RT-PCR experiments to test for the increase in hypoxic 
markers (VEGF and/or GLUT1) as described in section 2.10. Only samples with 
increased hypoxic markers, were used in the NanoString assay.  
2.13.3 NanoString hybridisation 
Hybridisation reactions were conducted following the NanoString 
manufacturers protocol. In brief, 100 µg of RNA was mixed with probe 
solutions as well as hybridisation buffer. Reactions were incubated at 67 oC 
with a thermal cycler lid temperature of 72 oC for 18 h. Samples were then 
transferred directly to the NanoString prep station (a multi-channel pipetting 
robot) for further processing. Steps completed by the prep station include 
purification of the hybridised samples and immobilisation of molecular labels 
to the sample cartridge. Once completed, the sample cartridge was sealed and 
transferred to the Digital Analyzer where the unique molecular identifier for 
each probe was counted and the data collated.  
2.13.4 Data analysis 
Data analysis was conducted using the nSolverTM Analysis Software (3.0) with 
nCounter® Advanced Analysis module (2.0.115). Details of the analysis steps 
are as follows.  
2.13.4.1 Quality control  
Before extensive analysis could be performed, several quality control 
parameters were assessed. Specifically, binding density, and image quality 
were calculated to determine the ability of the Digital Analyser to count the 
immobilised molecules (see nSolver 3.0 manual for further details). 
Additionally, within each experiment, positive controls were included to 
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assess the efficiency of the assay, the linearity and limit of detection. Negative 
controls were included to allow for background subtraction to control for 
noise within the experiment. Probes were also scored as detected or 
undetected, whereby detected probes have counts that are more than double 
the median count of the negative controls. Undetected probes were excluded 
from further analysis.   
2.13.4.2 Normalisation 
To eliminate technical variation between samples due to any potential 
deviation in input material (mass and integrity), 12 housekeeping (HK) genes 
were included in the gene set. To normalise data, each count obtained was 
divided by the geometric mean of the HK genes. Additionally, before 
normalisation, rigorous selection of appropriate HK genes was conducted 
using the geNorm algorithm (Vandersompele, 2002), by calculating the 
pairwise variation statistic of each gene (Figure 2.2). For each sample the 
normalisation factor and mean squared error (MSE) of HK genes from 
expected profile are calculated. A positive normalisation factor indicates 
higher than average expression of HK genes. Large MSE indicates that 
expression of HK deviates significantly from the expected profile. This was a 
key quality control step as it can indicate the run efficiency as well as input 
material quality or quantity.  
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Figure 2.2: Example normalisation output for the NanoString experiment. 12 
housekeeping genes (HK) were included in each NanoString reactions. 
Selection of appropriate HK genes was completed using geNorm algorithm. 
(A) Visualisation of the geNorm procedure for HK gene selection, where 
pairwise variation statistics were calculated after removal of individual 
genes. (B) Summary of normalisation depicting the mean squared error 
(MSE) for each sample as well as the normalisation factor. Green dots 
represent each individual sample in a dataset.  
 
2.13.4.3 Differential expression 
To determine differential expression of genes, the nCounter® Advanced 
Analysis Software (2.0.115) utilised multivariate linear regression, whereby 
oxygen condition was defined as the predictor variables and no confounder 
variables were specified. Data from samples incubated in 21% O2 were defined 
as the reference level of expression. Log2 fold change of gene expression and 
associated p-values were determined. To reduce the likelihood of false positive 
results of significance, a p-value threshold of 0.01 was utilised instead of the 
commonly used 0.05.  
 
A B 
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2.13.4.4 DE call  
In the situation of too few replicates for differential expression analysis, DE 
call was used as an alternative. DE call is a test developed specifically for 
nCounter data, which gives an indication as to whether count values between 
conditions are larger than can be explained, by noise or background. This is 
more robust than fold changes alone. Output of this metric is ‘yes’ or ‘no’, and 
can help identify whether the expression level of a gene is likely to be 
significant.  
2.13.4.5 Global and directed significance scoring 
The overall extent of differential expression of defined sets of genes (i.e each 
DNA repair pathway) can be measured with the global significance statistic. 
This was calculated as the square root of the pathway’s average squared 
t-statistic.  
Global significance statistic = ( Σ ti2)1/2 
ti is the t statistic from the ith pathway gene.  
Directed global significance measures the tendency of a pathway to have over 
or under expressed genes, calculated as the square root of the average sign 
squared t-statistic.  
Directed global significance statistic = sign(U)|U|1/2 
where U = Σ sign(t)i •ti2 
and where sign(U) is -1 if U is negative or 1 if U is positive. 
Formulas were taken from the nCounter Advanced Analysis User Manual.  
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2.14 Molecular biology techniques 
2.14.1 Bacterial transformation 
Escherichia coli (E.coli) DH5α was subject to a heat shock based 
transformation protocol for the propagation of plasmids. 5 ng of plasmid DNA 
was added to competent DH5α and cooled on ice for 30 min. The bacteria 
were then heat shocked by incubation at 42oC for 45 s, before returning to ice 
for 2 min. 500 µl of SOC medium (Clonetech) was added and transformed 
cells were incubated for 1 h at 37oC in a shaking incubator (225 rpm). After 
recovery, 200 µl of the bacterial mixture was spread across an agar plate 
containing the appropriate antibiotic for selection of plasmid containing cells. 
Plates were kept at 37oC overnight to allow for colony growth. Single colonies 
were picked and added to 5 ml LB broth and left to grow for at least 8 h at 
37oC in a shaking incubator (225 rpm). 
2.14.2 Plasmid purification 
For purification of plasmids, 5 ml of bacterial culture was added to 200 ml LB 
broth with the appropriate antibiotic. Liquid cultures were grown overnight at 
37oC shaking at 225 rpm. Bacteria was then harvested by centrifugation at 
6000 g for 30 min in 4oC. Harvesting and purification of plasmid DNA was 
achieved using a HighPure Plasmid Maxi Prep Kit (Invitrogen) following the 
manufacturers protocol. The concentration of purified plasmid DNA was 
measured using a NanoDrop 1000 Spectrophotometer (Thermo Scientific), 
then diluted to 1 µg/µl with TBE. Plasmid DNA was stored at -20oC until use.  
2.14.3 Restriction digest 
Plasmid DNA was incubated with restriction enzymes (1 µl/5 µg) and the 
appropriate buffer for 2 – 4 h at 37oC. DNA fragments were separated on a 1% 
agarose gel containing Midori Green Nucleic Acid Stain. DNA was visualised 
under UV light using a Syngene gel imaging G-box. 
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2.15 Multiphoton laser microirradiation 
EGFP-XRCC4 was a gift from Steve Jackson (Addgene plasmid # 46959). Cells 
were transfected with EGFP-XRCC4 (Figure 2.3) in a 60 mm culture dish. 24-
48 h post-transfection, dishes were transferred to a Zeiss LSM 880 (upright) 
where culture conditions were maintained (37oC, 5% CO2). An argon laser 
(488 nm) was used for EGFP excitation with a 40x 1.4 NA water-dipping 
objective and 5x digital zoom. Laser microirradiation was conducted using a 
Coherent Chameleon Vision II Ti:Sapphire multiphoton laser. Laser power 
output was measured at the objective with a laser power meter (ThorLabs), 
enabling parameters to be adjusted to obtain 10 mW output for 800 nm 
wavelength. A circular region of the nucleus, 2 µm in diameter, was irradiated 
with 10 mW 800 nm laser for 20 iterations. Images were subsequently 
acquired at specified intervals post irradiation. 
 
Figure 2.3: Plasmid map of EGFP-XRCC4. The coding sequence of the 
XRCC4 gene lies directly downstream of the EGFP coding sequence. Gene 
expression is driven through the CMV promotor. Map was drawn using 
SnapGene (4.1.4).  
Materials and methods 
61 
 
2.15.1 Analysis of DNA repair protein recruitment 
Registration of acquired movies was completed using StackReg plug-in 
(Thévenaz et al., 1998) for Fiji (Schindelin et al., 2012). Intensity 
measurements of the irradiated region (ROI 1), a non-damaged region (ROI 2) 
and background signal were taken for each frame using Fiji. Subsequent data 
analysis was completed in Matlab (R2017a) (see appendix 1.3 for custom 
Matlab script). In brief, average background signal (ROI 3) was subtracted 
from ROI 1 and ROI 2. Remaining figures were normalised to the average pre-
damaged intensity values. Finally, data from the irradiated region (ROI 1) was 
normalised to the non-damaged region (ROI 2), see Figure 2.4 for analysis 
workflow. Curves for each individual cell was defined as a ‘trace’.  
2.15.1.1 Determining recruitment kinetics.  
For each trace, a first order response curve 1 − exp⁡(−
𝑡
𝜏
) was fitted from the 
start of the trace to the smoothened maximum intensity (smoothened over a 
window of 30% of the data set); using the least sum of squares method. Using 
the curve fitting parameters, the time to 50% of the maximum intensity as 
well as the kinetic constant τ could be determined (Figure 2.5) 
(see appendix 1.4 for Matlab scripts). 
2.15.1.2 Determining rate of dissociation 
For each trace, an exponential decay curve 𝑦 = 𝑎𝑏𝑡 was fitted five datum after 
the smoothened maximum intensity, using the least sum of squares method. 
Traces with insufficient points for fitting were excluded from the analysis. 
Using the curve parameters, the rate of intensity loss as well as the time to 
50% loss could be determined (Figure 2.5) (see appendix 1.4 for Matlab 
scripts). 
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Figure 2.4: Protein recruitment analysis workflow. Custom Matlab scripts 
were used to perform background subtraction of raw intensity data followed 
by multiple normalisation steps to obtain finalised intensity data. Graphs 
are an example of data for a single cell. ROI 1 represents data from damage 
spot, ROI 2 is from non-damaged region, ROI 3 is background signal.  
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Figure 2.5: Example trace with curve fits. A first order response curve (first 
dashed orange line) was fitted to an example trace (blue dots = datum). 
Green intersecting line represents the determined time to 50 % of maximal 
smoothened intensity (black solid line). An exponential decay curve (second 
dashed orange line) was fitted to data after the maximal smoothened 
intensity. Green circles represent data used in exponential decay curve fit. 
Intersecting magenta line signifies the determined time at which the 
intensity is reduced by 50%.  
 
2.17 Statistical analysis 
Prism 7.0 was used for all statistical analysis unless otherwise stated. A 
significant threshold of p<0.05 was used to define statistical significance. 
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Chapter 3: The impact of hypoxia 
on treatment sensitivity and 
double strand break recognition 
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3.1 Introduction 
Patients presenting with hypoxic tumours have a poor prognosis, in part due 
to the chemo- and radio-resistant phenotype of these tumours. The tortuous 
vasculature of solid tumours makes drug delivery to the whole cell population 
challenging. Yet, the tumour microenvironment itself can have a direct impact 
on drug efficacy as well as causing cellular adaptations that lead to acquired 
resistance.  
A number of chemotherapeutic agents require oxygen to function efficiently. 
For example, bleomycin is less effective in a low oxygen environment due to 
reduced production of reactive oxygen species (Cunningham et al., 1984). 
Additionally, drugs that require cells to be actively cycling can be rendered 
ineffective due to hypoxia-induced cell cycle arrest (Amellem and Pettersen, 
1991; Gardner et al., 2001). Radioresistance in hypoxia can be attributed to 
reduced free radical production. Irradiating in a normal oxygen environment 
causes exposed ends of broken DNA to react with oxygen creating stable 
organic peroxides, which are less easily repaired. This is known as the oxygen 
enhancement effect (Chapman et al., 1973). However, in hypoxia, less oxygen 
is available to react with the ends of DNA, therefore repair of DNA damage is 
more effective. Overall, hypoxia can have a direct impact on the efficacy of 
both chemotherapeutic agents and radiotherapy.   
Acquired resistance in tumour cells can occur due to hypoxia-induced cellular 
adaptations. For example, hypoxia can upregulate multi-drug resistance genes, 
such as MDR-1 and MRP-1 (Comerford et al., 2002; Wartenbert et al., 2003; Lv 
et al., 2015). Also, hypoxia-induced upregulation of Pim-1, a regulator of 
apoptosis, results in resistance to cisplatin (J. Chen et al., 2009). Although 
numerous cellular adaptions have been attributed to hypoxia-induced 
resistance, these are often tumour type specific. For example, upregulation of 
the MDR-1 gene by hypoxia was not observed in D283-MED cells, a common 
medulloblastoma cell line (Fan, 2014). Therefore, further investigations are 
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needed to fully understand acquired resistance in hypoxic medulloblastoma 
(MB) and glioblastoma (GBM).  
Current treatment protocols for MB and GBM involve the use of DNA 
damaging agents. For example, temozolomide, the primary drug used against 
GBM, is an alkylating agent. TMZ treatment creates highly toxic 
O6-methylguanine DNA lesions which trigger apoptosis (Roos et al., 2007). 
Whereas for MB, cisplatin and cyclophosphamide, can crosslink DNA. 
Radiotherapy, the cornerstone of GBM and MB treatment, results in multiple 
types of DNA lesions including oxidative bases, single strand breaks and 
double strand breaks. DNA DSB are highly lethal as an individual DSB can 
cause cell death (Bennett et al., 1993). However, DSB can be repaired by non-
homologous end joining (NHEJ) and homologous recombination repair (HRR) 
(Takata et al., 1998). The choice between these repair mechanisms is 
dependent on the cell cycle, with HRR occurring in G2 and S phase when 
homologous DNA is present, yet NHEJ predominates in G0 and G1. 
Acknowledgement of the presence of a double strand break is essential for the 
repair process and activation of the DNA damage response (DDR). The 
principle DSB sensor in HRR is the MRN complex composed of meiotic 
recombination 11 homolog A (MRE11A), RAD50 homolog (RAD50), and Nibrin 
(NBN or NBS-1). Upon DSB recognition, NBN’s primary role is to recruit 
Ataxia Telangiectasia Mutated (ATM) to the damage site (Lukas et al., 2003; 
Falck et al., 2005; You et al., 2005). ATM phosphorylates key proteins 
involved in DNA repair, checkpoint control and apoptosis (You et al., 2005). If 
the level of DNA damage is too high, phosphorylation of p53 directly or 
indirectly via ATM occurs leading to the transcription of pro-apoptotic genes 
and the induction of apoptosis (Banin et al., 1998; Canman et al., 1998; Epstein 
et al., 2001; Turenne et al., 2001; Saito et al., 2002). Overall, initial recognition 
of a DSB break is an essential step necessary to trigger downstream signalling 
in the response to DNA damage.   
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Previous work in the Sée lab found that, Nibrin (NBN), a key component of 
the MRN complex, is downregulated in hypoxic D283-MED cells (Fan, 2014). 
It was hypothesised that this downregulation caused reduced detection of DSB 
leading to a dampening of downstream damage signalling. This lead to a 
reduction in p53 stabilisation and activity. Consequently, the hypoxic 
D283-MB cells were less sensitive to the DNA damaging agent, etoposide (Fan, 
2014). The current study aimed to explore this further and to determine 
whether this mechanism of acquired resistance, involving downregulation 
ofMRN complex in hypoxia, is universal, occurring in other MB cell lines and 
GBM cell lines. 
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3.2 Objectives 
The experimental aims for this chapter were as follows:  
1. Determine the effect of hypoxia on sensitivity to common DNA 
damaging agents used in the clinic for MB and GBM. 
2. Examine the expression of the main components of the MRN complex 
(MRE11/RAD50/NBN) under hypoxia.  
3. Assess the impact of hypoxia on the upstream regulator ATM, a key 
signal transducer in the response to double strand breaks.  
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3.3 Observations of Fan 2014 
Previous work by Fan 2014, exploring the impact of hypoxia on MB observed 
the following in hypoxic D283-MED cells: 
1. Resistance to etoposide. 
2. Downregulation of NBN (mRNA + Protein) and MRE11 (mRNA). 
3. Reduced induction of γH2AX after etoposide treatment.  
4. Reduced p53 stability and activity after etoposide treatment. 
The aim of the current chapter was to build on the work of Fan 2014, with a 
particular focus on the following questions: 
1. Do hypoxic D283-MED cells display altered sensitivity to other 
common cancer treatments? 
2. Is the observed resistance to etoposide in hypoxia as a result of reduced 
DNA damage signalling as suggested by Fan 2014? 
3. Are these findings universal across other brain tumour cell lines? 
 
Work from both Fan 2014 and the data presented in the current chapter 
contributed to the production of a publication:  
Decrease of Nibrin expression in chronic hypoxia is associated with 
hypoxia-induced chemoresistance in medulloblastoma cells. 
Sophie Cowman, Yuen Ngen Fan, Barry Pizer, Violaine See. 2018 Under review 
in BMC Cancer 
(pre-print: https://www.biorxiv.org/content/early/2017/11/30/227207) 
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3.4 Results 
3.4.1 Exploring hypoxia-induced treatment resistance in MB and GBM 
Treatment resistance is a common characteristic of hypoxic brain tumours. 
Fan 2014 determined that chronic hypoxic exposure in D283-MED (MB cells) 
resulted in resistance to etoposide, a chemotherapeutic agent used to treat 
many cancers including medulloblastoma, neuroblastoma, lung cancer and 
testicular cancer. Here, sensitivity to several anti-cancer therapies under 
normoxic (21% O2) and hypoxic (1% O2) environments was examined in MB 
(D283-MED, MEB-Med8A) and GBM cell lines (U87-MG, U251-MG, 
D566-MG). Experiments were conducted as described in Figure 3.1 unless 
otherwise stated.  
 
Figure 3.1: Schematic of experimental protocol for treatment sensitivity 
experiments. (A) Cells that were pre-incubated in 1% O2 remained in 
hypoxia throughout treatment yet viability was assayed in normoxia. 
(B) Cells that were pre-incubated in 21% O2 remained in normoxia during 
treatment and viability assay. All hypoxic and normoxic experiments were 
performed in parallel.  
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3.4.1.1 Temozolomide is ineffective for inducing U87-MG cell-death in 
vitro 
The DNA alkylating agent, temozolomide (TMZ), is the primary drug used to 
treat GBM in the clinic. Therefore, determining its effectiveness in vitro in 
different oxygen conditions was essential. Unlike its close relative, 
decarbazine, TMZ does not require metabolic activation, and therefore can 
methylate DNA at physiological pH (Stevens et al., 1987; Brada et al., 1999). 
The classical GBM cells line, U87-MG, along with the MB cell line, D283-MED 
were assessed for their response to TMZ.  
TMZ has a short half-life (~2 h); therefore, repeated doses were applied to 
U87-MG cells. This was not possible for D283-MED as they are in suspension, 
meaning repeated doses would result in a build-up of toxic DMSO. TMZ had 
little impact on the viability of U87-MG cells, even with long-term drug 
exposure (96 h) (Figure 3.2 A, B). Similarly, for D283-MED, sensitivity to TMZ 
was minimal (Figure 3.2 C, D, E). However, after 72 h and two doses of TMZ 
(200 µM each), viability decreased to 44%, indicating that TMZ can effectively 
impact viability for this cell line, yet high doses and long treatment times are 
required (Figure 3.2 E).  
Serum in cell medium can influence the effectiveness of alkylating agents. To 
understand whether serum removal would improve the ability of TMZ to 
induce cell death, U87-MG cells were treated with a 200 µM dose of TMZ for 
2 h in serum free medium, before a further 72 h incubation in complete 
medium. Similar to previous experiments, viability of U87-MG cells was not 
impacted by TMZ, with 96% cells remaining viable (data not shown). In order 
for TMZ to be effective, the methylguanine transferase enzyme (MGMT) must 
be silenced by methylation. In U87-MG cells, MGMT is indeed silenced (Qiu 
et al., 2014), therefore this lack of effectiveness of TMZ cannot be explained by 
the MGMT status of the cells. However, previous publications have 
documented the minimal impact of TMZ on U87-MG viability, and the need 
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for strong doses (up to 2 mM) and long drug exposure (>6 days) to observe 
cell death (Castro et al., 2015; Akbarnejad et al., 2017; Borhani et al., 2017).  
Taken together, TMZ was ineffective for in vitro assays performed with 
U87-MG cells, shown by the high level of viable cells after treatment. 
D283-MED were more sensitive to TMZ than U87-MG, yet a high dose and 
long incubation times are necessary to impact cell viability. Based on these 
results, TMZ was not used further in this work.  
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Figure 3.2: Temozolomide-induced cell death is limited in vitro. U87-MG 
cells were treated with 50-200 µM temozolomide for (A) 48 h and (B) 96 h 
with 1-2 doses daily. D283-MED were treated on day 1 with 50-200 µM 
temozolomide with a single dose or two doses. Cells were then incubated for 
(C) 24 h, (D) 48 h, (E) 72 h. Cell viability was determined using MTS assay 
with data normalised to DMSO control. Data for (A, B) represents the mean 
of two independent experiments with SEM, and a single experiment with SD 
for (C, D, E).  
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3.4.1.2 Etoposide sensitivity in hypoxic MB and GBM cells   
Previous studies determined that the classical MB cell line, D283-MED, 
displayed sensitivity to the topoisomerase II inhibitor, etoposide, which 
induces cell death via the p53 pathway (Meley et al., 2010). Pre-incubation of 
these cell in hypoxia for 5 days reduced sensitivity to etoposide (Fan, 2014). To 
explore this further, the impact of hypoxia on etoposide sensitivity was 
investigated in a range of MB and GBM cell lines.  
In line with the findings of Fan 2014, for D283-MED cells, pre-incubation in 
1% O2 for 5 days (chronic exposure) resulted in reduced sensitivity to 
etoposide treatment. For example, treatment with 20 µM etoposide in 
normoxic cells resulted in 26% viability whereas viability was 74% in hypoxic 
cells (p=0.003) (Figure 3.3 A). In contrast, acute hypoxic exposure (1 day) had 
little impact on etoposide sensitivity, with 23% and 26% viability in normoxia 
and hypoxia respectively with 20 µM etoposide. For the MB cell line, 
MEB-Med8A, pre-incubation in 1% O2 did not result in statistically significant 
alteration of cell viability compared to the normoxic control (Figure 3.3 B). 
Therefore, the reduced sensitivity to etoposide in hypoxia may be specific to 
the D283-MED cells.  
In comparison to MB cells, GBM cell lines were overall more resistant to 
etoposide as higher doses and longer treatment durations (48 - 72 h) were 
required to induce cell death (Figure 3.3 C, D). However, similar to 
D283-MED, pre-incubation in 1% O2 for 5 days resulted in reduced sensitivity 
to etoposide in U87-MG cells (Figure 3.3 C). After exposure to 20 µM 
etoposide for 72 h, U87-MG viability in normoxia was 39%, yet increased to 
67% for hypoxic cells (p=0.006) (Figure 3.3 C). Similar results were obtained 
for U251-MG cells, with 26% viability for normoxic cells compared to 36% for 
hypoxic cells (Figure 3.3 D) upon 50 µM etoposide for 48 h. In contrast, in 
D566-MG cells the sensitivity to etoposide was not altered by hypoxic 
incubation. (Figure 3.3 D).  
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Taken together, chronic hypoxic exposure reduced sensitivity to etoposide in 
the MB cell line D283-MED, and two GBM cell lines U87-MG and U251-MG. 
Acute hypoxic exposure (1 day) had less effect on etoposide sensitivity in 
comparison to chronic exposure (5 days).  
 
Figure 3.3: Sensitivity to etoposide in chronic and acute hypoxia.                
(A) D283-MED, (B) MEB-Med8A and (C) U87-MG cells were pre-incubated 
in 1% O2 or 21% O2 for 1 day or 5 days before treatment with 20-100 µM 
etoposide. (D) D566-MG and U251-MG were pre-incubated in 1% O2 or 21% 
O2 for 5 days before treatment with 50 µM etoposide. Cell viability was 
assayed with MTS assay 24 h (D283-MED), 48 h (MEB-Med8A, D566-MG, 
U251-MG) or 72 h (U87-MG) post-treatment. Absorbance values were 
normalised to DMSO control. Data is representative of the mean of at least 
three independent experiments. Error bars represent S.E.M. * denotes 
significant data where p<0.05 indicated by student t-test.  
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3.4.1.3 Cisplatin sensitivity in hypoxic MB and GBM cells   
Cisplatin is a platinum-based chemotherapeutic agent used to treat MB as well 
as other cancers such as testicular, ovarian, cervical and breast cancers. This 
DNA damaging agent creates interstrand crosslinks that can result in the 
formation of double strand breaks leading to apoptosis (Barry et al., 1990).  
Previous studies have determined that hypoxia can induce resistance to 
cisplatin in non-small cell lung cancer (Song et al., 2006; Wohlkoenig et al., 
2011; Shin et al., 2014), therefore this concept was explored in GBM and MB 
cell lines.  
D283-MED, MEB-Med8A and U87-MG cells were pre-incubated in 21% or 
1% O2 for 5 days before treatment with cisplatin (Figure 3.4). In D283-MED 
cells, there was a general trend of increased viability in cells pre-cultured in 
hypoxia, in comparison to those in normoxia. However, this did not reach 
statistical significance (Figure 3.4 A). For MEB-Med8A cells, hypoxic pre-
incubation resulted in statistically significant reduction in sensitivity to 
cisplatin, with 36% and 55% viability in normoxic and hypoxia cells 
respectively after 5 µg/ml cisplatin treatment (p=0.02) (Figure 3.4 B). For the 
GBM cell line, U87-MG, reduced sensitivity to cisplatin in hypoxic cells was 
observed, yet to a lesser extent compared to MEB-Med8A cells (Figure 3.4 C).   
Overall, hypoxia globally reduced the sensitivity to cisplatin in all cell lines 
tested. This correlates with previous findings in the literature. In non-small 
cell lung cancer, hypoxia-induced cisplatin resistance is thought to be 
mediated through SIRT and AMPK (Shin et al., 2014). Whether the same 
mechanism is occurring in MB and GBM cell lines would require further 
exploration.  
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Figure 3.4: Cisplatin sensitivity in hypoxia. (A) D283-MED, (B) MEB-Med8A 
and (C) U87-MG cells were pre-incubated in 1% or 21% O2 for 5 days, before 
treatment with cisplatin. Cells were assayed for viability 48 h after 
treatment using MTS assays. Absorbance values were normalised to DMSO 
control and data is representative of the mean of three independent 
experiments. Error bars show S.E.M. * denotes significant data where 
p<0.05 indicated by student t-test. 
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3.4.1.4 Hypoxia and phleomycin sensitivity 
Phleomycin, a glycol-peptide antibiotic, can directly induce DNA double 
strand breaks (Sleigh., 1976). Phleomycin is not currently used clinically, yet 
the closely related compound, bleomycin is utilised for the treatment of 
testicular cancer and ovarian cancer. General resistance to bleomycin is 
thought to be attributed to a number of cellular adaptation such as the 
enhanced repair of bleomycin induced DNA damage (Tuimala et al., 2002). 
Whether hypoxia-induced cellular adaptions contribute to bleomycin or 
phleomycin resistance has not yet been explored. 
To determine whether hypoxia could affect sensitivity to phleomycin in GBM, 
U87-MG cells were pre-incubated in 21% or 1% O2 prior to phleomycin 
treatment. The cells remained in their respective O2 condition throughout the 
treatment duration before assaying viability, as previously done with etoposide 
and cisplatin (Figure 3.5 A, C). The U87-MG cells were sensitive to phleomycin 
treatment shown by the ~39% viability in normoxia. However, phleomycin 
was not effective in hypoxia (100% viability) (Figure 3.5 C). Molecular oxygen 
is required for the production of reactive oxygen species by phleomycin 
(Sleigh., 1976), which explains the lack of  activity in hypoxia. To combat this, 
U87-MG cells and D283-MED cells were pre-incubated in 21% or 1% O2 for 
5 days but treated in 21% O2 (Figure 3.5 B). Similar viability was observed 
U87-MG cells irrespective of pre-incubation in hypoxia (Figure 3.5 B). In 
contrast, for D283-MED reduced viability in hypoxic cells (48%) was observed 
in comparison to normoxia (58%) (Figure 3.5 C), yet this was not statistically 
significant (p=0.20). 
In summary, for U87-MG and D283-MED cells, pre-incubation in hypoxia 
does not significantly reduce sensitivity to phleomycin. Due to the 
re-oxygenation step, any hypoxia-induced adaptions may be lost. From a 
clinical perspective, the use of phleomycin against hypoxic tumours would 
likely be ineffective due to a lack of activity.  
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Figure 3.5: Pre-incubation in hypoxia does not influence sensitivity to 
phleomycin. (A, B) Schematic of experimental procedure. (C, D) U87-MG 
and (E) D283-MED cells were pre-incubated in 1% or 21% O2 for 5 days, 
before treatment with phleomycin either in (C) hypoxic conditions for 
U87-MG (50µg/ml) or (D, E) in normoxia for U87-MG (50 µg/ml) and 
D283-MED (40 µg/ml). Cell viability was determined after 72 h treatment 
using MTS assay, where absorbance values were normalised to untreated 
control. Data in (C) is a single experiment, (D, E) is representative of the 
mean for three independent experiments, with error bars indicating S.E.M. * 
denotes significant data where p<0.05 indicated by student t-test. 
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3.4.1.5 X-ray irradiation sensitivity in hypoxic MB and GBM cells 
Resistance to radiotherapy is a common characteristic of hypoxic tumours, 
shown by countless studies in vitro and in a clinical setting. Treatment of MB 
and GBM relies heavily on RT, therefore it is important to understand whether 
hypoxic MB and GBM present a resistance phenotype. To address this, GBM 
and MB cells were pre-incubated for 5 days in 21% or 1% O2 before irradiating 
in a normoxic environment. Subsequently, cells were returned to their 
respective oxygen environment for 48 h before assaying cell viability 
(Figure 3.6 A). Irradiating in normoxia enables the examination of acquired 
resistance rather than resistance due to reduced effectiveness of radiotherapy 
in a low oxygen environment.  
Preliminary experiments were preformed to establish the adequate dose of 
X-ray irradiation in order to induce cell death (data not shown). GBM cells 
were less sensitive to irradiation compared to MB cells, as they required a 
significantly higher doses (~80Gy), yet 30-40 Gy was sufficient for MB cells. 
This reduced sensitivity of GBM cells to anti-cancer treatments was previously 
observed with etoposide and correlates with the poor treatment response of 
GBM in the clinic.  
Hypoxic D283-MED cells were less sensitive to X-ray irradiation, with 29% cell 
viability in normoxic cells compared to 38% in hypoxic cells (Figure 3.6 A). 
However, this was not statistically significant, likely due to the high variability 
in the data. In contrast, for MEB-Med8A cells, a reverse trend was observed 
with higher viability in normoxic cells (Figure 3.6 A). However, these cells 
were stressed during the irradiation procedure (cooling, transportation etc.), 
which caused highly variable data, thus the observed trends are hard to 
interpret. Similar to D283-MED cells, hypoxic U87-MG were less sensitive to 
X-ray irradiation, with 23% and 36% cell viability for hypoxia and normoxia 
respectively (p=0.03) (Figure 3.6 B). The same trend was also observed in 
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D566-MG cells, yet with no statistical significance. In contrast, hypoxia did 
not impact X-ray irradiation sensitivity in U251-MG (Figure 3.6 B).  
In summary, pre-incubation in hypoxia resulted in reduced sensitivity to X-ray 
irradiation in D283-MED, U87-MG and D566-MG cells. However, hypoxic 
U251-MG cells responded similar to normoxic cells.  
 
Figure 3.6: Sensitivity to X-ray irradiation in chronic hypoxia. (A) schematic 
detailing the experimental procedure for hypoxic cells. (B) MB cells and (C) 
GBM cells were pre-incubated in 1% O2 or 21% O2 for 5 days before 
irradiation in 21% O2 with 30 Gy D283-MED, 40 Gy MEB-Med8A, 80 Gy 
U251-MG and D566-MG, two doses 80 Gy U87-MG. Cells were assayed for 
viability with MTS assay 48 h after treatment, absorbance values were 
normalised to DMSO control. Data are the mean of at least three 
independent experiments, with exception of MEB-Med8A n = 2. Error bars 
represent S.E.M. * denotes significant data where p<0.05 indicated by 
student t-test.  
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3.4.1.6 Exploration of alternative cell survival assays 
The MTS/MTT assay is widely used for the determination of drug sensitivity. 
This method relies on metabolic activity of cells, resulting in the reduction of a 
tetrazolium compound to a coloured formazan product (Berridge and Tan, 
1993), where the number of viable cells is proportional to absorbance. Benefits 
of this assay include ease of use, suitability for many cell lines and high-
throughput drug testing. However, the MTS assay may not be a good indicator 
of cell survival, as senescent cells are measured as metabolically active even 
though these cells would not proliferate and generate future cell populations. 
Alternative methods to determine cell viability include crystal violet (CV) 
proliferation assays and clonogenic assays. For the classical GBM cell line, 
U87-MG, pre-incubation in hypoxia results in reduced sensitivity to etoposide 
(Figure 3.3 C), therefore to complement this study, U87-MG cells were used 
CV proliferation assays to compare with the MTS assay results. Additionally, 
preliminary experiments were conducted to test the suitability of U87-MG in 
the clonogenic assay; however, these cells formed overlapping colonies, which 
were difficult to count. Therefore, optimisation and investigation of analysis 
methods would be required if the clonogenic was used further.   
The crystal violet (CV) proliferation assays is based on the proliferation rate of 
cells. In summary, cells are seeded at a low density followed by treatment with 
a cytotoxic agent. Cells are then left to grow for 5 -7 days in fresh medium 
before staining with crystal violet. Unlike the clonogenic assay, colonies are 
not counted, but instead the CV is solubilised and optical density measured. 
As colony formation is not a requirement, cells unsuitable for the clonogenic 
assay can be utilised in the CV proliferation assay. However, in comparison to 
the MTS assay, it can be time consuming (up to 7 days) and does not allow for 
the assessment of multiple cell lines and cytotoxic agents in parallel.  
To determine whether reduced sensitivity to etoposide was observed in 
hypoxic U87-MG cells with the CV proliferation assay, cells were pre-
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incubated in 1% or 21% O2 before treating with etoposide (24 h) and 
measuring CV absorbance 5 days post-treatment. Similar to the clonogenic 
assay, low doses of etoposide were sufficient to induce cell death (Figure 3.7). 
Additionally, it appears that pre-incubation in hypoxia results in increased cell 
survival after etoposide treatment (Figure 3.7), a similar finding to the MTS 
assay. However, experimental data was highly variable shown by the large 
error bars, potentially due to variations in staining efficiency.  
Overall, the proliferation assay confirmed the MTS data obtained in normoxic 
and hypoxic U87-MG cells treated with etoposide. However, given the low 
throughput and time consuming nature of this assay, a low number of 
biological repeats were obtained.  
 
 
 
 
 
 
 
 
Figure 3.7: Sensitivity to etoposide in hypoxia shown by CV proliferation 
assay. Cells were pre-incubated in 21% or 1% O2 prior to treatment with 1-5 
µM etoposide for 24 h. Cells were then left to grow for 5 days before staining 
with crystal violet, which was then dissolved in 10%  SDS. Absorbance was 
measured at 595 nm and normalised to untreated control. Data represent 
two independent experiments. Error bars represent S.E.M.  
 
E to p o s id e  ( M )
C
e
ll
 s
u
r
v
iv
a
l
n
o
r
m
a
li
s
e
d
 t
o
 D
M
S
O
 c
o
n
tr
o
l 
(%
)
1 3 5
0
5 0
1 0 0
1 5 0
2 1 %  O 2 1 %  O 2
The impact of hypoxia on treatment sensitivity and DSB recognition 
84 
 
3.4.1.7 Summary of hypoxia and treatment sensitivity results 
Hypoxia-induced treatment resistance is highly problematic from a clinical 
perspective. Here, the impact of hypoxia on the sensitivity to a number of 
common cancer treatments was explored for multiple MB and GBM cell lines 
(Table 3.1). Chronic exposure to 1% O2 resulted in reduced sensitivity to 
etoposide, cisplatin and irradiation for a number of cell lines. In particular, 
D283-MED and U87-MG cells exhibited the greatest reduction in treatment 
sensitivity after hypoxic exposure.  
The agents tested here caused different types of DNA damage. Nevertheless, 
DNA damage such as interstrand crosslinks for example, can lead to DSB, the 
most toxic damage type. Often, DSB arise due to the stalling and collapse of 
replication forks, which occurs when the replication machinery encounters 
damage such as a crosslink. Microarray analysis by Fan 2014, identified that 
the MRN complex, responsible for initial recognition of double strand breaks, 
was downregulated in hypoxic D283-MED cells. It was hypothesised that this 
could contribute to hypoxia-induced reduction in etoposide sensitivity. 
Therefore, to understand whether changes to MRN could induce the hypoxia-
related resistance identified here, the level of MRN as well as other DNA 
damage response proteins were assessed.  
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Table 3.1: Summary of reduced sensitivities in hypoxia  observations in MB 
and GBM cell lines. Light blue ticks denote statistically significant results.  
 Reduced sensitivity in hypoxia? 
Cell Line Etoposide  Cisplatin Phleomycin 
X-ray 
Irradiation 
D283-MED       
MEB-Med8A   N/A  
U87-MG     
U251-MG  N/A N/A  
D566-MG  N/A N/A  
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3.4.2 Downregulation of the double strand break recognition complex 
in hypoxic MB cells  
The MRN complex composed of MRE11, RAD50, and NBN, is responsible for 
the recognition of double strand breaks. Previous studies determined that 
hypoxic exposure results in the downregulation of NBN (To et al., 2006; Fan, 
2014). Specifically, Fan 2014 observed reduced expression of both NBN and 
MRE11 in hypoxic D283-MED cells. This observation was to be confirmed in 
D283-MED and explored in other MB and GBM cell lines. 
3.4.2.1 NBN and MRE11 gene expression in hypoxic MB and GBM cells  
RT-PCR was utilised to determine the mRNA level of MRE11, RAD50, NBN, in 
MB and GBM cells incubated in 21% or 1% O2 for 5 days. Similar to Fan 2014, 
hypoxia caused a 2.3-fold (-1.2 log2) downregulation of NBN and MRE11 in 
D283-MED (Figure 3.8 A), yet there was little impact on RAD50. In 
MEB-Med8A cells there was no significant change in expression of either NBN, 
MRE11 or RAD50, indicating that downregulation of NBN and MRE11 is not a 
general phenomenon across all MB cells. Additionally, there was no change in 
expression levels of the MRN components in U87-MG or U251-MG upon 
hypoxic exposure (Figure 3.8 B). Whilst the downregulation of NBN in 
D566-MG was statistically significant (Figure 3.8 B), the fold reduction was 
small (1.6-fold) with potentially little functional impact. 
To understand whether the reduced levels in MRN are specific to chronic 
hypoxia (5 days), D283-MED cells were pre-incubated in 21% or 1% O2 for 6-
96 h. The chosen time points correlate with peaks of HIF accumulation in 
long-term hypoxia (Fan 2014). Short hypoxic exposure (6 h) had no impact on 
the expression of NBN, MRE11 or RAD50 yet from 24 h onwards significant 
downregulation of NBN and MRE11 occurred. At later time points (>48 h) the 
strongest downregulation was observed (4.5-fold NBN, 3.2-fold MRE11) 
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(Figure 3.9 A). Interestingly, at 48 h hypoxic exposure RAD50 was 
downregulated 2-fold (-1 log2), yet this was not statistically significant.  
Additionally, U87-MG cells were also subjected to 1% O2 for 6-96 h and the 
levels of NBN, MRE11 and RAD50 assessed. Although no downregulation of the 
MRN complex was observed at 5 days hypoxic exposure (Figure 3.8 B), 
changes may occur at earlier time points, which could contribute to the 
hypoxia-induced reduction in sensitivity to DNA damaging agents previously 
identified. The expression level of all three components of the MRN complex 
was highly variable, and the observed changes did not reach the 2-fold 
threshold for RT-PCR sensitivity (Figure 3.9 B). Therefore, regardless exposure 
time, hypoxic incubation did not significantly affect gene expression of the 
MRN complex in U87-MG cells.  
Taken together, this data corroborates data of Fan 2014, whereby the 
expression of NBN and MRE11, key components of the MRN complex are 
downregulated by hypoxia in D283-MED cells. This downregulation appears 
to require long hypoxic exposure (>48 h), which could explain why reduced 
etoposide sensitivity is not observed after 24 h of hypoxic exposure.  
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Figure 3.8: NBN and MRE11 mRNA levels in chronic hypoxia. (A) MB cells 
and (B) GBM cells were incubated in 1% or 21% O2 for 5 days. After 
incubation, RNA was extracted and converted to cDNA for RT-PCR 
experiments, probing for NBN, MRE11 and RAD50. Data is represented as 
log2 fold change in mRNA levels with respect to level for 21% O2 samples. 
Data are representative of the mean for at least three independent 
experiments, with error bars showing S.E.M. * denotes significant data 
where p<0.05 indicated by one-way student t-test. 
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Figure 3.9: NBN and MRE11 mRNA levels over time in hypoxia. (A) D283-
MED and (B) U87-MG cells were incubated in 1% or 21% O2 for 6-96 h. After 
incubation, RNA was extracted and converted to cDNA for RT-PCR 
experiments, probing for NBN, MRE11 and RAD50. Data is represented as 
log2 fold change in mRNA levels with respect to level for 21% O2 samples. 
Data are representative of the mean for at least three independent 
experiments, with error bars showing S.E.M. * denotes significant data 
where p<0.05 indicated by one-way student t-test. 
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3.4.2.2 NBN and MRE11 protein levels in hypoxic MB and GBM cells  
Chronic hypoxic exposure resulted in downregulation of NBN and MRE11 
mRNA in D283-MED cells. To confirm these hypoxia-induced changes 
translate to the protein level, western blotting was performed. Similar to the 
RT-PCR data, there was a ~2-fold downregulation of both MRE11 and NBN in 
hypoxic D283-MED cells (Figure 3.11 A, B). For each experimental condition, 
25-30 µg of protein was loaded equally per sample as determined by BCA assay 
(see Figure 3.10 for example calculations for the BCA assay). Additionally, after 
protein transfer, membranes were stained with Ponceau to ensure the amount 
of protein from each sample was similar, and the transfer was even (data not 
shown). However, downregulation of β actin was observed, which is unlikely 
due to uneven loading. The level of other common housekeeping genes, 
cyclophilin A and Histone2B, were tested, and were all regulated by hypoxia 
similar to β actin (data not shown), specifically in the D283-MED cells. 
Therefore, for quantification, intensity was not normalised to the loading 
control in this cell line. Further explanation of housekeeping protein 
regulation by hypoxia can be found on p102. 
Hypoxia can result in direct changes to DNA repair protein levels through 
regulation of translation (reviewed in Scanlon and Glazer, 2015), therefore 
both MEB-Med8A and GBM cells were included in western blotting 
experiments for NBN and MRE11. However, in line with the RT-PCR results, 
there was no significant downregulation in NBN or MRE11 in these cell lines 
(Figure 3.11, Figure 3.12), with the exception of a small change in MRE11 in 
hypoxic U251-MG (Figure 3.12 B).  
Overall, significant downregulation of both NBN and MRE11 was observed in 
D283-MED cells, similar to the RT-PCR data. This correlates with the findings 
of Fan 2014, who determined that NBN (mRNA, protein) and MRE11 (mRNA) 
were downregulated by hypoxia (Fan, 2014).  
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Figure 3.10: Example BCA assay of D283-MED cells. Protein was collected 
from D283-MED cells incubated in 21% or 1% O2 for 5 days. (A) A standard 
curve was produced using a BCA assay and bovine serum albumin at 
0-1.5 μg/μl. B) Using the standard curve, the stock concentration of 
D283-MED protein samples was determined, and the volume required for 
25 μg was calculated. This ensured that an equal amount of protein was 
loaded into a western blot for each sample.   
 
A 
B 
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Figure 3.11: NBN and MRE11 protein levels in hypoxic MB cells. D283-MED 
and MEB-Med8A cells were incubated in 1% or 21% O2 for 5 days before 
protein extraction. (A) Levels of NBN and MRE11 were determined by 
western blotting. (B) Densitometry was measured using Image J.  Data 
represent the mean of at least three independent experiments, with error 
bars indicating S.E.M. * denotes significant data where p<0.05 indicated by 
one way student t-test.  
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Figure 3.12: NBN and MRE11 protein levels in hypoxic GBM cells. U87-MG, 
U251-MG and D566-MG cells were incubated in 1% or 21% O2 for 5 days 
before protein extraction. (A) Levels of NBN and MRE11 were determined by 
western blotting. (B) Densitometry was measured using Image J. Data 
represent the mean of at least three independent experiments, with error 
bars indicating S.E.M. * denotes significant data where p<0.05 indicated by 
one way student t-test. 
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3.4.3 Assessing DNA damage signal transduction in hypoxia 
Upon double strand break recognition, ATM is recruited and activated at the 
damage site. The primary role of ATM is to transduce the damage signal via 
multiple targets including γH2AX, which can be used as an indicator of double 
strand breaks. To further understand how the DNA damage machinery is 
affected by hypoxia, the impact of the impact of hypoxia on both γH2AX and 
ATM was explored further.  
3.4.3.1 Increased ɣH2AX in hypoxic U87-MG after long exposure to 
etoposide  
Fan 2014 previously observed reduced γH2AX in hypoxic D283-MED cells 
(Figure 3.13). This could be explained by 1) etoposide being less effective in 
hypoxia resulting in reduced γH2AX signal. 2) downregulation of the MRN 
complex could reduce transduction of the damage signal leading to less H2AX 
phosphorylation. To explore these two possibilities further, the level of γH2AX 
after etoposide treatment was assessed in U87-MG cells, which did not exhibit 
reduced MRN expression in hypoxia.  
U87-MG cells were pre-incubated in 21% or 1% O2 for 5 days before treatment 
with etoposide and γH2AX levels were measured using immunocytochemistry. 
Interestingly, the γH2AX signal after etoposide treatment appeared somewhat 
pan nuclear with small foci. This unexpected patterning was not due to 
problematic antibody specificity, as with other cells (D283-MED, HeLa) 
classical foci formation was observed. Therefore, pan nuclear γH2AX is a 
feature specific to U87-MG, and could imply a high level of DSB. After 
15-30 min of etoposide treatment, the levels of γH2AX were similar in hypoxic 
and normoxic U87-MG, suggesting that etoposide is able to induce DSB 
regardless the oxygen environment and preconditioning (Figure 3.14). At later 
time points, there was a general tendency for increased γH2AX in hypoxic 
etoposide-treated cells. For example, after 360 min, a 3.6-fold increase in 
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γH2AX was observed in normoxic cells, compared to 12.0-fold in hypoxic cells 
(Figure 3.14 C). Throughout the treatment period, DNA repair mechanisms 
will be actively repairing the DSB present resulting in loss γH2AX, therefore 
increased γH2AX in hypoxia could be due to reduced effectiveness of repair in 
hypoxia. Residual γH2AX in hypoxia after DNA damage has previously been 
reported (Kumareswaran et al., 2012). The effectiveness of DSB repair in GBM 
cells will be explored further in Chapter 5. Interestingly, a number of reports 
suggest that hypoxia alone results in the phosphorylation of H2AX 
(Hammond, Dorie, et al., 2003; Bencokova et al., 2009; Harding et al., 2011), 
however, this was not the case here, as there was minimal γH2AX staining in 
untreated hypoxic cells (Figure 3.14 B). A possible explanation for this is that 
previous studies utilised serve hypoxia (<0.1%), compared to the mild hypoxia 
(1%) used here.  
Overall, residual γH2AX was observed in hypoxic U87-MG cells after long 
exposure to etoposide. This is in contrast to hypoxic D283-MED cells where 
γH2AX was reduced (Fan, 2014). The hypoxia-induced downregulation of the 
MRN complex in D283-MED may impact the DNA damage signalling cascade 
resulting in reduced γH2AX. To explore this concept further, the impact of 
hypoxia on ATM activation needed to be addressed.  
 
 
 
 
Figure 3.13: γH2AX levels in hypoxic and normoxic D283-MED after 
etoposide treatment observed by Fan 2014. D283-MED cells were 
pre-incubated in 21% O2 and 1% O2 for 5 days prior to etoposide treatment 
and staining for γH2AX. Signal intensity was measured for >350 cells. Data 
represent mean and S.E.M. Figure taken directly from Fan 2014.  
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Figure 3.14: γH2AX levels in hypoxic and normoxic U87-MG after etoposide 
treatment. U87-MG cells were incubated in (A) 21% O2 or (B) 1% O2 prior to 
treating with 100 µM etoposide for 0-360 min. Cells were fixed and 
subjected to immunocytochemistry for γH2AX. (C) Intensity measurements 
were taken using Image J. Data are represented as intensity fold change 
with respect to untreated control. Figure depicts mean of at least three 
independent experiments with error bars representing S.E.M. >200 cells 
were analysed per experimental condition. * denotes significant data where 
p<0.05 indicated by student t-test 
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3.4.3.2 ATM activation in hypoxic MB and GBM cells 
In order to determine the appropriate etoposide treatment duration to observe 
sufficient ATM activation, U87-MG cells were treated with 100 µM etoposide 
for 0 – 24 h, and the level of ATM and ATMSer1981 was assessed (Figure 3.15). 
U87-MG cells were utilised here as their culture requirements are less complex 
compared to D283-MED (faster growing, do not require large cell amounts of 
cells to obtain adequate protein), meaning that multiple samples for a range of 
time points could be readily produced. The level of ATM remained relatively 
stable regardless of treatment duration (Figure 3.15 A, C). 1 h of etoposide 
resulted in the accumulation of ATMSer1981, which plateaued after 2 h 
(Figure 3.15 B, C). For further experiments, a 4 h treatment duration was 
chosen to detect ATMSer1981 changes. Longer exposure may have negative 
effects on the health of the cells, yet accumulation at earlier time points was 
more variable, shown by repeated experiments.  
The level of ATM and ATMSer1981 was determined for MB and GBM cell lines 
incubated in normoxia as well as moderate (1% O2) and severe (0.1% O2) 
hypoxia. Severe hypoxia was included here as others suggest that in extreme 
hypoxia, ATM can be activated without DNA damage induction. Treatment of 
cells pre-incubated in 0.1% O2 was done in normoxia to ensure that severe 
hypoxia did not impact etoposide efficacy. However, a ‘control’ sample was 
included, which remained in 0.1% O2, to determine whether severe hypoxic 
exposure could indeed induce ATM activation. For the D283-MED cells, there 
was a clear downregulation of ATM in 1% O2 (Figure 3.16 A), which 
strengthened with increased hypoxia severity (Figure 3.17 A). In addition, the 
levels of ATMSer1981 was downregulated to a similar extent (Figure 3.16 A, 
Figure 3.17 B). Whether this downregulation of ATMSer1981 is due to reduced 
DNA damage signalling or reduced total ATM protein cannot be determined 
here. However, the reduced ATMSer1981 in hypoxia may explain the decrease 
in γH2AX signal in this cell line. In contrast, MEB-Med8A, cells had a small 
reduction in ATM protein at 0.1% O2 (Figure 3.17 B), but not at 1%, nor was 
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there any impact of hypoxia on ATMSer1981 (Figure 3.16 B). Additionally, in all 
GBM cells examined both moderate and severe hypoxia did not affect the level 
of ATM or ATMSer1981 (Figure 3.18, appendix 1.5 & 1.6). Therefore, the signal 
transduction via ATM is unlikely to be affected by hypoxia in GBM cells.  
In all the MB and GBM cell lines examined here, 0.1% O2 alone did not induce 
ATM activation, nor did reoxygenation induce ATM activation 
(Figure 3.16 - 3.18). This contrasts previous reports which suggest that severe 
hypoxic exposure can result in ATM activation independent of DNA damage 
(Hammond, Dorie, et al., 2003; Bencokova et al., 2009). 
To conclude, hypoxia results in a significant reduction of ATM and 
ATMSer1981 in D283-MED cells. This could have an impact on the DNA 
damage signalling within these cells, and could explain the reduced p53 
phosphorylation in hypoxia observed by Fan 2014. It could be argued that 
D283-MED cells have an unspecific response to hypoxia as multiple proteins 
are regulated. However, Fan 2014 did not observe any change in p53 protein 
levels, nor was there any difference in γH2AX levels after short etoposide 
exposure, suggesting that H2AX protein level is likely to be similar in 
normoxia and hypoxia (Fan 2014). Regulation of common housekeeping genes 
by hypoxia, similar to the observations in D283-MED, has previously been 
reported. Caradeck et al found that hypoxia regulates a number of 
housekeeping genes as the mRNA level including GAPDH and β Actin. Yet, the 
direction and extent of regulation was dependant on cell type and hypoxia 
severity (Caradec et al., 2010). Additionally, cell-type specific regulation of 
GAPDH protein in hypoxia, through post-translational mechanisms, has been 
observed (Graven et al., 1994; Said et al., 2009). As regulation of housekeeping 
genes is a common feature of hypoxic exposure, the response of D283-MED to 
hypoxia is likely specific, resulting in adaptations previously observed and 
discussed in the literature.  
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Figure 3.15: ATM activation by etoposide. U87-MG cells were treated with 
100 µM etoposide for 0-24 h. Western blotting was conducted for (A) ATM 
and (B) ATMSer1981, for three independent experiments. (C) Densitometry 
of a representative blot was performed using Image J.  
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Figure 3.16: ATM and ATMSer1981 levels in MB cells exposed to moderate 
hypoxia. (A) D283-MED and (B) MEB-Med8A cells were incubated in in 1% 
or 21% O2 for 5 days before treatment with either 20 µM (D283-MED) or 
50 µM (MEB-Med8A) etoposide for 4 h. Protein was extracted and a western 
blot performed for ATM and ATMSer1981. At least three independent 
experiments were conducted. Densitometry was performed on a single 
representative blot using Image J.  
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Figure 3.17: ATM and ATMSer1981 levels in MB cells exposed to severe 
hypoxia. (A) D283-MED and (B) MEB-Med8A cells were incubated in in 
0.1% or 21% O2 for 5 days before treatment with 20 µM (D283-MED) or 
50 µM (MEB-Med8A) etoposide for 4 h in 21% O2. Western blot was 
performed for ATM and ATMSer1981. Control represents cells remaining in 
0.1% O2 during treatment. At least three independent experiments were 
conducted. Densitometry was performed on a single representative blot 
using Image J.  
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Figure 3.18: ATM and ATMSer1981 in hypoxic U87-MG cells. U87-MG were 
incubated in (A) 1% and (B) 0.1% as well as 21% O2 for 5 days before 
treatment with 100 µM etoposide for 4 h (in 21% O2 for 0.1% cells). Protein 
was extracted and a western blot performed for ATM and ATMSer1981. 
Control represents cells remaining in 0.1% O2 during treatment. At least 
three independent experiments were conducted. Densitometry was 
performed on a single representative blot using Image J.  
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3.4.4 Summary of Results  
This current chapter aimed to build on the work of Fan 2014, to explore the 
mechanism behind reduced etoposide sensitivity in hypoxic D283-MED cells. 
In addition to etoposide, D283-MED cells were resistant to cisplatin and X-ray 
irradiation, although to a lesser extent. Downregulation of NBN and MRE11 
was confirmed at both the gene expression and protein level, which required 
chronic (>48 h) hypoxic exposure. Furthermore, both ATM and ATMSer1981 
were downregulated in hypoxic D283-MED cells. These findings, along with 
observations of Fan 2014, suggest that DSB signalling is dampened by chronic 
hypoxia in D283-MED cells, which leads to reduced treatment sensitivity, as 
described in Figure 3.19. Overall, work in this chapter successfully supported 
and built on the previous findings. Table 3.2 highlights the confirmed and 
additional findings between Fan 2014 and the work presented here.  
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Table 3.2: Findings in Fan 2014 and Chapter 3. 
Finding  
Fan 2014 
D283-MED cells 
Chapter 3 
Confirmation of finding? 
Etoposide 
sensitivity in 
hypoxia   
Chronic hypoxia reduces 
sensitvity 
 
Sensitivity to 
other agents 
in hypoxia 
Not investigated 
 
Cisplatin, Irradiation 
The MRN 
complex 
NBN and MRE11 downregulated 
in hypoxia (mRNA) 
 
NBN and MRE11 downregulated 
in hypoxia (mRNA + Protein) 
 
γH2AX 
Decreased in hypoxia after long 
term treatment 
 
Lower γH2AX due to less 
signalling not reduced 
effectiveness of etoposide in 
hypoxia  
ATM Not investigated 
 
Hypoxia reduced total ATM 
and active ATM  
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Figure 3.19: The impact of chronic hypoxia on D283-MED. Chronic hypoxia 
downregulates the MRN complex and ATM in D283-MED cells. This leads to 
reduced damage signalling to H2AX and p53 resulting in a decrease in cell 
death.   
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3.5 Discussion 
Tumour hypoxia correlates with a poor patient outcome, in part due to the 
highly resistant nature of hypoxic cells. To combat this, identification of the 
molecular mechanism behind resistance is essential. The cellular response to 
DNA damage is the cornerstone of cancer therapy for MB and GBM, and the 
effect of hypoxia on the DNA damage response (DDR) has been well explored. 
However, discrepancies arise due to variations in hypoxic exposure and the 
diversity of cell lines.  
3.5.1 DNA damage response and hypoxia  
Treatment of MB and GBM relies heavily on the induction of DNA damage to 
initiate the DDR. Data presented here suggest that downregulation of the DSB 
recognition complex (MRN) and ATM in hypoxic D283-MED leads to 
dampened DNA damage signalling, resulting in reduced treatment sensitivity 
(Figure 3.19). Regulation of several DSB repair components by hypoxia has 
been identified in the literature, including downregulation of RAD51, RAD52, 
BRCA2 and BRCA1 leading to reduced repair of DSB in hypoxia (Bindra et al., 
2004, 2005; Meng et al., 2005; Bindra and Glazer, 2007; Chan et al., 2008). 
These changes are thought to cause enhanced sensitivity to DNA damaging 
agents. For example, hypoxia-induced decrease in HRR proteins increased 
sensitivity to mitomycin C, cisplatin and radiation (Chan et al., 2008). 
However, alternatively, downregulation of the MRN complex, required for 
DSB recognition, results in reduced sensitivity to etoposide in MB cells. 
Previous studies observed downregulation of NBN and ATM in hypoxic cells 
(To et al., 2006; Eren and Tabor, 2014), correlating with findings in 
D283-MED. Reduced ATM signalling will cause decreased p53 stabilisation, 
therefore reduced induction of pro-apoptotic genes, leading to survival after 
chemotherapeutic exposure. Low levels of p53, thus less p53 activity, has been 
attributed to chemoresistance in renal carcinoma (Roberts et al., 2009). 
Overall, studies exploring the impact of hypoxia on DNA repair have gained 
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mixed results with many discrepancies. For example, reports suggest that 
hypoxia results in the activation of ATM, p53, and γH2AX independent of 
DNA damage (Hammond, Dorie, et al., 2003; Bencokova et al., 2009). 
However, no induction of ATMSer1981 or γH2AX was observed in hypoxic MB 
or GBM cells. Induction of ATM phosphorylation independent of DNA 
damage is likely due to replication stress caused by severe hypoxia (0.02%) 
(Hammond et al., 2002; Hammond, Dorie, et al., 2003; Bencokova et al., 
2009). Mild hypoxic exposure (1%), used here, is unlikely to induce sufficient 
replication arrest. Therefore, ATM and p53 are not activated. It is imperative 
to consider the specific protocol of hypoxic exposure when assessing hypoxia-
induced cellular adaptations. Length and severity of exposure, as well as cell 
lines used, can influence the observed response to hypoxia.  
3.5.2 Genetic and environmental heterogeneity 
Heterogeneity of the cellular response to hypoxia has somewhat hindered the 
development of targeted treatment for hypoxic tumours. The differential 
response of MB and GBM cells to hypoxia is likely due to variations in the 
molecular signature of cell lines. For example, MEB-Med8A is a Group 3 MB 
due to classical characteristics of MYC amplification and PTV1-MYC fusion 
(Langdon et al., 2006; Northcott et al., 2012). In contrast, D283-MED does not 
have amplified MYC, and the sub-grouping is less clear (Sengupta et al., 2014). 
The molecular signature of tumours can impact treatment response. Wnt MB 
tumours, for example, respond well to therapy, therefore, have the highest 
overall survival (Cho et al., 2011; Northcott et al., 2011; Kool et al., 2012; Taylor 
et al., 2012). Therefore, it is to be expected that brain tumour cell lines 
respond differently to hypoxia. Work by Cosse et al. found that acquired 
resistance to etoposide in hypoxia is cell line specific (Cosse et al., 2007). 
Understanding the genetic background of tumours, and how this affects the 
response to the microenvironment, is essential in order to develop targeted 
treatments for a personalised medical approach.  
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Specifics of hypoxic exposure adds further complexity when studying the 
cellular response to hypoxia. In D283-MED and U87-MG cells, chronic 
hypoxia (5 days), not acute (1 day), was required to reduce etoposide 
sensitivity. The definition of chronic (1 day to several weeks) and acute 
hypoxia (1 h to 48 h), is not so clear-cut. However, acute hypoxia, not chronic, 
is thought to lead to a highly aggressive phenotype with increased metastatic 
potential. For example, acute hypoxic exposure enhanced lymph node 
metastasis in a murine model of human cervical carcinoma (Cairns and Hill, 
2004). However, chronic hypoxia can have a direct impact on treatment 
response, as shown here. This is highlighted by the requirement of long 
hypoxic exposure (>48 h) to induce downregulation of the MRN complex. Few 
studies utilise hypoxic exposure over 72 h. Therefore the effects of long-term 
exposure may have been overlooked. Overall, chronic and acute hypoxia 
differentially affect cell biology, adding further complications when identifying 
the mechanism of hypoxia-induced resistance.  
3.5.3 Alternative mechanisms leading to reduced treatment sensitivity 
The resistance phenotype of hypoxic cells can be attributed to 1) acquired 
resistance 2) reduced treatment efficacy in hypoxia, contributing to a poor 
patient outcome. Teasing these two factors apart is challenging. 
Chemotherapeutic agents and irradiation may be less effective in a hypoxic 
environment. For example, studies suggest that etoposide requires oxygen for 
functionality (Wozniak and Ross, 1983; Wozniak et al., 1984). Here etoposide 
was capable of inducing a comparable levels of cell death in moderate hypoxia 
(1%) and normoxia, as well as similar levels of DNA damage (comet assays, 
γH2AX), shown by Fan 2014. The effectiveness of anti-cancer therapy may be 
dependent on the hypoxia severity within pockets of a tumour. However, 
successful treatment can be thwarted by hypoxia-induced acquired resistance. 
Downregulation of DNA damage signalling in hypoxic D283-MED resulted in 
reduced sensitivity to etoposide, cisplatin and irradiation. Acquired resistance 
to etoposide and cisplatin has previously been observed in several studies 
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(Kalra et al., 1993; Cosse et al., 2007, 2009; Sermeus et al., 2008; L. Chen et al., 
2009). No change in MRN or ATM was identified in hypoxic U87-MG cells, 
suggesting an alternative mechanism causing reduced drug sensitivity must be 
at play. In the glioma cell line, T98G, hypoxia-induced expression of MPR-1, a 
multidrug resistance gene, resulting in resistance to etoposide and 
doxorubicin (L. Chen et al., 2009). Additionally, acquired resistance to 
etoposide has been attributed to reduced p53 protein levels and an increase in 
c-jun DNA binding in hypoxia (Cosse et al., 2009). Hypoxic U87-MG were also 
less sensitive to irradiation. This could be explained by reduced proliferation 
in hypoxia, alterations to DNA damage response mechanisms, or increased 
levels of ROS scavengers. To explore this further, determination of U87-MG 
proliferative ability as well as further assessment of U87-MG DNA repair 
capacity in hypoxia would be ideal. With many potential causes of treatment 
resistance and reduced sensitivity in hypoxia, it is challenging to find a one-
size-fits-all mechanism. Determination of a universal mechanism across 
multiple tumour types appears unlikely due to the significant variations in 
cellular genetic background, hypoxic environment and treatment choices, 
which add further complexity.  
3.5.4 Direct targeting of the hypoxic response  
Reversing the hypoxia-induced resistance phenotype is essential to improve 
treatment response. Targeting the hypoxic response poses a potential 
therapeutic option. Inhibition of HIF, the activator of hypoxia-related cellular 
changes, is becoming a popular strategy. For example, in the U251-MG cell 
line, camptothecins (CPTs) analogues can inhibit the accumulation of HIF-1α 
protein (Rapisarda et al., 2004). Tumours that have reduced HIF-1 function 
have an enhanced response to radiotherapy (Williams et al., 2005). NBN, a 
component of the resistance mechanism in D283-MED, is downregulated 
through HIF activity (To et al., 2006). Inhibiting HIF may be useful to restore 
NBN to ‘normoxic’ levels, and resensitise cells to anti-cancer treatment. 
Interfering with HIF may have direct therapeutic benefits. However, this 
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requires the molecular mechanism of resistance to be HIF dependent, which 
may not be the case. Therefore, alternative molecular targets need to be 
identified. The involvement of HIF in hypoxia-induced DNA repair changes 
will be explored further in Chapter 5. 
3.5.5 Concluding remarks and future work 
Hypoxia-induced resistance to cancer treatment is a life-threatening issue in 
the clinic. In the current study, downregulation of components of the DSB 
repair pathway caused reduced treatment sensitivity hypoxic D283-MED cells. 
Whether hypoxia-induced changes to DNA repair mechanisms play a role in 
altered treatment response in GBM is yet unknown. The impact of hypoxia on 
DNA repair gene expression in both MB and GBM will be explored using an 
unbiased transcriptomic approach in Chapter 4. Additionally, future 
exploration of alternative mechanims of reduced treatment sensitivity in 
hypoxia as well as the adoption of clonogenic assays to examine cell survival 
would be advantageous. Development of targeted therapies against 
mechanism causing altered treatment sensitivity may reduce the requirement 
of high dose chemo- and radiotherapy, a desirable outcome for young MB 
patients. 
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Chapter 4: Global impact of 
hypoxia on DNA repair gene 
expression 
Global impact of hypoxia on DNA repair gene expression 
112 
 
4.1 Introduction 
In the previous chapter, the impact of hypoxia on the double strand break 
recognition machinery was explored. In D283-MED, the MRN complex was 
downregulated in hypoxia, yet this was not universal across multiple cell lines. 
Therefore, a thorough investigation of multiple DNA repair genes is required 
to gain a comprehensive view of the effect of hypoxia on DNA repair gene 
expression.  
Mild hypoxia itself is not capable of inducing DNA damage, as shown in 
Chapter 3 and by the work of others (Hammond et al., 2002; Hammond, 
Dorie, et al., 2003; Hammond, Green, et al., 2003). However, hypoxia can lead 
to alterations to DNA repair through transcriptional, translational and post-
translational modifications of the DNA repair machinery, resulting in an 
altered response to DNA damage. Often these changes to DNA repair 
mechanisms are highly dependent on the severity and duration of hypoxia.  
Both chronic and acute hypoxic exposure can alter transcription of DNA repair 
proteins (reviewed in Scanlon and Glazer, 2015). The effect of hypoxia on the 
transcription of DNA repair genes has been reported to be primarily 
downregulation. For example, the expression of nucleotide excision repair 
gene, ERCC1, is downregulated by hypoxia even after periods of reoxygenation 
(Dudás et al., 2014). Additionally, hypoxia downregulates UBE2T, an E2 
conjugating enzyme involved in the repair of interstrand crosslinks in the 
Fanconi anaemia pathway (Ramaekers et al., 2011).  
One additional complication is the significant overlap between DNA repair 
pathways. For example, in the repair of double strand breaks, the MRN 
complex was initially thought to participate primarily in HRR, however roles 
of MRE11 in NHEJ, dependant and independent of XRCC4, have now been 
identified (Rass et al., 2009; Anyong Xie& Amy Kwok, 2010). Additionally, loss 
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of functionality of a single DNA repair pathway, often found in cancer can, in 
some cases, be compensated for by the use of alternative pathways. For 
example, if base excision repair (BER) is defective and the single strand breaks 
formed cannot be repaired, these become DSBs, which are repaired by HRR or 
NHEJ. Also, nucleotide excision repair (NER) is thought to repair some 
oxidative lesions, suggesting that, in a BER deficient setting, NER may be used 
as a compensatory mechanism (Reardon et al., 1997). In most studies focusing 
on the impact of hypoxia on DNA repair mechanisms, often only a single 
repair pathway is investigated, which can be limiting. Therefore a more global 
investigation into the effect of hypoxia on multiple DNA repair pathways is 
required. 
4.1.1 NanoString technology 
To assess the broad impact of chronic hypoxia on DNA repair gene expression, 
a NanoString approach was adopted. The NanoString nCounter gene 
expression system is a multiplexed assay, which enables the assessment of the 
expression of up to 800 genes in an individual reaction. In summary, the 
technology works through the use of a ‘capture count system’, whereby two 
specific probes bind to target mRNA. A ‘capture’ probe enables hybridisation 
to a cartridge, and a ‘reporter’ probe contains a colour-coded tag, which is 
unique to the mRNA in question. These tags, made up of ordered 
fluorophores, are detected by a CCD camera. The number of identified tags 
relate to the level of expression of each gene. This approach enables the 
examination of the expression of a number of DNA repair genes without the 
need for extensive RT-PCR experiments or costly microarrays. Additionally, 
the NanoString system is deemed as more sensitive than microarrays (Geiss et 
al., 2008), and does not require complex analysis.  
In order to understand the broader impact of hypoxia on DNA repair gene 
expression, four glioblastoma, two medulloblastoma and one neuroblastoma 
cell line was incubated in moderate (1% O2) and severe hypoxia (0.1% O2). 
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Experimental conditions are detailed in Table 4.1. Target genes from various 
DNA repair pathways as well as other key genes involved in the cellular 
response to DNA damage (Table 4.2) were analysed using the NanoString 
nCounter gene expression system, with a total of 180 genes, plus 12 
housekeeping genes (appendix 1.2). 
In brief, the experimental procedure of the NanoString study involved pre-
incubation of cells for 5 days in 21%, 1% and 0.1% O2, except D283-MED cells, 
which were cultured only in 21% and 1% O2 due to poor RNA quality from cells 
cultured in 0.1% O2. RNA was extracted and a portion converted to cDNA for 
RT-PCR to ensure that an increase in hypoxic markers (GLUT1 or VEGF) was 
present for hypoxic samples. Only samples with an evident hypoxic effect were 
taken forth into the NanoString experiment. Total RNA was used in the 
experimental protocol (see methods 2.14). Analysis of NanoString data was 
conducted using the nSolverTM Analysis Software (3.0).  
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Table 4.1: Tumour type, cell lines and oxygen conditions assessed in the 
NanoString study. 
Table 4.2: Details of the gene annotation groups analysed with the 
NanoString nCounter system. 
Tumour Type Cell Line O2 Conditions Tested 
Glioblastoma 
U87-MG 21%, 1%, 0.1% 
U251-MG 21%, 1%, 0.1% 
D566-MG 21%, 1%, 0.1% 
T98G 21%, 1%, 0.1% 
Medulloblastoma 
MEB-Med8A 21%, 1%, 0.1% 
D283-MED 21%, 1% 
Neuroblastoma SK-N-AS 21%, 1%, 0.1% 
Annotation Group Number of Genes 
Base Excision Repair 29 
Nucleotide Excision Repair  23 
Homologous Recombination  21 
Non-homologous End Joining 5 
Fanconi Anemia 14 
Mismatch Repair 13 
Translesion Synthesis 7 
Checkpoint Activation  12 
Apoptosis 17 
Cell Cycle and Signalling 44 
Independent Repair Enzymes/Polymerases  25 
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4.2 Objectives 
The experimental aims for this chapter were as follows: 
1. Analyse the expression level of DNA repair genes under hypoxic and 
normoxic conditions in GBM and MB cell lines. 
2. Determine the impact of moderate (1% O2) versus severe (0.1% O2) 
hypoxia on the expression of DNA repair genes.  
3. Determine common hypoxia-induced changes in expression between 
cell lines. 
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4.3 NanoString results 
4.3.1 Unsupervised clustering 
Before data from the NanoString experiments could be analysed, several 
quality control (QC) steps had to be passed. These steps included an 
examination of probe binding density and image quality as described in 
methods 2.14.4.1. A common QC procedure in gene expression studies is the 
unsupervised clustering of the data. Clustering is a visual tool, which allows 
easy identification of samples with similar gene expression patterns. 
Therefore, if samples (i.e. biological replicates) from an experimental 
condition cluster together, this indicates their expression patterns are similar. 
Random clustering of replicates could be caused by several factors including 
uncontrolled elements during experimentation, or for biological reasons.  
Expression data for each cell line was subjected to unsupervised clustering. For 
each experimental replicate, gene ‘counts’ were normalised to the selected 
housekeeping genes and scaled to give each expression value equal variance. 
From this, unsupervised clustering was performed and heat-maps produced 
(Figure 4.1 and Figure 4.2). Between biological replicates, for example, 
U87-MG 21% samples (Figure 4.1 A) there was significant variation in the data 
shown by the varied colour pattern (representing up and down regulated 
genes). This could imply that the NanoString platform is unreliable, as similar 
results are not being achieved for each biological replicate. However, in the 
D566-MG cell line, the samples at 0.1% O2 show a very similar patterning 
suggesting that the NanoString assay is capable of producing robust data. 
Therefore, the sample variation in the remaining cell lines tested is likely due 
to unknown factors such as biological variation. Interestingly, only D566-MG 
appeared to show reproducible gene changes with respect to oxygen 
conditions. This could suggest that these cells are more sensitive to hypoxia, 
resulting in a more distinct and global impact of hypoxia on DNA repair gene 
expression.   
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When examining the clustering of experimental samples with respect to 
oxygen concentration, in the GBM cell lines, U87-MG and D566-MG, each 
experimental sample clustered with other samples from the same oxygen 
condition (Figure 4.1 A, C.) This suggests that the expression patterns are 
similar to one another. In contrast, whilst normoxic T98G samples clustered 
together, the hypoxic samples (1% and 0.1% O2) clustered randomly 
(Figure 4.1 D), suggesting that changes in 1% and 0.1% O2 cannot be 
differentiated. In U251-MG, D283-MED and MEB-Med8A, clustering of 
samples was random (Figure 4.1 B, Figure 4.2), indicating that the gene 
expression patterns in 21%, 1% and 0.1% O2 are not discernible from each 
other. The cause of this ‘random’ clustering suggests that gene expression is 
not dramatically altered in hypoxia, resulting in clustering with less distinct 
separation.  
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Figure 4.1: Heat-map with unsupervised clustering of gene expression data 
for GBM cell lines. The gene ‘counts’ of (A) U87-MG, (B) U251-MG, 
(C) D566-MG and (D) T98-MG were normalised to selected housekeeping 
genes, then scaled to ensure equal variance. Clustering of data was 
performed based solely on gene expression patterns. Orange indicates 
upregulation; blue indicates downregulation of gene expression.  
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Figure 4.2: Heat-map with unsupervised clustering of gene expression data 
for MB cell lines. The gene ‘counts’ of (A) D283-MED and (B) MEB-Med8A 
were normalised to selected housekeeping genes, then scaled to ensure equal 
variance. Clustering of data was performed based solely on gene expression 
patterns. Orange indicates upregulation; blue indicates downregulation of 
gene expression 
4.3.2 Differential gene expression analysis 
Normoxia (21 % O2) was used as the reference condition to compare hypoxic 
expression levels. Using multivariate linear regression, differentially expressed 
genes in 1% and 0.1% O2 were identified, and the number of significantly 
regulated genes for each cell line and hypoxic condition was determined 
(Table 4.3). Here significantly regulated refers to genes whose log2 fold change 
in expression (hypoxia versus normoxia) is at least +/- 0.58 (representing a 
1.5-fold change), as well as having a significance value of p≤0.01.  
Overall, the MB lines, MEB-Med8A and D283-MED, had the fewest 
significantly regulated genes in hypoxia. Specifically, in D283-MED, only three 
genes met these significance criteria, whereas in MEB-Med8A one gene was 
regulated at 1% O2, and eight genes in 0.1% O2 (Table 4.3). In contrast, the 
GBM cell lines have a higher number of hypoxia-regulated genes. In particular, 
in U87-MG and D566-MG 16 and 12 genes respectively were regulated at 
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1% O2, which increased to 37 and 59 genes respectively with increased severity 
of hypoxia (Table 4.3). Therefore, hypoxia has a greater influence on the gene 
expression of DNA repair genes in GBM than MB cell lines. Additionally, as a 
comparison, a single experiment of SK-NA-S cells (Neuroblastoma) was 
performed (data not shown). Similar to MB cell lines, there were few changes 
in gene expression (four genes in 1% O2, six genes in 0.1% O2), which might be 
characteristic of paediatric tumours. These data are based on a log2 fold 
change in expression of at least +/- 0.58 and a ‘yes’ DE call (see methods 
2.14.4.4).  
Table 4.3: Number of significantly regulated genes for each cell line and 
hypoxic condition. Significantly regulated represents genes which 
expression level (compared to 21% O2) is at least +/- 0.58 log2 fold change 
(representing a 1.5-fold change), as well as having a significance of p≤0.01 
based on multivariate linear regression. 
 
Cell Line O2 Condition Number of significantly regulated genes 
U87-MG 
1% 16 
0.1% 37 
U251-MG 
1% 17 
0.1% 8 
D566-MG 
1% 12 
0.1% 59 
T98G 
1% 13 
0.1% 18 
MEB-Med8A 
1% 1 
0.1% 8 
D283-MED 1% 3 
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4.3.2.1 Volcano plots 
A simple way to visualise the differential expression of genes in large datasets 
is with volcano plots. Volcano plots display a datum for each gene, where the 
log2 fold change (mean of 3 biological replicates) is plotted against the p-value. 
This produces a ‘volcano’ shaped plot where any datum, which is high on the 
y-axis as well as either the far left or far right of the on the x-axis, is a highly 
differentially expressed and highly statistically significant gene. This enables 
the easy identification of greatly regulated and strongly significant genes.  
Volcano plots were produced for GBM cells (Figure 4.3, Figure 4.4) and MB 
cells (Figure 4.5). In U87-MG cells, a number of genes in both 1% and 0.1% O2 
reached the critical significance value of p≤0.01, with 20 genes reaching the 
stricter statistical threshold of  p≤0.001 in 0.1% O2  (Figure 4.3 A). Also, the 
data appear to be spread equally across both left and right-hand-side of the 
x-axis, indicating that neither up or downregulation of gene expression is 
predominating in this cell line. In contrast, D566-MG shows a clear preference 
for downregulation. Particularly in the more serve hypoxic condition of 
0.1% O2 with 70/180 genes reaching high statistical significance (Figure 4.4 A). 
For U251-MG, there are more statistically significant genes in 1% O2 compared 
to 0.1% O2 yet the volcano is quite narrow suggesting the fold change in gene 
expression is small (Figure 4.3 B). In contrast, for T98G the volcano plots are 
spread across the x-axis. Therefore, there is strong regulation of many genes, 
yet neither up, or downregulation is predominating (Figure 4.4 B). In the MB 
cell lines, MEB-Med8A and D283-MED, similar to U251-MG the volcanos are 
very narrow implying only small and potentially negligible fold changes in 
expression (Figure 4.5).  
In summary, hypoxia significantly influences gene expression in GBM cells 
lines compared to MB. Specifically, in U87-MG and D566-MG, a significant 
proportion of genes reach statistical significance (28% U87-MG, 38% 
D566-MG in 0.1%).  
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Figure 4.3: Gene expression volcano plots for U87-MG and U251-MG. Gene 
expression data for (A) U87-MG and (B) U251-MG is represented as log2 fold 
change for each gene plotted with log10 p-value. Each point represents the 
average of three experimental replicates. Green filled circles signify genes 
that have a p-value above the p<0.01 threshold. Grey hollow circles 
represent non-statistically significant genes. The top 5 statistically 
significant genes are identified with the gene name.  
D T98G 
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Figure 4.4: Gene expression volcano plots for D566-MG and T98G. Gene 
expression data for (A) D566-MG and (B) T98G is represented as log2 fold 
change for each gene plotted with log10 p-value. Each point represents the 
average of three experimental replicates. Green filled circles signify genes 
that have a p-value above the p<0.01 threshold. Grey hollow circles 
represent non-statistically significant genes. The top 5 statistically 
significant genes are identified with the gene name.  
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Figure 4.5: Gene expression volcano plots for MB cell lines. Gene expression 
data for (A) MEB-Med8A and (B) D283-MED is represented as log2 fold 
change for each gene plotted with log10 p-value. Each point represents the 
average of three experimental replicates. Green filled circles signify genes 
that have a p-value above the p<0.01 threshold. Grey hollow circles 
represent non-statistically significant genes. The top 5 statistically 
significant genes are identified with the gene name. 
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4.3.3 Significance scoring 
To understand the influence of hypoxia on the expression of genes within each 
annotation group (DNA repair pathway), global significance (GS) and directed 
global significance (DGS) scores were calculated and displayed as heat-maps 
(Figure 4.6, Figure 4.7). GS scores measure the overall differential regulation 
of a set of genes with respect to the reference condition (21% O2); with DGS 
adding directionality (see methods 2.11.4.5). This enables the visualisation of 
gene regulation in each DNA repair pathway. Overall, the strongest gene 
regulation, shown by a high GS score (dark blue), was observed in D566-MG 
(Figure 4.6 C), correlating with the increased number of differentially 
regulated genes in this cell line (Table 4.3). At 0.1% O2, apoptosis, homologous 
recombination repair and mismatch repair, are the top three annotation 
groups, which had the strongest gene regulation (Figure 4.6 C), with 
downregulation predominating for most pathways in this cell line 
(Figure 4.7 C).  
For U87-MG and U251-MG, up and downregulation was observed across the 
annotation groups (Figure 4.7 A, B). However, in U87-MG the strongest 
regulation was observed in non-homologous end joining genes (Figure 4.6 B), 
which was identified as downregulation (Figure 4.7 A). Interestingly, the 
direction of expression in both U87-MG and U251-MG does not correlate with 
changes in hypoxia severity. For example, checkpoint activation in U87-MG is 
upregulated in 1% O2 but downregulated in 0.1% O2 (Figure 4.7 A). Although 
it could be assumed that changes in moderate hypoxia would be heightened in 
severe hypoxia, often altering the degree of hypoxia can result in activation of  
different signalling pathways. Therefore, in the case of U87-MG and U251-MG, 
the differing severities of hypoxia may cause alternative mechanisms of gene 
regulation, resulting in the switch from up to downregulation of a DNA repair 
pathway for example.  
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In MB cells, upregulation of gene expression predominates in MEB-Med8A, 
with nucleotide excision repair showing strongest overall regulation (Figure 
4.6 E, Figure 4.7 E). In D283-MED the pathways are mostly downregulated, 
yet regulation of gene expression is very weak (Figure 4.6 F). 
Overall, U87-MG and D566-MG showed the strongest level of gene regulation, 
with non-homologous end joining, mismatch repair and apoptosis having high 
rates of gene regulation. In contrast, for the MB cell lines, GS and DGS 
suggested low levels of regulation of gene expression, which correlates with 
the differential gene expression analysis. 
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Figure 4.6: Global significance heat-maps. Global significance scores were 
calculated for each defined annotation group and cell line. Scores are 
represented in a heat map (white = weak regulation, dark blue = strong 
regulation). An individual plot was produced for each cell line and hypoxic 
condition. Data representative of three independent experiments.  
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Figure 4.7: Directed global significance heat-maps. Directed global 
significance scores were calculated for each defined annotation group and 
cell line. Scores are represented in a heat map (blue = downregulation, 
red = upregulation). An individual plot was produced for each cell line and 
hypoxic condition. Data representative of three independent experiments.  
Global impact of hypoxia on DNA repair gene expression 
130 
 
4.3.4 Gene level analysis of DNA repair pathways 
Both differential gene expression analysis (volcano plots) and global 
significance scoring indicate how hypoxia affects collective gene expression for 
several genes within a defined pathway. However, the individual gene level is 
key to fully comprehend how different DNA repair pathways are influenced by 
hypoxia. This is because the protein products of DNA repair genes can play 
varied roles within a pathway, with differing degrees of redundancy. 
Homologous recombination repair, non-homologous end joining, base 
excision repair and mismatch repair (Chapter 1, Figure 1.8) were the focus of 
further exploration. These pathways were selected based on their role in repair 
of many common DNA damage types induced by chemo- and radiotherapy. 
4.3.4.1 Homologous recombination repair 
HRR is responsible for the repair of double strand breaks. Repair steps involve 
recognition of the break and processing of DNA ends, followed by DNA strand 
invasion, DNA synthesis and resolution of complex structures. In the previous 
chapter, the impact of hypoxia on the expression of genes involved in damage 
recognition was examined, namely, NBN, MRE11 and RAD50. The NanoString 
set-up enabled the measurement of expression of 21 genes involved in HRR. 
For each cell line, the log2 fold change in expression with respect to expression 
at 21% O2 was determined (Figure 4.8).  
Across all cell lines, very few genes reached the designated fold change 
threshold in both 1% and 0.1% O2 (Figure 4.8), yet genes that did cross the 
threshold were primarily downregulated. In the T98G cell line, 8/21 genes 
were downregulated by at least -1 log2 fold in 1% O2, but the majority did not 
reach statistical significance (Figure 4.8 A). Similarly, D566-MG had a number 
of strongly downregulated HRR genes, which were also statistically significant. 
Yet, this strong downregulation was only observed at 0.1% O2, with 2/21 in 
1% O2 compared to 12/21 in 0.1% O2. 
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For components of the MRN complex, there was little change in MRE11 except 
-0.78 log2 fold downregulation at 0.1% O2 in D566-MG (Figure 4.8 B). Also, 
RAD50 is predominantly unchanged across the cell lines tested. However, the 
expression levels of NBN were decreased in T98G at 1% O2 (-0.95 log2 fold) 
(Figure 4.8 A) and both T98G (-0.79 log2 fold) and D566-MG (-1.0 log2 fold) at 
0.1% O2 (Figure 4.8 B). Interestingly, in D283-MED, MRE11 and NBN were not 
downregulated to the same extent as described in Chapter 3. Previously, in 
1% O2, NBN and MRE11 were downregulated -1.20 and -1.10 log2 fold 
respectively. However, in the NanoString study, NBN was downregulated -0.45 
log2 fold and MRE11 -0.33 log2 fold (Figure 4.8 A). A potential explanation for 
this could be that the RT-PCR primers may pick up different transcript 
variants to the NanoString probes, which could alter the fold changes 
observed. As discussed in Chapter 3, the downregulation of NBN in hypoxia 
has previously been documented and is thought to occur through the 
displacement of MYC by HIF on the NBN gene promoter (To et al., 2006).  
After damage recognition and end processing, RAD51 binds to DNA forming a 
nucleoprotein filament. There was no change in RAD51 expression at 1% O2 
(Figure 4.8 A). However, at 0.1% O2, there is a strong and statistically 
significant -1.7 log2 and -1.0 log2 fold downregulation in D566-MG cells and 
T98G respectively. This matches previous studies that found RAD51 to be 
downregulated by 0.2% - 0.01% O2 (Bindra et al., 2004, 2005; Meng et al., 
2005), suggesting that a more severe hypoxic environment is required for 
these changes to occur.  
In a severe hypoxic environment (0.01% O2), BRCA1 is reported to be 
downregulated after 48 h exposure (Bindra et al., 2005, 2004). BRCA1 was 
downregulated in a number of GBM cell lines incubated in 1% O2 (U251-MG, 
U87-MG, and T98G) (Figure 4.8 A). However, in more severe hypoxia 
(0.1% O2) a -1.0 log2 fold downregulation was observed only in D566-MG 
(Figure 4.8 B). In prostate cancer, exposure to 0.2% O2 for 48 h resulted in the 
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downregulation of both BRCA1 and BRCA2 (Meng et al., 2005). Similarly, 
BRCA2 was downregulated by hypoxia in breast cancer (Fanale et al., 2013). 
These studies very much contrast the NanoString observations as there was 
minimal change, particularly in BRCA2. Therefore, hypoxia-induced changes 
to BRCA1 and BRCA2 may be a cell type-specific phenomenon.  
Finally, significant downregulation of WRN, involved in Holliday junction 
resolution (Constantinou et al., 2000), was observed in U87-MG and 
D566-MG at 1% O2, with -0.69 and -0.71 log2 fold change respectively (Figure 
4.8 A).  Both of these cell lines, plus T98G, showed clear downregulation of 
WRN in 0.1% O2, with all changes being statistically significant (Figure 4.8 B). 
Interestingly, WRN has been implicated in HIF-1 repression, with depletion 
of WRN leading to accumulation of HIF-1 (Labbé et al., 2012). 
In summary, the expression of a number of HRR genes is impacted by hypoxia, 
specifically WRN, and RAD51 were strongly downregulated in 0.1% O2 in two 
or more GBM cell lines. However, several previously documented changes 
such as downregulation of BRCA2, RAD52 and RAD54 (Bindra et al., 2005; 
Meng et al., 2005; Bindra and Glazer, 2007) were not identified in the cell 
lines tested here. This supports the notion that hypoxia-induced changes can 
be subjective to the cell type as well as to the severity and duration of hypoxia 
used in each study.  
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Figure 4.8: Differential expression of HRR genes in 1% and 0.1% O2. 
Differential gene expression was calculated for each gene as log2 fold 
change for (A) 1% O2 and (B) 0.1% O2 with respect to the expression level in 
21% O2. Red shaded area denotes fold change values below the 
+/-0.58 log2 fold (+/-1.5-fold) threshold of change. Blue area denotes fold 
change values above the designated threshold. Filled shapes represent data 
which is statistically significant (p<0.01), whereas hollow shapes show no 
statistical significance. Data are represented as the mean of three 
independent experiments. 
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4.3.4.2 Non-homologous end joining 
NHEJ is a second pathway responsible for the repair of DSB. Unlike HRR, 
NHEJ does not require the presence of homologous DNA. This simple process 
involves recognition of damage, end processing and ligation of DNA strands. 
Several studies have attempted to deduce the impact of hypoxia on NHEJ gene 
expression, yet little consensus has been achieved. In the NanoString study, 
the majority of genes did not cross the fold change threshold (Figure 4.9). 
However, in all GBM cell lines analysed, LIGIV (DNA Ligase IV) is at 
least -0.58 log2 fold (1.5 fold) downregulated by hypoxia (1% and 0.1% O2.), 
although, this was only statistically significant in U87-MG. Interestingly, this 
downregulation appears to strengthen for T98G and D566-MG with increasing 
hypoxia severity. In contrast, the expression level of XRCC4, the binding 
partner of DNA Ligase IV, was not impacted by hypoxia. Work by Meng et al 
2005, observed similar hypoxia-induced gene expression changes for LIGIV, 
also with no change in XRCC4 (Meng et al., 2005).   
In 0.1% O2, PRKDC (DNA-PKcs) was downregulated -0.86 and 0.63 log2 fold 
in T98G and D566-MG respectively (Figure 4.9 B). The gene expression of 
PRKDC in hypoxia has not previously been reported, however in breast cancer 
cells exposed to moderate hypoxia (1.8%) DNA-PKcs protein was upregulated 
(Madan et al., 2012). Additionally, a large-scale proteomic analysis showed an 
increase in Ku70 and Ku80 protein under hypoxia (Ren et al., 2013). However, 
the NanoString data does not indicate any change to Ku gene expression 
(XRCC5 and XRCC6) (Figure 4.9).  
Taken together, it is clear that LIGIV is strongly downregulated by hypoxia, 
shown here and by the work of others (Meng et al., 2005). However, very few 
changes were observed for the other genes involved in the NHEJ. Previously 
observed changes to DNA-PKcs, Ku70 and Ku80 protein might not be due to 
gene expression changes.  
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Figure 4.9: Differential expression of NHEJ genes in 1% and 0.1% O2. 
Differential gene expression was calculated for each gene as log2 fold 
change for (A) 1% O2 and (B) 0.1% O2 with respect to the expression level in 
21% O2. Red shaded area denotes fold change values below the 
+/-0.58 log2 fold (+/-1.5-fold) threshold of change. Blue area denotes fold 
change values above the designated threshold. Filled shapes represent data 
which is statistically significant (p<0.01), whereas hollow shapes show no 
statistical significance. Data are represented as the mean of three 
independent experiments. 
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4.3.4.3 Base excision repair 
BER is responsible for the removal of aberrant DNA bases. Specific 
glycosylases recognise the DNA base, which is removed. The DNA ends are 
then processed and ligated back together. Similar to NHEJ, the effect of 
hypoxia on BER gene expression is not well known. The expression of 27 BER-
related genes were assessed in the NanoString experiment (Figure 4.10). For 
the DNA glycosylase, NEIL1 a 1.11 log2 fold upregulation U251-MG and 
0.96-fold in MEB-Med8A at 1% O2 was observed (Figure 4.10 A). However, the 
data for NEIL1 could be deemed unreliable due to low count numbers for these 
genes, which in some cases did not reach the noise threshold (data not 
shown). UNG, responsible for the removal of incorrectly inserted uracil, was 
downregulated in both T98G and D566-MG at 1% O2 and 0.1% O2, which was 
statistically significant (Figure 4.10). Additionally, MUTYH was downregulated 
in all the GBM cell lines tested at 0.1% O2, and to a lesser extent in 1% O2. 
Previous studies in colorectal cancer cells found OGG1 protein to be 
downregulated by hypoxia (Chan et al., 2014). Altered OGG1 gene expression 
was only observed in D566-MG cells at 0.1% O2 (Figure 4.10 B). However, the 
same study found MUTYH protein to be downregulated by hypoxia similar to 
the NanoString results (Chan et al., 2014), suggesting that the decrease in 
protein may be attributed to reduced transcription. 
For both PARP1 and PCNA, critical facilitators of BER, at 0.1% O2 
downregulation in T98G, U87-MG and D566-MG were observed 
(Figure 4.10 B). Interestingly, PARP1 has been shown to interact with both 
HIF-1α and HIF-2α and aid in the expression of hypoxia-inducible genes (Elser 
et al., 2008; Gonzalez-Flores et al., 2014). The observed downregulation of 
PARP1 gene expression in hypoxia, suggest that PARP-1 could be part of a 
negative feedback loop ensuring controlled expression of HIF target genes.  
For the DNA polymerases involved in BER, POLE2 was downregulated in 1% 
and 0.1% O2 for U87-MG, T98G and D566-MG. For D566-MG cells incubated 
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in 0.1% O2, the strongest downregulation of POLE2 was observed 
(-2.28 log2 fold, p<0.000; Figure 4.11 B). POLB was also downregulated in 
D566-MG cells. The downregulation of POLB protein by hypoxia been 
reported in previous studies (Chan et al., 2014), yet less is known about the 
effects of hypoxia on gene expression. Finally, in T98G, U251-MG and U87-MG 
at 1% O2, FEN1 was downregulated, yet downregulation was observed in T98G 
and D566-MG only, at 0.1% O2.  
In summary, significant regulation of the DNA glycosylases MUTYH and UNG 
in hypoxia was observed, in addition to regulation of POLE2, PARP1, PCNA 
and FEN1. These changes could impact the functionality of BER, particularly in 
the removal of incorrectly inserted uracil and adenine. Also, long-patch BER 
will be affected by the downregulation of FEN1. Few studies explore the impact 
of hypoxia on BER. Therefore this NanoString based study provides further 
potentially valuable knowledge for this field.  
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Figure 4.10: Differential expression of BER genes in 1% and 0.1% O2. 
Differential gene expression was calculated for each gene as log2 fold 
change for (A) 1% O2 and (B) 0.1% O2 with respect to the expression level in 
21% O2. Red shaded area denotes fold change values below the 
+/-0.58 log2 fold (+/-1.5-fold) threshold of change. Blue area denotes fold 
change values above the designated threshold. Filled shapes represent data 
which is statistically significant (p<0.01), whereas hollow shapes show no 
statistical significance. Data are represented as the mean of three 
independent experiments. 
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4.3.4.4 Mismatch repair 
MMR removes incorrectly inserted nucleotides added during DNA replication. 
Search processes identify the incorrect nucleotide, which is excised and the 
gap is filled and sealed. As part of the NanoString study, the expression of 13 
genes involved in mismatch repair was assessed (Figure 4.11). Overall, few 
genes are regulated by hypoxia, as they do not reach the fold change 
threshold. However, strong regulation was observed in some crucial players of 
MMR.  
Initial steps of MMR involve the formation of the MutSα complex composed of 
MSH2 and MSH6. MSH6 was not regulated by hypoxia. However, MSH2 was 
strongly downregulated -1.18 log2 fold in D566-MG and -1.01 fold in T98G 
incubated in 0.1% O2 (Figure 4.11 B). In a previous study by Koshiji et al, MSH2 
and MSH6 were downregulated in 1% O2 in a HIF-1 dependent manner 
(Koshiji et al., 2005). In contrast, a second study found no significant 
downregulation of MSH2 or MSH6 after incubation in <0.001% (Mihaylova et 
al., 2003), suggesting that anoxia causes a different response with regards to 
expression of MMR genes.  
PMS2, a central component of the MutLα complex, was downregulated in 
T98G, D566-MG and U87-MG cell (Figure 4.11). Specifically, the expression of 
PMS2 in D566-MG at 0.1% O2 was -1.41 log2 fold change (Figure 4.11 B). 
Previous studies did not observe PMS2 downregulation at the mRNA level, but 
at the protein level (Mihaylova et al., 2003). The expression of PMS2’s binding 
partner, MLH1, was found to be downregulated in hypoxic stem cells 
(Rodríguez-Jiménez et al., 2008), which is thought to be via transcriptional 
repression (Nakamura et al., 2008). However, there was no change to MLH1 in 
GBM or MB cell lines tested here. Similarly, Koshiji et al determined that 
MLH1 is unchanged by hypoxia (Koshiji et al., 2005). 
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Further observed changes include the downregulation of MSH5 in a number of 
cells lines in 1% O2 and 0.1% O2, with particularly strong downregulation in 
D566-MG (-2.04 log2 fold) at 0.1% O2 (Figure 4.11 B). Additionally, MSH4 
appears to be upregulated in U251-MG, MEB-Med8A and D283-MED in 1% O2 
but without reaching statistical significance (Figure 4.11 A). There is no data 
available for the expression of MSH4 in other cell lines due to the gene being 
deemed as ‘undetectable’ early rounds of analysis (see methods for 
information on quality control of data). Both MSH5 and MSH4 are primarily 
involved in meiosis (Bocker et al., 1999; Snowden et al., 2004), therefore the 
impact of these hypoxia-induced changes in brain tumour cell lines is 
debatable. However, activation of meiotic genes is thought to aid in the 
initiation and maintenance of oncogenesis (McFarlane and Wakeman, 2017). 
Therefore hypoxia-induced changes in MSH5 and MSH4 may indeed play an 
unknown role in brain tumour cells.   
Overall, hypoxia-induced gene expression changes have been observed for two 
key players in the initial steps of mismatch repair, namely MSH2 and PMS2, 
which correlates with previous findings in the literature. As both genes are 
involved in critical steps of MMR, this reduction of gene expression may have 
a significant consequence for MMR capacity in hypoxia.  
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Figure 4.11: Differential expression of MMR genes in 1% and 0.1% O2. 
Differential gene expression was calculated for each gene as log2 fold 
change for (A) 1% O2 and (B) 0.1% O2 with respect to the expression level in 
21% O2. Red shaded area denotes fold change values below the 
+/-0.58 log2 fold (+/-1.5-fold) threshold of change. Blue area denotes fold 
change values above the designated threshold. Filled shapes represent data 
which is statistically significant (p<0.01), whereas hollow shapes show no 
statistical significance. Data are represented as the mean of three 
independent experiments. 
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4.4 Validation 
4.4.1 mRNA validation 
Several studies comparing the NanoString gene expression platform and 
RT-PCR, deemed the NanoString platform to be a robust and reliable method 
for the determination of gene expression (Malkov et al., 2009; Veldman-Jones 
et al., 2015; Bentley-Hewitt et al., 2016). However, to ensure this was the case 
for this current NanoString based study, several genes were subjected to 
further gene expression analysis by RT-PCR. Genes were selected on the basis 
that they were regulated in at least one cell line. In total, the expression of 
seven genes was confirmed by RT-PCR using cDNA from U87-MG, U251-MG 
and D566-MG RNA samples (Figure 4.12).  
There is a strong correlation between the NanoString and RT-PCR expression 
data. For example, the extent of upregulation for ABL was similar between the 
RT-PCR and NanoString data (Figure 4.12). However, there were some 
exceptions. For example, MSH5 in U251-MG showed opposite regulation in 
RT-PCR and NanoString, with 0.36 log2 and -0.59 log2 fold change 
respectively. Additionally, there was a notable fold change difference for 
MSH5 in D566-MG at 1% O2 (Figure 4.12 C). This is potentially due to the low 
overall expression of MSH5 (data not shown), which would increase the 
likelihood of more substantial discrepancies in fold changes between the two 
analysis platforms. Overall, the NanoString platform is a reliable method to 
assess gene expression however further validation with other gene expression 
analysis platforms or assessment of the protein level is always valuable.  
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Figure 4.12: NanoString Validation by RT-PCR. Seven genes were selected 
from the NanoString panel for validation by RT-PCR. cDNA samples for 
(A) U87-MG, (B) U251-MG and (C) D566-MG was utilised in RT-PCR 
experiments to assess the expression levels of selected genes. Data are 
expressed as log2 fold change with respect to expression at 21% O2. Data 
from NanoString is included for direct comparison. RT-PCR data is 
represented as the mean of three independent experiments.  
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4.4.2 Protein level validation 
In order for hypoxia-induced gene expression changes to directly impact DNA 
repair functionality, the protein levels must be affected. Previous reports 
suggest this is not always the case. For example, hypoxia-induced 
downregulation of Ku70 mRNA in prostate cancer cells did not impact the 
Ku70 protein levels (Meng et al., 2005). To determine whether the hypoxia-
induced gene expression changes observed in the NanoString assay translated 
to the protein level, three proteins (PARP1, PCNA, PMS2) were selected for 
analysis by western blotting. These three proteins were chosen due to the 
availability of suitable antibodies. Protein levels were examined in D566-MG 
and U87-MG cells, which displayed downregulation of PARP1, PCNA and 
PMS2 gene expression in hypoxia. Cells were pre-incubated in 21%, 1% or 0.1% 
O2 for 5 days before western blotting. Actin or Vinculin was used as a loading 
control, and densitometry measurements were performed to determine the 
fold change in protein with respect to the level at 21% O2 (Figure 4.13).  
PARP1 and PCNA protein levels were relatively similar in hypoxia and 
normoxia for both cell lines (Figure 4.13 A, B), yet a decrease (0.58 fold) in 
PARP1 was observed in U87-MG pre-incubated in 1% O2. In contrast, the gene 
expression data suggested a 1.49 (-0.58 log2) and 1.97 (-0.98 log2) fold change 
at 1% O2 for D566-MG and U87-MG respectively (Figure 4.10 A). PMS2, a 
component of mismatch repair, was strongly downregulated in hypoxic 
D566-MG and U87-MG, particularly at 0.1% O2, where a 0.55 fold and 
0.72 fold change was observed (Figure 4.13 C). Similarly, a 2.66 (D566-MG) 
and 1.58 (U87-MG) mRNA fold change was identified in the NanoString assay.  
Overall, not all proteins tested were downregulated by hypoxia. However, the 
mismatch repair protein, PMS2, was strongly downregulated in both GBM cell 
lines at the mRNA and protein level. This suggests that some of the hypoxia-
induced changes to gene expression are likely to impact the amount of protein 
available to repair mechanisms.  
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Figure 4.13: The impact of hypoxia on PARP1, PCNA, PMS2 protein levels. 
D566-MG and U87-MG cells were pre-incubated in 21%, 1% or 0.1% O2 for 5 
days before western blotting for (A) PARP1 (B) PCNA and (C) PMS2. Image J 
was used for blot quantification, with the mean fold change in protein levels 
with respect to 21% O2 for three independent experiments, shown below 
bands. PARP1 and PCNA blots were repeated twice. PMS2 blots conducted 
at least three times. Figure shows representative blots.  
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4.5 Discussion 
Hypoxic exposure can alter the expression of essential DNA repair genes, yet 
this had not yet been explored in GBM and MB. Using a NanoString based 
approach, multiple changes to gene expression were identified across several 
cell lines, with a variable impact of increasing hypoxia severity. Understanding 
the functional consequences and the molecular mechanism driving these 
changes will enable an improved understanding of the impact of hypoxia in 
GBM and MB.  
4.5.1 Moderate versus severe hypoxic exposure  
Within a brain tumour, the median oxygen concentration is ~1.7%, yet this can 
vary from close to anoxia (0%) to more moderate hypoxia (~3%) (Rampling et 
al., 1994). These extremes in the microenvironment can have a varied impact 
on cell biology. However, the effect of moderate and severe hypoxia on DNA 
repair gene expression was not so clear-cut, in the current study. Previous 
work exploring hypoxia and DNA repair primarily utilise severe hypoxic 
exposure (0.0 – 0.2%) over short time periods. For example, the hypoxia-
induced downregulation of RAD51, BRCA1, DNA-PKcs, Ku70 and LIGIV, was 
determined after exposure to <0.2% O2 (Bindra et al., 2004, 2005; Meng et al., 
2005). Within brain tumours, the proportion of cells exposed to such extreme 
hypoxia is low, with most cells experiencing ~0.5% O2 (Evans et al., 2004). 
Therefore, using such severe hypoxia in DNA repair studies may be less 
valuable. Such extreme hypoxic exposure can have devastating consequences 
for many cellular processes resulting in cell death. In 0.02% O2, cell cycle 
arrest is induced, and p53 protein accumulates (Amellem and Pettersen, 1991; 
Graeber et al., 1994). This could directly influence the response of cells to DNA 
damaging agents, in part, due to the requirement of cycling cells for damage 
induction. Additionally, in severely hypoxic cells, replication arrest occurs 
leading to the activation of ATR, ATM, H2AX, Chk2 and p53, independent of 
DNA damage (Hammond et al., 2002; Bencokova et al., 2009), and further 
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issues can arise upon reoxygenation. Within the tumour microenvironment, 
fluctuations in tumour oxygenation is common due to the hectic architecture 
of the vasculature. Cellular reoxygenation can lead to replication restart and 
the induction of excessive DNA damage (Pires et al., 2010). Overall, severe 
hypoxia (close to anoxia), causes multiple cellular events that can lead to the 
induction of apoptosis. Therefore, it is unlikely that these cells would affect 
the tumour population as a whole, and may have little relevance clinically. To 
enable a consensus between findings related to hypoxia and DNA repair, 
standardising the definitions of hypoxia would be ideal. This is challenging 
due to cell line variations, primarily impacted by the physioxia of the 
originating tissue.  
4.5.2 PMS2 and the mismatch repair pathway  
The findings of the NanoString assay were not so clear-cut, with multiple 
changes in different cell lines. However, some common gene expression 
changes dominate, particularly in GBM cells. Specifically, downregulation of 
PMS2 and LIGIV was found in nearly all GBM cell lines tested. The functional 
consequence of LIGIV downregulation is to be explored in Chapter 5. 
Therefore, only the potential impact of PMS2 downregulation will be 
discussed here. 
During DNA replication, polymerase errors can occur leading to the insertion 
of incorrect nucleotides. These mismatched base pairs are removed and 
replaced by MMR. PMS2 is essential for this process, and alterations to PMS2 
expression may impact MMR activity. Defects in any of the critical MMR 
repair proteins (PMS2, MLH1, MSH2, MSH6), can lead to hypermutation and 
microsatellite instability, due to the increased number of point mutations 
(Kim et al., 1999). Point mutations drive tumorigenesis and cancer 
progression. For example, in a brain tumour based multicellular tumour 
spheroid cultures, downregulation of PMS2 and MLH1 promoted the initiation 
of tumour cell formation and growth (Collins et al., 2011). Therefore, it is likely 
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that the downregulation of PMS2 in hypoxic GBM will increase the mutation 
rate and drive further tumour progression.  
In addition to an increased mutation rate, MMR deficiencies have been 
implicated in treatment resistance. In 1996, the link between MMR and 
cisplatin resistance was established, when cisplatin-resistant human ovarian 
adenocarcinoma cells were found to have reduced MLH1 protein (Aebi et al., 
1996). In the same year, both MLH1 and MLH2 downregulation was found to 
induce both cisplatin and carboplatin resistance (Fink et al., 1998), although 
this was only a low-level resistance. Similarly, in U87-MG cells, which display 
PMS2 downregulation, a low level of cisplatin resistance was observed 
(Chapter 3). MMR defects can have further clinical impact for GBM, due to the 
requirement of MMR for temozolomide sensitivity. In 1997, the necessity of 
functional MMR for apoptosis induced by temozolomide was determined 
(D’Atri et al., 1998). Further work established that loss of MSH6 was 
associated with increased tumour progression during temozolomide treatment 
in GBM (Cahill et al., 2007), and alterations of MSH2 expression could predict 
patient response to TMZ therapy, with reduced expression correlating with 
decreased overall patient survival (McFaline-Figueroa et al., 2015). 
Downregulation of PMS2 in hypoxia could have a significant clinical impact 
for GBM. Increased mutation rate driving tumorigenesis and reduced 
sensitivity to temozolomide would be disastrous for the successful treatment 
of GBM, potentially reducing overall survival rates. Identifying the mechanism 
behind MMR gene regulation would be essential in order to develop targeted 
molecular-based therapies.  
4.5.3 Mechanisms of hypoxia-induced gene regulation 
Regulation of gene expression in hypoxia can arise due to a number of 
mechanisms. Epigenetic modifications can lead to long-term alterations to 
gene expression. For example, alterations to histone methylation and 
acetylation at the promoters of BRCA1 and RAD51 can lead to reduced gene 
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expression (Lu et al., 2011). However, transient changes to DNA repair gene 
expression are more common, with both HIF dependent and independent 
mechanisms described in the literature. HIF can directly modulate the 
transcription of genes through binding at the hypoxia response elements 
within promoters of DNA repair genes. In the MLH1 promoter, HREs have 
been identified (Mihaylova et al., 2003). The presence of HREs does not 
necessarily suggest that regulation is entirely through HIF binding, as hypoxia-
induced downregulation of MLH1 was found also to be independent of HIF 
(Mihaylova et al., 2003). However, contradicting mechanisms of MLH1 
regulation with regards to the requirement of HIF, are reported due to 
differences in hypoxia severity and duration (Koshiji et al., 2005; Rodríguez-
Jiménez et al., 2008).  
A well characterised HIF independent mechanism affecting DNA repair gene 
expression is an alteration of E2F transcription binding. In normoxia, the 
expression of BRCA1 is mediated through the binding of the activating factor 
E2F1 as well as the E2F4/P130 suppressor. However, under hypoxic conditions, 
p130 binding to E2F4 is enhanced, due to alterations to p130 post-translational 
modifications. This results in an increase in E2F4/p130 transcriptional 
suppressor binding at the BRCA1 promotor, reducing the rate of transcription 
(Bindra et al., 2005). Regulation of RAD51 and FANCD2 are thought to occur 
by a similar E2F related mechanism (Bindra and Glazer, 2007; Scanlon and 
Glazer, 2014). Overall, the direct mechanism of hypoxia-induced expression of 
DNA repair genes has only been determined in a limited number of cases, 
however in order to further understand how hypoxia influences DNA repair 
within a tumour setting, defining the molecular mechanism behind the 
observed changes is essential.  
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4.5.4 Concluding remarks and future work  
To conclude, changes to DNA repair gene expression by hypoxia is not so 
clear-cut, with the specifics of hypoxic exposure and cell lines creating a high 
level of variation. However, several genes were found to be downregulated in 
multiple GBM cell lines, such as PMS2 and LIGIV. A reduction in crucial MMR 
components could reduce repair efficiency, having a significant clinical 
consequence for GBM, due to the increased mutation rate and treatment 
resistance of MMR deficient cells. The consequences of hypoxia on NHEJ 
efficiency through examination of XRCC4 kinetics is to be explored in 
Chapter 5. Beneficial future work includes the examination of DNA repair 
gene expression in cells with knocked down HIF to aid in further identifying 
the drivers of the observed gene changes. Understanding the molecular 
mechanism behind gene expression changes in hypoxia is required in order to 
develop targeted therapies to tackle these highly resistant tumours.    
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Chapter 5: Exploring the impact of 
hypoxia on LIGIV expression and 
XRCC4 kinetics 
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5.1 Introduction 
In Chapter 4, several genes were downregulated by hypoxia in multiple cell 
lines. In particular, LIGIV, encoding DNA ligase IV, was downregulated in all 
GBM cell lines. Similarly, Meng et al, observed LIGIV downregulation in 
hypoxic prostate cancer cells (Meng et al., 2005). DNA ligase IV (named ligase 
IV from here) is an essential component of the canonical NHEJ, responsible 
for the repair of DSB. Therefore, downregulation of LIGIV may lead to reduced 
functionality of NHEJ.   
NHEJ is the primary pathway for repair of DSB. To summarise, when a DSB is 
present Ku70/80 and DNA-PKcs are initially recruited to stabilise the DNA 
ends (Gottlieb and Jackson, 1993; Kurimasa et al., 1999). The exposed ends are 
processed by Artemis, PNK, WRN or DNA polymerases (Mahaney et al., 
2009), followed by the recruitment of XRCC4 : ligase IV, triggered by the 
interaction of XLF and XRCC4 (Yano et al., 2009). XLF can stimulate ligase 
activity, yet this is cell line dependent (Roy et al., 2015). Additionally, the 
presence of Ku70/80 is essential for XRCC4 and ligase IV recruitment (Nick 
McElhinny et al., 2000; Mari et al., 2006). Ligase IV is responsible for ligation 
of the DNA ends, the final step of NHEJ (Chapter 1, Figure 1.8). 
In 1997, Grawunder et al and Critchlow et al observed the dimerisation of 
XRCC4 and ligase IV, an essential step for ligase IV activity (Critchlow et al., 
1997; Grawunder et al., 1997). XRCC4 binds to ligase IV via the XRCC4 
interacting region (XIR) between the BRCT domains (Grawunder et al., 1998). 
During DNA ligation, AMP bound to ligase IV is transferred to the 5’ 
phosphate end of DNA, which is then displaced by the 3’OH, resulting in the 
covalent bonding of DNA strands (Ellenberger and Tomkinson, 2008). 
Afterwards, ligase IV requires re-adenylation, which is stimulated by XRCC4, 
leading to protein stabilisation (Modesti et al., 1999). The C-terminal region of 
ligase IV, containing the XIR and BRCT domains, is essential for nuclear 
localisation of XRCC4 (Fonslow et al., 2015). In ligase IV-deficient cells, 
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XRCC4 localisation was dysregulated, and reduced XRCC4 protein levels were 
observed with LIGIV mutations (Fonslow et al., 2015). Therefore, ligase IV 
plays a fundamental role in XRCC4 localisation and stabilisation. This 
dynamic relationship between XRCC4 and ligase IV is crucial for efficient 
NHEJ. Disruption of this relationship through ligase IV downregulation may 
be catastrophic for NHEJ functionality.  
Traditionally, assessment of DNA repair efficiency and function was 
conducted using cell-free biochemical assays, which have provided great 
insight into the role of essential repair proteins. For example, Ku80 was found 
to be essential for precise NHEJ in cell-free assays (Feldmann et al., 2000). 
However, measuring repair mechanisms directly within the cellular 
environment is critical for an accurate understanding of these complex 
interdependent mechanisms. Methods that address this include ionising 
radiation-induced focus formation (IRIF) and laser microirradiation studies. 
IRIF is a popular method, which has been highly valuable for the identification 
of recruited proteins and understanding their modification. For example, IRIF 
experiments led to the observation that γH2AX is essential for BRCA1, RAD50 
and RAD51 recruitment (Paull et al., 2000). However, not all repair proteins 
can recruit to IRIF, which limits its use. Therefore, laser microirradiation 
methods have been developed.  
In 1999, Rogakou et al first described the use of a UVA laser with 
bromodeoxyuridine (BrdU) to induce DNA damage in specific sites of the 
nucleus, triggering DSB repair protein recruitment (Rogakou et al., 1999). 
Since these initial studies, several groups commonly use UVA lasers 
(337-405 nm), to study DNA repair protein recruitment. However, as well as 
DSB, irradiation with a UVA laser leads to other damage types including 
cyclobutane-pyrimidine dimers (CPDs), which is not ideal. Also, sensitisers 
(BrdU, Hoechst) are required for DNA breaks to form, which can have 
unwanted side effects (Dinant et al., 2007). Therefore, UVA lasers may not be 
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the most suitable choice for DNA damage induction. Alternatively, irradiating 
with a near-infrared laser (near-IR) (≥780 nm) removes the requirement for 
sensitisation, and may reduce the unwanted DNA damage products (i.e. 
CPDs). Work by Träutlein et al compared the specificity of DNA damage 
induced by an infrared multiphoton femtosecond laser, tuned to wavelengths 
775 nm and 1050 nm. Using a 1050 nm laser increased the specificity for DSB, 
with a marked reduction in unwanted DNA damage. However, 775 nm 
resulted in CPD formation (Träutlein et al., 2009). Similarly, irradiation with 
an 800 nm femtosecond laser causes CPD formation and recruitment of 
nucleotide excision repair proteins (Dinant et al., 2007). The specifics of laser 
tuning can significantly affect the resultant DNA damage induced. However, 
in comparison to UVA lasers, near-IR pulsed femtosecond lasers enable high 
spatial resolution of DNA damage, with 3D confinement and a reduction of 
overall photo-toxicity (Meldrum and Botchway, 2003), making them a better 
choice. Overall, laser microirradiation can provide valuable insight into DNA 
repair protein dynamics in live cells. Therefore, to induce DNA breaks and 
assess the functional impact of LIGIV downregulation, a near-IR pulsed laser 
was used.    
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5.2 Objectives 
The experimental aims for this chapter were as follows:  
1. Explore the impact of hypoxia on LIGIV expression.   
2. Develop a multiphoton laser microirradiation protocol to assess DNA 
repair protein recruitment.  
3. Compare the kinetics of XRCC4 recruitment in hypoxic and normoxic 
GBM cells.  
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5.3 Results  
5.3.1 Further investigation of LIGIV regulation in hypoxia  
In Chapter 4, hypoxia-induced LIGIV downregulation was identified in the 
GBM cell lines, U87-MG, D566-MG, U251-MG and T98G. These changes were 
observed in both 1% and 0.1% O2, albeit to a lesser extent in 1%. Here, the 
hypoxia-induced regulation of LIGIV was explored further, to understand how 
the length of hypoxic exposure, reoxygenation and HIF inhibition can affect 
LIGIV expression.  
5.3.1.1 Assessment of LIGIV expression across multiple cell types 
To validate the NanoString data, RT-PCR experiments were performed to 
assess the LIGIV mRNA levels of cells pre-incubated in 21%, 1% or 0.1% O2 for 
5 days. Hypoxia-induced downregulation of LIGIV was observed in U87-MG, 
D566-MG, U251-MG, and T98G, yet data for T98G were highly variable and 
not statistically significant (Figure 5.1). In D566-MG, pre-incubation in 1% and 
0.1% O2 resulted in 2.0-fold (-1.0 log2) and 3.9-fold (-1.9 log2) decrease in 
LIGIV expression respectively, yet without statistical significance. In U87-MG, 
statistically significant downregulation of LIGIV was observed for cells 
incubated in both 1% (p=0.0191) and 0.1% O2 (p=0.0135) (Figure 5.1). In MB 
cells, D283-MED and MEB-Med8A, there was little change in LIGIV 
expression in hypoxia, which correlates with the NanoString data. 
Additionally, HeLa cells were included in RT-PCR experiments. If HeLa cells 
displayed hypoxia-induced LIGIV downregulation, they could be used in later 
studies as they are easier to manipulate and transfect. However, LIGIV mRNA 
levels were highly variable, suggesting there is no clear impact of hypoxia on 
LIGIV expression in these cells (Figure 5.1). 
Overall, LIGIV is downregulated by hypoxia in U87-MG, U251-MG and 
D566-MG, which correlates with the NanoString data. Ideally, assessment of 
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the protein levels would further validate these findings. However, a specific 
and good quality DNA ligase IV antibody could not be sourced despite several 
trial experiments (appendix 1.7).  
 
Figure 5.1: LIGIV expression in multiple cell lines pre-incubated in hypoxia. 
Cells were incubated in 21%, 1% or 0.1% O2 for 5 days. After incubation, 
RNA was extracted and converted to cDNA for RT-PCR experiments, 
probing for LIGIV. Data is represented as log2 fold change in mRNA levels 
with respect to level for the 21% O2 samples. Data are the mean for at least 
three independent experiments, with error bars showing S.E.M. * denotes 
significant data where p<0.05 indicated by one-way student t-test. 
 
5.3.2 LIGIV expression in chronic and acute hypoxia 
In Chapter 3, chronic hypoxia was necessary to reduce sensitivity to chemo 
and radio-therapy. This, in part, was linked to the downregulation of the MRN 
complex after chronic hypoxic exposure (>48 h). Also, Fan 2014 observed a 
high level of DNA repair gene regulation in chronic hypoxia (96 h) (Fan, 
2014). With this in mind, for the NanoString study, chronic hypoxic exposure 
(5 days) was used, however, the timing for LIGIV downregulation needs to be 
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established. Therefore, D566-MG cells, which displayed the strongest hypoxia-
induced downregulation of LIGIV, were exposed to 21% and 1% O2 for 1-5 days, 
before performing RT-PCR experiments to assess LIGIV and GLUT1 expression. 
GLUT1, a common hypoxic marker, was elevated as expected throughout the 
time course (Figure 5.2). Overall, LIGIV was downregulated at all-time points 
(1-5 days). The strongest regulation was observed after only 1-day hypoxic 
exposure, with 3.0-fold downregulation (-1.6 log2, p=0.002) (Figure 5.2). 
Therefore, both acute and chronic hypoxic exposure can induce LIGIV 
regulation. Similarly, PARP1 and PMS2 expression was also reduced in both 
chronic and acute hypoxia (appendix 1.8).  
 
Figure 5.2: LIGIV is downregulated after chronic and acute hypoxic 
exposure. D566-MG cells were incubated in 1% O2 for 1-5 days, as well as 
21% O2. After incubation, RNA was extracted and converted to cDNA for 
RT-PCR experiments, probing for LIGIV and GLUT1. Data is represented as 
log2 fold change in mRNA levels with respect to level for the 21% O2 
samples. Data are the mean of at least three independent experiments, with 
error bars showing S.E.M. * denotes significant data where p<0.05 indicated 
by one-way student t-test. 
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5.3.3 Restoration of LIGIV expression upon reoxygenation 
Within the tumour microenvironment, oxygen levels fluctuate due to the 
dynamic nature of tumour blood vessel formation. Therefore, tumour cells can 
experience periods of hypoxia and reoxygenation events. In previous studies, 
Bindra et al observed hypoxia-induced downregulation of RAD51, which 
persisted up to 48 h after reoxygenation (Bindra et al., 2004), suggesting that 
alterations to repair protein expression may continue. To understand whether 
this was true for hypoxia-induced LIGIV downregulation, D566-MG cells were 
pre-incubated in 21% and 1% O2 before reoxygenating for 24-72 h. The levels 
of LIGIV and GLUT1 (hypoxic marker) mRNA was determined using RT-PCR. 
During hypoxic exposure, GLUT1 mRNA increased in cells incubated in 1% O2 
(control), yet decreased upon reoxygenation as expected (Figure 5.3). For cells 
incubated in 1% O2, there was a 3.9-fold (-1.9 log2) reduction in LIGIV mRNA 
levels, and after 24 h reoxygenation, the level of LIGIV mRNA was restored to 
the normoxic levels (1.13-fold), which was maintained up to 72 h (Figure 5.3). 
Therefore, hypoxia-induced LIGIV downregulation does not persist upon 
reoxygenation in D566-MG cells.  
 
 
 
 
 
 
Figure 5.3: Reoxygenation restores LIGIV mRNA levels. D566-MG cells were 
incubated in 21% and 1% O2 for 5 days before reoxygenation for 24-72 h. 
After incubation, RT-PCR experiments were performed for LIGIV and 
GLUT1. Control represents samples from 5 days 1% O2 incubation. Data is 
represented as log2 fold change with respect to 21% O2. Data are the mean 
of two independent experiments, with error bars showing S.E.M. 
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5.3.4 Acriflavin treatment restores LIGIV mRNA levels 
The hypoxia-inducible factor, HIF, is the master regulator of the hypoxic 
response. HIF can influence the expression of many genes including GLUT1, 
VEGF and EPO, as well as DNA repair genes. The HIF pathway forms a 
negative feedback loop, which results in the downregulation of HIF after long 
periods of hypoxia. However, in D566-MG and U87-MG cells, after 5 days of 
hypoxic exposure, HIF-1α remained high, with similar levels to 6 h and 24 h 
exposure (Figure 5.4). Therefore, it is feasible that hypoxic downregulation of 
LIGIV is dependent on HIF activity. To explore this further, an inhibitor of HIF 
was used to block HIF activity.   
Several commercially available inhibitors of HIF have been developed, which 
result in the reduction of HIF activity through various mechanisms. Acriflavin 
(AF) can inhibit HIF-1 and HIF-2 through binding to the PAS-B subdomain in 
the α subunit, preventing dimerisation of the α and β subunits, and reducing 
HIFs transcriptional activity (Lee et al., 2009). However, AF can also 
significantly impact other signalling pathways therefore is not a specific and 
‘clean’ HIF inhibitor. In order to determine whether hypoxia-induced 
downregulation of LIGIV is dependent on HIF transcriptional activity, D566-
MG and U87-MG cells were treated with 5 µM AF and incubated in 21%, 1% 
and 0.1% O2 for 24 h before assessing LIGIV mRNA levels (Figure 5.6). 
Preliminary experiments, assessing GLUT1 expression after 1 - 10 µM AF 
treatment, determined that 5 µM of AF was sufficient to reduce GLUT1 
expression in hypoxia (Figure 5.5). However, due to the toxicity of AF, cells 
could be treated for 24 h only. In both D566-MG and U87-MG, 
downregulation of LIGIV was observed in control untreated hypoxic cells 
(Figure 5.6). With AF treatment, LIGIV mRNA levels remained similar to 
normoxic conditions. For example, in U87-MG cells incubated in 0.1% O2, a 
1.8 fold (-0.87 log2 fold) reduction of LIGIV was observed, yet with AF, there 
was no downregulation of LIGIV mRNA (Figure 5.6). However, the expression 
levels of LIGIV with AF were highly variable.  
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Overall, treatment with the HIF inhibitor, acriflavin, inhibits the hypoxia-
induced downregulation of LIGIV in D566-MG and U87-MG, suggesting LIGIV 
regulation may be HIF dependent. Additionally, in D566-MG cells treatment 
with DMOG results in LIGIV downregulation (Figure 5.7). DMOG is a 
competitive inhibitor of PHDs, which causes the accumulation of HIF in 
normoxia. This finding strengthens the notion that HIF is involved in LIGIV 
downregulation. 
Interestingly, PARP1, PMS2 and WRN, which were downregulated in the 
NanoString assay, were not restored by acriflavin addition (appendix 1.9), 
suggesting that the regulation of some DNA repair genes may not be through 
the canonical HIF pathway. Yet, this does not rule out the indirect 
involvement of HIF. To explore this further, knockdown of HIF using siRNA 
would be ideal. However, this requires 2-3 days transfection, which would 
trigger stress to D566-MG and U87-MG as they are highly sensitive to the 
transfection reagents. As an alternative, digoxin, a cardiac glycoside, inhibiting 
the translation of HIF (Zhang et al., 2008) and thereby reducing HIF protein 
levels was used. However, with dioxin treatment, no change to HIF protein 
levels was observed at non-lethal doses, nor was there any reduction in 
hypoxia-induced GLUT1 expression (appendix 1.10). 
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Figure 5.4: HIF-1α and HIF-2α is upregulated in chronic hypoxia. U87-MG 
and D566-MG cells were incubated in 1% O2 and 21% O2 for 0-120 h. Protein 
was extracted and the levels of HIF-1α and HIF-2α determined by western 
blotting for two independent experiments 
 
Figure 5.5: Hypoxia-induced GLUT1 upregulation is eliminated with 
acriflavin treatment. D566-MG cells were incubated in 0.1% O2 with treated 
with 0-10 µM Acriflavin for 24 h. Control cells remained in 21% O2. RT-PCR 
experiments were performed to assess GLUT1 expression levels. Data 
represents the fold change in GLUT1 expression relative to 21% O2. Data are 
from a single experiment.  
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Figure 5.6: Acriflavin treatment restores LIGIV mRNA levels in hypoxia. (A) 
D566-MG and (B) U87-MG cells were incubated in 21% and 1% O2 for 24 h 
with and without 5 µM Acriflavin. After incubation, RNA was extracted and 
converted to cDNA for RT-PCR experiments, probing for LIGIV. Data is 
represented as log2 fold change in mRNA levels with respect to level for the 
21% O2 samples. Data are the mean of at least three independent 
experiments, with error bars showing S.E.M. Data not significant indicated 
by one-way student t-test. 
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Figure 5.7: DMOG treatment induces LIGIV downregulation. D566-MG cells 
were treated with 0.5 mM DMOG for 24 h. RT-PCR was performed to 
examine the mRNA levels of LIGIV and GLUT1. Data are relative to the 
mRNA levels in the 21% O2 control. Data represent the mean of three 
independent experiments, with error bars showing S.E.M. Data not 
significant indicated by one-way student t-test. 
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5.3.5 Development of a multiphoton laser microirradiation protocol 
Assessment of the recruitment of DNA repair factors to the nucleus has 
traditionally been accomplished with IRIF and laser microirradiation studies. 
IRIF has provided a wealth of data, specifically for DSB repair, and is 
commonly favoured due to the simplistic protocols and opportunities for high 
throughput assessment. However, use of an ionising radiation source is 
essential to induce foci formation. Etoposide and phleomycin were 
investigated to determine whether they could induce foci of NBN and MRE11, 
yet no foci was observed (appendix 1.11). Therefore, without an ionising 
irradiation source, these foci formation assays are challenging. Alternatively, 
laser microirradiation can be employed.  
Ligase IV and XRCC4 form a heterodimer, which is recruited to double strand 
breaks as part of the NHEJ pathway. A reduction of ligase IV may therefore 
impact the behaviour of XRCC4, and alter the effectiveness of NHEJ. To 
explore the impact of hypoxia on XRCC4 kinetics, a multiphoton laser 
microirradiation protocol was developed  
5.3.5.1 Optimisation of multiphoton laser to induce DNA damage 
Within the Centre for Cell Imaging at the University of Liverpool, laser 
microirradiation for DNA damage studies had not yet been attempted. 
Therefore, optimisation was required in order to ensure that 1) recruitment of 
EGFP-XRCC4 was identifiable and 2) cells were not excessively damaged 
during experimentation. The initial optimisation was conducted in HeLa cells, 
due to ease of transfection and suitability for live cell imaging.  
Work by Träutlein et al determined that irradiating with long wavelengths 
(1050 nm) could selectively induce DNA breaks, with a reduction in unwanted 
cyclobutane-pyrimidine dimers (Träutlein et al., 2009). Therefore, irradiation 
with the Ti:Sapphire multiphoton laser, was done using various wavelengths 
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to determine whether EGFP-XRCC4 recruitment to the damage site could be 
observed. Irradiation with long wavelengths (900 nm and above) resulted in 
no observable recruitment of EGFP-XRCC4, even with increased power 
(Figure 5.8). A common characteristic of the multiphoton laser is a decreasing 
power output with increasing wavelength, therefore observing reduced or no 
visible EGFP-XRCC4 recruitment is not surprising. Increasing the laser 
iterations (number of times laser hits the sample) can result in higher energy 
delivery. However, a high number of iterations increases the time required to 
irradiate the cell. Therefore, increasing the iterations further (over 100) for 
longer wavelengths is not ideal. Previous publications successfully induced 
DNA damage at high wavelengths (1050 nm) (Träutlein et al., 2009). 
However, lasers can vary, with differences in pulse length and overall energy 
output.   
Irradiating with shorter wavelengths (700-850 nm) successfully induced 
EGFP-XRCC4 recruitment (Figure 5.8). After irradiating with the 700 nm 
laser, in some cases, recruitment was very rapid and not localised specifically 
to the damage region. This could suggest that proteins are aggregating rather 
than recruiting, likely due to the high-power output with shorter wavelengths. 
Therefore, an 800 nm laser was chosen for future experiments (Figure 5.9), as 
irradiating with this wavelength created distinct regions of the recruited 
protein. 
Further optimisation of irradiation with the 800 nm laser was conducted to 
determine the minimum laser power and iterations required to observe 
EGFP-XRCC4 protein recruitment reliably. Ideally, fewer iterations are 
preferable to reduce the time taken to irradiate, therefore 20 iterations were 
chosen. Over time, the efficiency of a laser can alter due to several variables 
such as alignment, age, usage etc. therefore, it was necessary to directly 
measure the laser power output with a laser power meter rather than relying 
on the arbitrary percentages of the acquisition software. The optimal power 
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output required to induce EGFP-XRCC4 recruitment was 10 mW. Due to the 
high-powered nature of a multiphoton laser, it is possible to create direct 
structural damage to cells and tissue. However, this was not the case with the 
optimised settings. The transmitted light images obtained showed no 
alterations to the nucleus at the site of irradiation (Figure 5.9). Additionally, 
after irradiation cells were left for 1-2 hours to recover, before observing their 
general appearance. The irradiation protocol did not appear to kill cells, nor 
did it have a negative impact on the overall observed cell morphology.  
After several optimisation steps, a laser microirradiation protocol with a 
multiphoton laser was successfully developed. Using the optimised parameters 
(800 nm, 10 mW, 20 iterations), EGFP-XRCC4 recruitment was observed with 
no direct impact on the structural integrity of the cell or induction of cell 
death. Ideally, a longer wavelength is desirable due to the reduction in 
unwanted DNA damage types (Träutlein et al., 2009), yet this was not possible 
with this specific laser. However, using a multiphoton laser is beneficial due to 
no requirement for sensitisers and an overall reduced photo-toxicity, making 
this method favourable compared to traditional UVA lasers.  
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5.3.6 Comparing XRCC4 kinetics in normoxic and hypoxic GBM cells 
D566-MG cells displayed the highest number of hypoxia-induced changes to 
DNA repair gene expression. Therefore, these cells were used in the laser 
microirradiation experiments to assess XRCC4 recruitment. In preliminary 
testing, D566-MG responded similarly to HeLa with the optimised laser 
settings. However, using D566-MG resulted in several challenges. Firstly, in 
comparison to HeLa cells, D566-MG transfected poorly. Therefore, 
transfection was optimised to ensure a sufficient number of cells were 
transfected with EGFP-XRCC4 without negatively affecting cell health. In 
addition, imaging D566-MG was difficult as the cells moved excessively, 
causing them to travel out of the field of view after a short period. Therefore, 
the length of image acquisition had to be limited to 20 minutes. However, this 
was sufficient to observe the recruitment of EGFP-XRCC4 (Figure 5.10 A).  
In order to determine the impact of hypoxia on XRCC4 kinetics, D566-MG 
cells were pre-incubated in 21% or 1% O2 for 5 days, before transfecting with 
EGFP-XRCC4. An 800 nm laser (10 mW, 20 iterations) was used to create 
DNA damage in a 2 µm region of the nucleus, and images acquired (488 nm 
laser) in 15 s intervals over 20 minutes (Figure 5.10 A). Imaging and laser 
microirradiation was conducted in 21% O2, to ensure the oxygen environment 
did not influence the extent of DNA damage induced by the laser. For each 
cell imaged, signal intensity of the damaged spot was measured for each frame 
and normalised to the background and to non-irradiated sections of the 
nucleus (see methods 2.15.1 for details), using Matlab scripts for batch 
processing (appendix 1.4 & 1.5). The normalised intensity at each time point 
was determined for each cell, defined here on out as a ‘trace’ (Figure 5.10 C, B). 
As expected, there is significant variation between each trace within datasets, 
in part due to imaging noise as well as cell-to-cell variability. However, when 
the average of each trace is determined, the variation (standard error of the 
mean) was similar between hypoxic and normoxic cells (Figure 5.11).  
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Overall, in normoxic and hypoxic cells, EGFP-XRCC4 was recruited within 
480 – 600 s (8 – 10 minutes). This is significantly slower than other 
components of the NHEJ, such as Ku70/80, which reached maximal 
accumulation after ~3 minutes (Mari et al., 2006). However, recruitment of 
XRCC4 first requires the recruitment of Ku70/80 and DNA-Pkcs, followed by 
DNA end processing. Therefore, a delay in XRCC4 recruitment compared to 
Ku70/80 was expected. Interestingly, normoxic cells (Figure 5.11 A) reached a 
higher peak intensity (i.e. recruit more protein) than hypoxic cells 
(Figure 5.11 B). This is unlikely due to differences in protein levels within the 
cells, as the fluorescent signal does not fully deplete from the surrounding un-
damaged nucleus. In general, DNA repair proteins are in excess to ensure 
rapid recruitment of proteins when DNA damage occurs. Therefore, it is 
possible that some of the XRCC4 recruited to the DNA damage site might not 
be complexed with ligase IV. During experimentation, cells were preferentially 
selected for low GFP signal, to reduce the pool of un-complexed XRCC4. 
However, it is not possible to completely separate the recruitment of 
complexed and un-complexed XRCC4 experimentally. Therefore, it is 
important to note that the recruitment of un-complexed XRCC4 may dampen 
any impact of hypoxia on complexed XRCC4 kinetics.   
After the initial accumulation of EGFP-XRCC4, rapid loss of protein occurs. 
This is thought to be indicative of DSB repair (Mari et al., 2006). In normoxia, 
dissociation of EGFP-XRCC4 appears to be quicker (steeper slope) than 
hypoxia, suggesting that DSB repair may be delayed in hypoxic cells. However, 
in order to fully assess and compare the recruitment/dissociation of 
EGFP-XRCC4, parameters representing EGFP-XRCC4 kinetics need to be 
measured for each trace individually, rather than examining the population as 
a whole. Each trace was divided into two features, protein recruitment and 
protein dissociation (Figure 5.12), which was the focus of further analysis.  
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Figure 5.10: XRCC4 protein dynamics in GBM cells. D566-MG cells were 
pre-incubated in 21% or 1% O2 for 5 days before EGFP-XRCC4 transfection. 
EGFP signal was excited with a 488 nm laser and imaged using a 40x 
objective and 5x zoom. A 2 µm region was irradiated with the nucleus with 
an 800 nm multiphoton laser (10 mW, 20 iterations). Images were acquired 
at 15-second intervals for 20 min post-irradiation. (A) Representative 
images of an irradiated cell. The red arrow indicates the irradiated region. 
(B, C) Intensity of the irradiated region was measured using Image J. 
Measured signal was background subtracted and normalised to the pre-
damage intensity (see methods). Normalised intensity for B) normoxic 
(n = 22) and (C) hypoxic cells (n =27) were plotted.  
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Figure 5.11: Mean normalised intensity of all irradiated cells. D566-MG cells 
transfected with EGFP-XRCC4 were subjected to laser microirradiation. 
Signal intensity was measured for each cell and normalised to several 
parameters (see methods). The mean signal intensity was calculated for all 
(A) normoxic (n = 22) and (B) hypoxic cells (n = 27), which was plotted 
(solid line). The shaded region represents the standard error of the mean. 
(C) An overlay of the hypoxic and normoxic data.  
Exploring the impact of hypoxia on LIGIV expression and XRCC4 kinetics 
174 
 
 
Figure 5.12: Schematic of the features of the intensity plots. After laser 
microirradiation, signal intensity rapidly increases due to protein 
recruitment, followed by a steady dissociation of protein from the irradiated 
site. 
 
5.3.6.1 Assessment of XRCC4 recruitment  
To determine whether pre-incubation in hypoxia influences XRCC4 
recruitment, D566-MG cells were pre-incubated for 5 days in 21% or 1% O2 
and subjected to the laser microirradiation protocol (Figure 5.13). Recruitment 
of protein can be described by a first order response to a step change, whereby 
XRCC4 recruitment is a function of the time-dependent generation of double 
strand breaks. This enables the fitting of a first order differential equation (see 
methods 2.15.1), from which parameters can be derived. Specifically, the time 
to 50% accumulation was determined for each trace (Figure 5.13 A). A similar 
time to 50% accumulation was obtained for hypoxic and normoxic cells, with 
125 s and 167 s and respectively (Figure 5.13 B). This difference was not 
statistically significant and relatively small (42 s) with respect to the total 8-10 
minutes required for recruitment. This is exemplified by the fact that both 
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normoxic and hypoxic datasets have a similar overall distribution 
(Figure 5.13 C), with the majority of data points below 200 s. Additionally, the 
time to time to maximal recruitment (intensity) was also determined for the 
normoxic and hypoxic dataset, which showed a similar results for both 
conditions (appendix 1.12). 
By fitting a first order differential equation, the recruitment time constant (τ) 
can be determined, which provides insight into the recruitment kinetics of 
XRCC4. In hypoxic cells, the recruitment of XRCC4 is similar to normoxia, 
with recruitment constants of 180.3 s and 204.9 s respectively (Table 5.1). This 
correlates with the time required to reach 50% intensity, supporting the 
notion that recruitment of XRCC4 to DSB is similar regardless of 
pre-incubation conditions. Therefore, hypoxia does not significantly impact 
XRCC4 recruitment. 
Table 5.1: EGFP-XRCC4 recruitment constant in D566-MG  
 
Condition Mean τ (s) S.E.M Significant? 
Normoxia 240.9 60.14 N/A 
Hypoxia 180.3 35.65 No; p=0.3913 
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Figure 5.13: Time to 50% of maximum intensity. D566-MG cells transfected 
with EGFP-XRCC4 were subjected to laser microirradiation. Signal intensity 
was measured for each cell. A first-order differential equation was fitted to 
normalised signal intensity, to determine the time to 50% of maximum 
intensity, as depicted by the schematic (A). (B) The mean time to 50% 
intensity for normoxic (n = 21) and hypoxic (n = 21) cells was determined, 
with error bars representing S.E.M. (C) The distribution of time to 50% 
intensity for each hypoxic and normoxic cell. The line represents the 
median. Data not significant indicated by student t-test. 
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5.3.6.2 Assessment of XRCC4 dissociation 
Once repair of a DSB by NHEJ is complete, repair proteins dissociate from the 
damage site. Little is known regarding the signals that initiate dissociation. 
Hypoxia my impact XRCC4 dissociation, potentially due reduced ligation 
events as a result of Ligase IV downregulation. To explore this, D566-MG cells 
were pre-incubated in 21% or 1% O2 for 5 days before laser microirradiation. 
For each normalised trace produced, an exponential decay curve (see methods 
5.15.1) was fitted after the peak intensity, and the time taken for 50% of the 
total protein to dissociate determined (Figure 5.14). In hypoxic cells, the mean 
time to 50% dissociation was higher than normoxia, with 813 s and 582 s 
respectively (Figure 5.14 B). However, the data was not statistically significant. 
A similar distribution of data was observed for both conditions, with a higher 
median for hypoxia, correlating with the increased mean (Figure 5.14 C). The 
rate of EGFP-XRCC4 loss from the irradiated site can be determined by the 
slope of the exponential decay curve, expressed as a.u s-1 (Figure 5.15 A). In 
hypoxic D566-MG, the rate of protein dissociation was less (slower protein 
dissociation) than normoxia, with a mean rate of 4.66 x 10-4 a.u s-1 and 
7.96 x 10-4 a.u s-1 respectively (Figure 5.15 B). This correlates with the longer 
time taken for hypoxic cells to have 50% of recruited protein dissociated.  
Overall, in hypoxia, it takes longer to achieve dissociation of 50% of the 
protein from the irradiation site. This is exemplified by the reduced rate of 
signal loss in hypoxic cells compared to normoxic cells. These results suggest 
that NHEJ may be less efficient in hypoxia.  
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Figure 5.14: Time to 50% intensity loss. D566-MG cells transfected with 
EGFP-XRCC4 were subjected to laser microirradiation. Signal intensity was 
measured for each cell. Normalised signal intensity was used to determine 
the time at which half of the maximal intensity is lost as depicted by the 
schematic in (A). (B) The mean time to half maximum intensity for 
normoxic (n = 21) and hypoxic (n = 22) cells was determined, with error bars 
representing S.E.M. (C) The distribution of time to half-maximal intensity 
for each hypoxic and normoxic cell. The line represents the median. Data 
not significant (with and without outliers) indicated by student t-test.  
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Figure 5.15: The rate of protein dissociation. D566-MG cells transfected with 
EGFP-XRCC4 were subjected to laser microirradiation. Signal intensity was 
measured for each cell. Normalised signal intensity was used to determine 
the rate of protein dissociation as depicted by the schematic in (A). (B) The 
rate for normoxic (n = 21) and hypoxic (n = 22) cells was determined, with 
error bars representing S.E.M. (C) The distribution of the rate of 
dissociation for each hypoxic and normoxic cell. The line represents the 
median. * denotes significant data where p<0.05 indicated by student t-test. 
Data remains significant after outliers removed.  
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Development of a multiphoton laser irradiation protocol has enabled the 
successful assessment of XRCC4 behaviour in hypoxic and normoxic cells. 
Overall, hypoxic D566-MG have a similar rate of EGFP-XRCC4 recruitment, 
yet a slower dissociation of the protein away from the damage site, suggesting 
a reduced efficiency of repair. Ideally, to examine this further, a longer 
acquisition period would be required to better measure the characteristics of 
XRCC4 dissociation. For example, Mari et al determined that 20% of recruited 
Ku protein remain 2 h post damage, which was similar to the level of damage 
remaining 2 h after ionising radiation (Mari et al., 2006). However, extending 
imaging periods was challenging due to cell movement out of the field of view. 
Significant time and effort was given to optimisation and this challenge was 
solved by using tile scanning and image stitching, to obtain a larger field of 
view, without losing magnification. However, unfortunately, due to multiple 
technical issues with equipment (loss of laser power, laser misalignment and 
other optical problems), this work had to cease, as it was becoming too time 
consuming in terms of troubleshooting. The laser irradiation protocol is a 
highly sensitive procedure; therefore, small changes in the instrument can 
significantly influence the extend of DNA damage and subsequent 
recruitment.  
Further experiments that were planned included the knockdown of ligase IV 
to determine whether hypoxia-induced ligase IV downregulation could be 
causing the altered XRCC4 kinetics. Also, fluorescence recovery after 
photobleaching (FRAP) of the recruited EGFP-XRCC4 would have given an 
interesting insight into the movement of XRCC4 within the nuclear 
compartment, and the extent of immobilisation. As further experimentation 
with the laser microirradiation protocol was not possible, an end joining assay 
was employed as an alternative assay for NHEJ activity.   
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5.3.7 The impact of hypoxia on DNA end joining   
Experimental techniques to directly assess cellular end joining capabilities are 
limited. However, plasmid end joining assays have recently been developed. 
For example, Nagel et al engineered a florescent constructs, which enabled the 
assessment of NHEJ (Nagel et al., 2014). Bindra et al, utilised a luciferase-
based ‘end joining’ (religation) assay to compare NHEJ capacity in normoxic 
and hypoxic cells (Bindra et al., 2005). Therefore, to assess the impact of 
hypoxia on end joining a similar approach was adopted.  
A luciferase expressing plasmid (CMV-pGL4.16) was linearised using a HindIII 
restriction enzyme (Figure 5.16 A). The HindIII restriction site lies between 
the CMV promoter and the start of the luciferase gene; therefore in order for 
the luciferase gene to be expressed, the plasmid requires ligation. Thus, end 
joining activity can be measured by the assessment of luciferase activity. To 
determine the impact of hypoxia on end joining activity, D566-MG cells and 
U87-MG cells were pre-incubated in 21%, 1% or 0.1% O2 for 1 day or 5 days, 
with transient transfection of the undigested and digested plasmid 24 h before 
assaying activity. Experimental workflow is described in Figure 5.14 B. In 
D566-MG cells, 1-day hypoxic incubation (1% and 0.1% O2) resulted in a 
significant increase in luciferase activity, thus end joining was enhanced 
(Figure 5.16 A). For example, in cells incubated in 0.1% O2, there was a 1.9 fold 
increase in luciferase activity compared to normoxia (Figure 5.17 A). Similarly, 
for D566-MG cells incubated for 5 days in hypoxia, higher luciferase activity 
was observed with 3.0 and 2.7 fold change for 1% and 0.1% O2 respectively 
(Figure 5.18 A). In contrast, U87-MG displayed no significant change in end 
joining activity after acute hypoxic exposure (Figure 5.17 B). However, after 
chronic exposure (5 days), cells pre-incubated in 0.1% O2 had a 1.5 fold 
increase in end joining activity, which was statistically significant (p = 0.0134) 
(Figure 5.18 B).   
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Overall, both acute and chronic exposure results in increased end joining in 
D566-MG, whereas, U87-MG cells required chronic severe hypoxia (5 days 
0.1% O2) for a similar trend to be observed. Although the end joining assay has 
been used in previous publications to examine NHEJ efficiency (Bindra et al., 
2005), the specificity of this assay for NHEJ is questionable. Firstly, the the 
DNA repair mechanims are acting upon plasmid DNA which is not consricted 
in nucleosomes, as with endogenous DNA. Thus the end joining activities may 
be different. Additionally, multiple DNA ligase enzymes exist within the cell, 
which would have the ability to religate the digested plasmid. Therefore, there 
is no direct specificity for ligase IV. Hypoxia could enhance the activity or 
levels of other DNA ligases, which may cause the increase in ligation activity. 
In order to determine the specificity of the end joining assay, inhibition of the 
NHEJ pathway or knockdown of LIGIV would be ideal. In 2012, SCR7, a 
potential chemical inhibitor of NHEJ was identified, which was thought to 
selectively inhibit DNA ligase IV (Srivastava et al., 2012). However, in 2016 
SCR7 was found not to be ligase IV specific, nor did it significantly inhibit 
NHEJ (Greco et al., 2016). Similarly, when SCR7 was applied to the luciferase 
end joining assay, no difference in luciferase activity was observed (data not 
shown). Therefore, there is currently no commercially available inhibitor of 
NHEJ.  
Since the specificity of the end joining assay for NHEJ is debatable, significant 
conclusions on the impact of hypoxia on NHEJ cannot be drawn. In contrast, 
the laser microirradiation assay specifically examined NHEJ proteins, and 
suggested that NHEJ may be less effective in hypoxic GBM as hypothesised.   
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Figure 5.16: The end joining assay protocol. (A) Schematic of the 
CMV-pGL4.16 plasmid encoding a luciferase gene used in the end joining 
assay. HindIII was used to digest the plasmid, with successful digest tested 
by DNA gel electrophoresis. (B) Schematic detailing the protocol for cells 
incubated for 1 day or 5 days in hypoxia, whereby transient transfection of 
the undigested and digested plasmid was done 24 h before assaying 
luciferase activity.  
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Figure 5.17: End joining activity in acute hypoxia. (A) D566-MG and 
(B) U87-MG cells were transfected with HindIII digested CMV-pGL4.16, 
before incubation in 21%, 1% and 0.1% O2. After 24 h, cells were lysed and 
subjected to a luciferase assay. Data were normalised to signal from un-
digested CMV-pGL4.16, before calculating fold changes relative to 21% O2 
samples. Data are representative of the mean for at least three independent 
experiments, with error bars showing S.E.M. * denotes significant data 
where p<0.05 indicated by one-way student t-test. 
Exploring the impact of hypoxia on LIGIV expression and XRCC4 kinetics 
185 
 
 
Figure 5.18: End joining activity in chronic hypoxia. (A) D566-MG and (B) 
U87-MG cells were pre-incubated in 21%, 1% and 0.1% O2 for 4 days followed 
by transfection of HindIII digested CMV-pGL4.16 for 24 h. Cells were then 
lysed and subjected to a luciferase assay. Data were normalised to signal 
from un-digested CMV-pGL4.16, before calculating fold changes relative to 
21% O2 samples. Data are representative of the mean for at least three 
independent experiments, with error bars showing S.E.M. * denotes 
significant data where p<0.05 indicated by one-way student t-test. 
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5.4 Discussion 
A rapid response to DNA damage is essential to maintain genome integrity. 
Small alteration to repair mechanisms, through a reduction in available repair 
proteins can be catastrophic, leading to reduced repair efficacy and the 
accumulation of DNA damage. Genetic and environmental factors can affect 
DNA repair proteins, such as tumour hypoxia, which can cause changes to 
transcription, translation and post-translational modifications of essential 
repair proteins. The expression of the LIGIV gene, encoding DNA ligase IV, a 
critical component of NHEJ, is reduced in hypoxic GBM. This resulted in an 
altered response to DNA damage, which might have significant clinical 
consequences. However, examining the impact of reduced levels of DNA 
repair proteins can be challenging.  
5.4.1 Laser microirradiation for DNA repair studies 
Laser microirradiation during live cell imaging is a popular technique in DNA 
repair studies enabling the assessment of DNA repair protein recruitment in 
live cells. To some degree, the classical technique of irradiation-induced foci 
formation, has been overtaken by laser microirradiation, in part due to the 
limited repertoire of factors that can be explored with IRIF (Kong et al., 2009). 
Mari et al first described the use of laser microirradiation for examination of 
NHEJ. Using a multiphoton laser to induce DNA damage, the group observed 
recruitment of Ku80, DNA-Pkcs, ligase IV and XRCC4, which co-localised 
with γH2AX, an indicator of DSB. Additionally, the Ku80 dissociation kinetics 
were established, which signified repair of the DSB, and Ku70/80 was found to 
be essential for XRCC4 recruitment (Mari et al., 2006). Using a similar laser-
based approach, in the current study, reduced levels of ligase IV were found to 
impact XRCC4 dissociation.  
Whilst laser microirradiation studies have provided valuable insight into the 
NHEJ repair pathway, many limitations remain. Specifically, UVC lasers 
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require sensitizers, which can alter chromatin structure, impact cell 
metabolism, and result in DNA damage after illumination with visible light 
(Turner and Denny, 1996; Wojcik and Dobrucki, 2008; Solarczyk et al., 2012). 
Lasers absorption also occurs along the whole irritated path, not just the focal 
plane, causing further nuclear damage above and below the area of interest 
(Ferrando-May et al., 2013). These issues can be avoided to some extent by 
using tuneable near-IR lasers (multiphoton), which have increased spatial 
resolution and reduced toxicity, without the need for sensitisers (Meldrum 
and Botchway, 2003). IRIF remains a popular experimental choice, due to 
extensive characterisation of ionising irradiation induced DNA damage, 
examination of endogenous protein and the ability to perform high-
throughput experiments. In contrast, laser microirradiation coupled with 
fluorescence confocal microscopy provides dynamic measurement of 
recruitment, dissociation and immobilisation (by using FRAP) of DNA repair 
proteins in live cells.  
5.4.2 Measuring DNA repair - challenges 
Although a number of techniques are available to assess DNA repair, such as 
laser microirradiation or IRIF, these are often limited and pose significant 
experimental challenges. For IRIF, antibodies are required to detect repair 
proteins, yet a large number of repair components do not have specific 
commercially available antibodies. Additionally, tools such as the homologous 
recombination assays require the transfection of multiple constructs with a 
high transfection efficiency (Nakanishi et al., 2011), yet this is not always 
possible for all cell types. For some DNA repair pathways, such as DSB repair, 
several tools are available to explore repair capacity. However, fewer options 
are available for other pathways such as mismatch repair (MMR). In 
Chapter 4, PMS2, a key component of MMR was shown to be downregulated 
in hypoxic GBM cells. Exploring the functional impact of this change is 
challenging with limited assays available. Plasmid-based MMR assays have 
been reported in the literature, yet these require complex and time-consuming 
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molecular biology, as well as highly efficient transient transfection (Lei et al., 
2004). Further development of DNA repair assays is required to enable rapid 
high-throughput analysis of DNA repair capacity of multiple DNA repair 
pathways. Nagel et al, has come somewhat close to making this a reality, by 
engineering several reporter constructs with varying DNA damage types, 
which activate different repair pathways including MMR, BER, HRR and NHEJ. 
Using these constructs, Negal et al were able to measure DNA repair capacity 
of multiple DNA repair pathways in primary GBM cells. Technology like this 
brings us one step closer to high-throughput assessment of DNA repair. This 
would enable further understanding of the impact of hypoxia-induced changes 
to DNA repair proteins, such as LIGIV downregulation, and the potential 
influence on cancer treatment.  
5.4.3 Consequences of LIGIV downregulation for NHEJ 
DNA ligase IV is essential for efficient re-ligation of DNA strands during NHEJ. 
Reduced ligase IV activity can lead to the accumulation of DNA damage, 
genomic instability, and the induction of apoptosis. In the current study, 
LIGIV was downregulated in hypoxic GBM cells. Similarly, hypoxia-induced 
LIGIV downregulation has previously been identified in prostate cancer cells 
(Meng et al., 2005), yet the molecular mechanism behind this reduction has 
not yet been identified. Here, it was determined that LIGIV downregulation 
was likely to be HIF dependent and potentially caused reduced NHEJ activity, 
as shown by the slow dissociation upon laser microirradiation-induced 
damage. This could lead to the accumulation of DSB after DNA damage. 
Sharpless et al observed that loss of a single copy of LIGIV resulted in the 
formation of chromosomal aberrations, arising from DSB (Sharpless et al., 
2001). Additionally, with reduced ligase IV levels the fidelity of NHEJ is 
compromised, as ligase IV plays an important role in end protection, 
preventing nucleotide loss (Smith et al., 2003). In the absence of efficient 
NHEJ, microhomology-mediated end joining (MHEJ) is utilised to repair 
breaks. MHEJ is highly mutagenic, as sequence deletions arise due to this 
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repair mechanism (Liang et al., 2008), which could further contribute to 
genome instability. Overall, a reduction in ligase IV will negatively affect 
NHEJ, resulting in increased chromosomal aberrations, genome instability and 
mutagenesis. These consequences will drive tumorigenesis and can have a 
significant clinical impact.  
5.4.4 Clinical implications of LIGIV downregulation   
Mutations in the LIGIV gene give rise to DNA ligase IV syndrome, a rare 
autosomal recessive disorder. Common characteristics include microcephaly, 
immunodeficiency and increased sensitivity to ionising radiation (Altmann 
and Gennery, 2016). Loss of function mutations are the primary cause, such as 
missense mutations which reduce ligase IV functionality by ~90% (Buck et al., 
2006). Downregulation of LIGIV in tumour cells is likely to result in a similar 
radiosensitive phenotype observed in DNA ligase IV syndrome, which would 
be ideal particularly for GBM. Increased sensitivity to DNA damaging agents 
as a result of ligase IV knockdown has previously been explored. For example, 
siRNA knockdown of ligase IV sensitised A172 glioblastoma cells to 
temozolomide, with a 3-fold reduction in colony formation (Kondo et al., 
2009). Also, sensitivity to nimustine (ACNU), a chemotherapeutic agent used 
for recurrent GBM, increased with ligase IV knockdown (Kondo et al., 2010). 
This could have significant implications for GBM treatment, suggesting that 
hypoxic GBM cells with LIGIV downregulation should display increased 
sensitivity to treatment. However, this was not the case (Chapter 3), 
suggesting that alternative resistance mechanisms may be masking the impact 
of reduced NHEJ functionality. LIGIV downregulation is likely causing the 
build-up of DSB, yet the residual damage may not be sufficient to trigger 
apoptosis. Alternatively, this low-level damage may lead to chromosomal 
aberrations, thereby driving tumour progression. To induce the 
radiosensitivity often associated with defects in NHEJ, knockdown or 
inhibition of ligase IV, may be required. This could be a potential therapeutic 
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option for GBM and would reduce the amount of high dose chemo- and 
radiotherapy required for effective treatment. 
5.4.5 Concluding remarks and future work 
To conclude, the laser microirradiation protocol was an invaluable and 
exciting tool for assessing DNA repair through observations of XRCC4 
kinetics. Future development of imaging modalities, allowing for a high 
throughput approach will likely make this method a popular choice for DNA 
repair studies. LIGIV downregulation in hypoxia may be responsible for the 
reduced XRCC4 dissociation, yet further experiments would be required to 
confirm this. Additionally, optimisation of the comet assay would enable a 
thorough examination of DSB repair kinetics and would undoubtedly give 
deeper insight into the impact of hypoxia on repair mechanism. Although the 
data presented here suggests reduced NHEJ capacity, increased sensitivity to 
DNA damaging agents was not observed. Therefore, it is likely that the 
residual DSB are low level and are not inducing apoptosis.  
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6.1 Project overview 
Work in this thesis aimed to explore the impact of hypoxia on DNA repair. A 
mechanism of hypoxia-induced reduction in treatment sensitivity involving 
double strand break recognition was proposed for some MB cells, yet found 
not to be universal. Alternatively, a broad exploration of DNA repair gene 
expression was undertaken, and the functional impact of the hypoxia-induced 
changes was investigated. Few DNA repair genes were regulated by hypoxia, 
with little commonality between cell lines. This suggests that clear-cut 
hypoxia-induced regulation of DNA repair may not be as prevalent as others 
suggest. Further development of tools for DNA repair studies as well as the use 
of 3D tumour spheroid models will enable additional exploration of the impact 
of hypoxia on DNA repair for MB and GBM. This will bridge the gap between 
in vitro 2D and in vivo based studies. Improving the understanding of brain 
tumour cell biology will aid in the development of new treatment methods, to 
increase overall survival rates.    
6.2 The future of DNA repair studies 
DNA repair is essential for maintenance of genome integrity. Dysregulation of 
repair leads to the build-up of mutations and genomic instability, promoting 
cancer progression. Assessment of the efficiency of DNA repair can be 
challenging, with limited experimental options suitable for varied cell types, as 
discussed in Chapter 5. The repertoire of tools for DNA repair studies have 
remained similar in the last 20 years, yet further technological advancements 
have enabled the recent improvement of classical techniques as well as the 
development of novel methods. Primarily, DNA repair is assessed through 
monitoring levels of DNA damage. With advancing technologies, further 
opportunities for highly accurate and high-throughput assessment of DNA 
damage is becoming a reality. 
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A classical technique for DNA damage assessment is the comet assay, known 
for high rates of variation (Collins, 2004; Azqueta and Collins, 2013), which 
was experienced in this thesis. Recently this commonly used technique has 
had a makeover. The CometChip, developed by Sykora et al., increases comet 
assay throughput enabling the analysis of thousands of comets within a single 
experiment (96 well, 400-500 microwells per well). This upgraded method 
reduces inter- and intra- assay variability compared to slide-based methods 
(Sykora et al., 2018). Using this technique, the authors successfully screened 
compound libraries for DNA damaging capabilities, highlighting its potential 
value in drug development studies (Sykora et al., 2018). Such a technique 
would be useful for hypoxia and DNA repair studies, particularly when using 
multiple cell lines, as in this thesis. However, the comet assay assesses global 
DNA damage with little understanding of the genomic location. Alternatively, 
PCR based assays can provide insight into damage position. For example, long 
run real-time PCR quantifies DNA damage within specific nucleotide 
sequences (Lehle et al., 2014). Also, mass spectrometry can identify altered 
DNA sequences arising due to polymerase errors (Su et al., 2018). However, 
these methods are still limited to specific pre-selected regions of the DNA, 
without high nucleotide resolution.  
Arguably, the gold star of DNA damage detection is DNA sequencing. Since 
completion of the human genome project in 2003 (Lander et al., 2001; Collins 
et al., 2004), sequencing technologies have boomed, with faster, cheaper and 
more precise methods available. Adoption of sequencing for DNA repair 
studies was inevitable. However, sequencing techniques are not without 
limitations. Illumina ‘short read’ sequencing has a high rate of incorrect 
nucleotide incorporation, due to the necessity of sequence amplification 
(Sloan et al., 2018). This high noise threshold makes the detection of single 
base mutations challenging. Therefore, Illumina-based sequencing methods 
have been adapted to increase fidelity through redundant sequencing, 
whereby multiple sequence reads are produced for a single DNA fragment 
(Ahn et al., 2015; Schmitt et al., 2015; Hoang et al., 2016). This enables the 
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reliable assessment of single nucleotide changes. Detection of chemical DNA 
damage using sequencing relies on the blocking of the polymerase by bulky 
adducts. Using this principle Hu et al developed a novel protocol for DNA 
damage sequencing, ‘Damage-seq’, which was used to map cisplatin and UV 
induced DNA damage and repair (Hu et al., 2016, 2017) Overall, sequencing-
based methods for the detection of DNA damage and repair enables high 
nucleotide resolution without bias for specific regions of the genome. 
Therefore, it is likely that such methods will be adopted for future DNA repair 
studies. These techniques will be particularly useful for investigations using 
patient-derived tumour samples, as no cell culture is required. Potential 
applications include the optimisation of chemotherapy regimens and 
exploration into why treatment sometimes fails, such as in the case of 
hypoxia-induced drug resistance.  
High-throughput comet assays and sequencing based methods will 
undoubtedly be adopted in the next few years. However, associated cost is 
likely to be a barrier. The current toolbox available to researchers, such as 
plasmid based assays, IRIF, laser microirradiation etc. have significant 
limitations, making selection of the perfect tool somewhat impossible. Most 
DNA repair studies are conducted in model cell lines (HeLa, U2OS), which are 
easily manipulated, making the DNA repair ‘toolkit’ appear sufficient. 
However, these cell lines no longer truly recapitulate the essence of 
physiological cell biology, making the relevance of any findings questionable. 
To take DNA repair studies one-step further, the development of techniques, 
which are easily applicable to multiple cell types, with a high-throughput and 
cost effective application, is required. However, whether this is possible is yet 
unknown. Likely, in the near future, techniques to examined DNA repair in 3D 
cell culture based studies will be developed as an alternative to 2D models, yet 
this may add further technical complexity.  
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6.3 Moving towards 3D and in vivo investigations  
In this thesis, MB and GBM cell lines provided valuable insight into the effect 
of hypoxia on DNA repair mechanisms. However, the extent to which 2D 
monolayer recaptures the tumour microenvironment is questionable. 
Alternatively, 3D tumour spheroids are a possibility. GBM and MB cells can 
successfully form tumour spheroids, which can replicate features such as 
oxygen, nutrient and pH gradients as well as cell-matrix interactions (Baker 
and Chen, 2012). Tumour spheroids have already been employed for DNA 
repair studies. For example, Mondesert et al developed a DNA damage 
response reporter consisting of a p21 promotor linked to an RFP gene. This 
construct enabled the visualisation of the activation of the DNA damage 
response in spheroids, using confocal microscopy (Mondesert et al., 2015). 
Further advances in live cell imaging technologies, such as the development of 
light sheet microscopy has taken spheroid imaging a step further enabling 3D 
live cell imaging. For example, the Sée group successfully used tumour 
spheroids with light sheet microscopy to assess invasion of U87-MG spheroids 
(Richards et al in preparation). Light sheet microscopy enables deeper yet less 
toxic imaging of samples in comparison to conventional confocal microscopy, 
with the added benefit of 3D imaging capabilities (Reynaud et al., 2008). This 
technology could be applied to DNA repair studies, and would enable the 
assessment of DNA repair in a 3D setting, where cells are exposed to varying 
oxygen tensions and nutrient gradients. However, the current resolution of 
commercial light sheet microscopy may not be sufficient to obtain single cell 
observations within the 3D environment (Santi, 2011). Combining light sheet 
microscopy with super resolution imaging would circumvent this issue but 
may not be a reality for many years to come.  
3D spheroid models to some extent can recreate the tumour 
microenvironment. However, often these do not represent the mixed cell 
types found within a tumour. Therefore, xenografts and tissue samples are 
undoubtedly one-step closer to true in vivo patient studies. Previous work 
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examining the impact of hypoxia on DNA repair proteins, found significant 
correlation between in vitro and in vivo observations using xenografts. For 
example, hypoxia is thought to induce ATM phosphorylation in vitro. 
Assessment of tumour xenografts showed that CAIX, a common hypoxic 
marker, co-localised with phosphoATM, correlating with the in vitro 
observations (Olcina et al., 2013). Additionally, hypoxia-induced 
downregulation of RAD51 was identified in vitro and in cervical and prostate 
cancer xenografts (Bindra et al., 2004). However, within the DNA repair field 
it is rare to find extensive DNA repair studies that heavily utilise xenografts or 
patient samples. Often these are additional experiments, potentially added to 
improve the impact factor of the publication. Does this highlight potential 
lack of applicability of DNA repair findings to actual human samples? Likely 
this is true for model cell line (HeLa, U2OS etc.) based work. However, due to 
the heterogeneous nature of patient samples and xenografts, variations in 
findings involving DNA repair or hypoxia are expected. Yet, in order to 
generate translational data, using patient samples or xenografts is essential 
and needs to be more commonplace in DNA repair and hypoxia studies. 
However, obtaining patient samples in particular can be difficult for rare 
cancers, such as MB. Therefore, a cheap and high-throughput animal model is 
desirable.  
Several genetically engineered mouse models exist for MB and GBM, however 
working with mice can be costly and requires extensive licencing. Recently, 
the chick embryo has been shown to be an effective model for cancer research, 
allowing for high-throughput experimentation (Herrmann et al., 2015). The 
use of this model in hypoxic studies has been exemplified by Herrmann et al. 
Authors showed that hypoxic neuroblastoma tumours grown within the chick 
embryo had metastasised to other organs, whereas normoxic tumours did not 
(Herrmann et al., 2015). Using this model, tumours of different cancer types 
can be grown, which are fully vascularised. Measurements of oxygen tension 
within these tumour have been taken in real time, and an average of ~1% O2 
was found (Al-Mutawa et al., 2018), which is physiologically relevant and 
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correlates with the oxygen levels in brain tumours (Evans et al., 2004). 
Currently, there are only a handful of publications using the chick embryo 
model for cancer studies, yet this would be an invaluable low cost resource 
GBM and MB studies. Exploration of DNA repair mechanism would also be 
possible, such as examining the impact of reduced levels of repair proteins on 
the response to DNA damaging agents. Tumours grown on the chick embryo 
model can be taken for further lab based in vitro experiments, such as the 
assessment of DNA repair capacity. This has previously been done with tissue 
samples, for example Slyskova et al. used colorectal cancer biopsies to extract 
DNA repair proteins, which were used in a comet assay (Slyskova et al., 2014). 
Development of the chick embryo model for cancer research is currently 
underway, and its adoption as a primary model is likely.  
6.4 Prospects for brain tumour treatment  
There have been little change to treatment protocols for brain tumours over 
the past few decades, with no new drugs having been developed. Tumour 
hypoxia can cause resistance to common treatment methods, however as 
exemplified in this thesis, the mechanism behind this resistance is not so 
clear-cut. Therefore, the extent to which tumour hypoxia and treatment 
resistance should influence brain tumour drug development currently is small. 
However, as the majority of MB and GBM treatments are based on the 
generation of DNA damage, understanding the DNA damage response within 
these tumours is essential, particularly for the generation of new and emerging 
therapies.  
Proton beam therapy is an emerging irradiation-based treatment protocol for 
brain tumours. Already, several clinical trials have provided evidence of the 
usefulness of proton beam therapy for GBM and MB (Mizumoto et al., 2014; 
Yock et al., 2016). Until recently, little was known regarding the type of DNA 
damage induced by this technique. However, extensive research by Carter et 
al, has provided further understanding of the complex DNA damage created 
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and the cellular response initiated (Carter et al., 2017). Studies like this will aid 
in assessment of the cancer killing power of proton beam therapy, and will 
provide further evidence for its usefulness in a clinical setting. However, this 
leads to the question, how does hypoxia influence the repair of proton beam 
induced DNA damage? Will hypoxia-induced resistance to proton beam 
therapy occur and will this be a significant clinical barrier? Further research 
conducted by teams at the University of Liverpool, will undoubtedly aid in 
answering these important questions. The UK government has provided £250 
million to proton beam therapy centres, suggesting that adoption of this 
technique by the NHS is likely.  
Drug-based precision medicine is becoming a fashionable trend within cancer 
research. Already this approach is being explored for MB treatment, with the 
use of GLI inhibitors for SHH MB (Kim et al., 2010, 2013). This is partly 
attributed to the successful evaluation of the molecular architecture of MB. 
However, attempts to generate targeted GBM therapies have been largely 
unsuccessful. Determination of potential mechanisms of hypoxia-induced 
resistance in these tumour may aid in development of targeted therapies, 
however as described in this thesis, there was no clear-cut mechanism of 
hypoxia-induced treatment resistance, nor were there any strong changes to 
DNA repair genes across multiple cells lines. Therefore, it is unlikely that this 
research will directly contribute to the generation of targeted treatments in 
the near future. However, brain tumour patients are still dying and a rapid 
short-term solution is desperately needed. Likely, this will come in the form of 
drug repositioning. Dissemination of GBM tumours can disrupt the blood-
brain barrier. However delivery of effective drug doses can still be challenging 
(Sarkaria et al., 2018). Repositioning of non-oncology based drugs, which 
already show high CNS activity, is becoming a popular strategy for brain 
tumour treatment. For example, the antidepressant, fluoxetine, has been 
shown to suppress GBM tumour growth in preclinical models (Liu et al., 2015). 
Additionally, Disulfiram used to manage alcoholism, can increase sensitivity to 
temozolomide through inhibition of MGMT (Triscott et al., 2012; Paranjpe et 
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al., 2014). Two clinical trials using Disulfiram in combination with standard 
GBM therapy are currently underway (ClinicalTrials.gov Identifier: 
NCT01907165, NCT03363659). Due to the wealth of safety information already 
available on these drugs, the initiation of clinical trials is accelerated. 
Therefore, repositioning of drugs is likely a viable short-term option for 
improving GBM treatment.  
6.5 Final remarks  
Both MB and GBM are complex diseases with devastating consequences. Due 
to the biological and environmental complexity of these tumours, creating 
advanced personalised treatments is challenging. Thus far, little research has 
been conducted exploring hypoxia and DNA repair in these brain tumours. 
Work in this thesis provides novel insight into the complex response of GBM 
and MB to hypoxia and the implications for DNA repair mechanisms. 
Investigating these findings in a 3D tumour spheroid models of would support 
the 2D culture work, yet further technical issues may arise in a 3D system. 
Hypoxia has not yet been shown to be a causative factor in the generation of 
pro-tumorigenic mutations. However, alteration to DNA repair mechanisms 
may drive further genome instability leading to cancer progression. It is hoped 
that exploration of the fundamental cell biology of these complex tumours will 
lead to the development of new treatment protocols to overcome the low rate 
of patient survival. The main findings of this thesis are as follows: 
1. Hypoxia can downregulate key components of the DSB recognition 
machinery leading to reduced treatment sensitivity in D283-MED cells. Yet 
this is not a universal mechanism. 
2. The impact of hypoxia on DNA repair gene expression is not clear-cut, and 
relies heavily on the severity of hypoxia and is cell line dependent.  
3. Hypoxia results in altered dissociation of XRCC4 from sites of DNA 
damage suggesting that NHEJ may be impaired in hypoxia. 
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Appendix 
1.1 Genes, proteins and their full names 
Gene Name Protein Name Full Name  
ABCB1 MDR1 Multidrug resistance protein 1 
ABCC1 MPR1 Multidrug resistance-associated protein 1 
ABL1 ABL1 
Abeison murine leukaemia viral oncogene 
homolog 1 
ACTA2 SMA Smooth muscle actin 
ADM ADM Adrenomedullin 
AKT AKT AKT serine/threonine kinase 1 
AMPK  AMP-activated protein kinase 
APC APC Adenomatous polyposis coli protein 
APEX1, 2 APE1, 2 DNA-(apurinic or aprymidinic site) lyase 
ATM ATM Ataxia telangiectasia mutated 
ATR ATR Ataxia telangiectasia and Rad3-related 
AXIN1 Axin-1 AXIN1 
BAX BAX BCL2 associated X protein 
BCL2 Bcl-2 B-cell lymphoma 2 
BID BID BH3 interacting domain death agonist 
BLM BLM Bloom syndrome protein 
BRCA1 BRCA1 Breast cancer type 1 susceptibility protein 
BRCA1 BRCA2 Breast cancer type 2 susceptibility protein 
CA9 CAIX Carbonic anhydrase 9 
CDKN1A p21 Cyclin-dependent kinase inhibitor 1 
CDKN1B P27 Cyclin-dependent kinase inhibitor 1B 
CHEK2 Chk2 Checkpoint kinase 2 
CHEK3 Chk3 Checkpoint kinase 3 
CREBBP/p300 CREBBP/p300 CREB-binding protein 
CTNNB1 CTNNB1 β-Catenin 
CXCR4 CXCR4 C-X-C chemokine receptor type 4 
CYCLOA CYCLOA Cyclophillin A 
DCLRE1C Artemis Artemis 
DDX3X DDX3X DEAD-box helicase 3 
EGFR EGFR Epidermal growth factor receptor 
EPO EPO Erythropoietin 
ERCC1 ERCC1 Excision repair cross-complementation group 1 
ERCC4 ERCC4 Excision repair cross-complementation group 4 
EXO1 EXO1 Exonuclease 1 
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FEN1 FEN1 Flap endonuclease 1 
FGF FGF Fibroblast growth factor 
FIF FIF Factor Inhibiting HIF 
GDF15 GDF15 Growth/differentiation factor 15 
GEN1 GEN1 Holliday junction 5’ flap endonuclease 1 
GLI1 GLI1 Glioma-associated oncogene 
GLUT1 GLUT1 Glucose transporter 1 
H2AFX H2AX H2A histone family member X 
IDH1 IDH1 Isocitrate dehydorgenase 1 
JMJD1A JMJD1A Jumonji domain containing 1A 
KDM1A LDS1 Lysine-specific histone demethylase 1 
KDM5B PLU-1 Lysine-specific demethylase 5B 
LIG1 DNA liagse I DNA liagse I 
LIG3 DNA Ligase III DNA Ligase III 
LIGIV DNA ligase IV DNA ligase IV 
MDM2 MDM2 Mouse double minute 2 homolog 
MGMT MGMT O6 methylguanine – DNA Methyltransferase 
MLH1 MLH1 MutL homolog 1 
MLH3 MLH3 MutL homolog 3 
MPG MPG DNA-3-methyladenine glycosylase 
MRE11 MRE11 
MRE11 homolog double strand break repair 
nuclease 
MSH2 MSH2 MutS protein homolog 2 
MSH3 MSH3 MutS protein homolog 3 
MSH5 MSH5 MutS protein homolog 5 
MSH6 MSH6 MutS protein homolog 6 
MTOR MTOR Mammalian target of rapamycin 
MUTYH MUTYH MutY homolog 
MYCN N-MYC N-myc proto-oncogene protein 
NBN NBN Nibrin 
NEIL1,2,3 NEIL1,2,3 Endonuclease VIII-like 1,2,3 
NF1 NF1 Nuclear factor 1 
NHEJ1 XLF XRCC4-like factor 
NTHL1 NTHL1 Endonuclease III-like 1 
OGG1 OGG1 8-Oxoguanine glycosylase 
PARP1,2,3,4 PARP1,2,3,4 Poly[ADP-ribose] polymerase 1,2,3,4 
PCNA PCNA Proliferating cell nuclear antigen 
PDGF PDGF Platelet-derived growth factor 
PHD1,2,3 PHD1,2,3 HIF prolyl-hydroxylase 
PI3K PI3K Phosphoinositide 3-kinase 
PIM1 PIM1 
Proto-oncogene serine/threonine-protein 
kinase 
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PMS1 PMS1 Mismatch repair endonuclease PMS1 
PMS2 PMS2 Mismatch repair endonuclease PMS2 
PNKP PNKP 
Bifunctional polynucleotide 
phosphatase/kinase 
POLB Pol β DNA polymerase β 
POLD1,3,4 Pol δ DNA polymerase δ 
POLE2 Pol ε DNA polymerase ε subunit 2 
POLL Pol λ DNA polymerase λ 
PRKDC DNA-Pkcs 
DNA dependent protein kinase catalytic 
subunit 
PTCH1 PATCHED1 Protein patched homolog 1 
PTEN PTEN Phosphate and tensin homolog 
RAD23B RAD23B UV excision repair protein RAD23 homolog B 
RAD50 RAD50 RAD50 homolog 
RAD51 RAD51 RAD51 homolog 
RAD54L RAD54L 
DNA repair and recombination protein 
RAD54-like 
RBL2 P130 Retinoblastoma-like protein 2 
RCF1 RCF1 Replication factor C subunit 1 
RCF3 RCF3 Replication factor C subunit 3 
RCF4 RCF4 Replication factor C subunit 4 
RECQL RECQL RecQ-like helicase 
RECQL5 RECQL5 RecQ-like helicase 5 
RPA RPA Replication protein A 
SIRT1 SIRT2 Sirtuin 1 
SLX4 SLX4/FANCP Structure specific endonuclease subunit 
SMARC4A SMARC4A 
ATP-dependent chromatin remodeler 
SMARCA4 
SMUG1 SMUG1 
Single-strand selective monofunctional uracil 
DNA glycosylase 
SNCAIP SNCAIP Synphillin-1 
SUFU SUFU Suppressor of fused homolog 
TDG TDG 
G/T mismatch-specific thymine DNA 
glycosylase 
TOP3A TOP3A DNA topoisomerase 3-alpha 
TOP3B TOP3B DNA topoisomerase 3-beta 
TP53 p53 Tumour protein P53 
TP53BP1 53BP1 Tumour suppression p53-binding protein 1 
UBE2T UBE2T Ubiquitin-conjugating enzyme 2 
UNG UNG Uracil-DNA glycosylase 
VEGF VEGF Vascular endothelial growth factor 
VHL pVHL von Hippel-Lindau tumour suppressor 
WRN WRN Werner syndrome ATP-dependent helicase 
 248 
 
XRCC1 XRCC1 X-ray repair cross-complimenting 1 
XRCC2 XRCC2 (FANCU) X-ray repair cross-complimenting 2 
XRCC3 XRCC3 X-ray repair cross-complimenting 3 
XRCC4 XRCC4 X-ray repair cross-complimenting 4 
XRCC5 Ku80 X-ray repair cross-complimenting 5 
XRCC6 Ku70 X-ray repair cross-complimenting 6 
 
1.2 Genes examined in NanoString assay. 
ABL1 NM_005157.3 ABL, JTK7, c-ABL, p150 
AKT3 NM_005465.4  
ALKBH2 NM_001001655.2  
ALKBH3 NM_139178.3  
APC NM_000038.3  
APEX1 NM_001641.2 APEX, APE, REF1, HAP1, 
APX, APEN, REF-1, APE-1 
APEX2 NM_014481.2  
ATM NM_138292.3 ATA, ATDC, ATC, ATD, 
TEL1, TELO1 
ATR NM_001184.2  
ATRIP NM_130384.1  
AURKA NM_003600.2 STK15, STK6, BTAK, AurA, 
STK7, ARK1, PPP1R47, AIK 
BCL2 NM_000657.2  
BCL2L1 NM_138578.1  
BLM NM_000057.2  
BRCA1 NM_007305.2  
BRCA2 NM_000059.3 FANCD1, FACD, FANCD, 
FAD, FAD1, BRCC2 
BRIP1 NM_032043.1  
BUB1B NM_001211.4  
CASP8 NM_001228.4  
CCND1 NM_053056.2 BCL1, D11S287E, PRAD1, 
U21B31 
Gene Accession Number Alias 
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CCND2 NM_001759.2  
CCND3 NM_001760.2  
CCNO NM_021147.3 CCNU, UDG2, FLJ22422, 
UNG2 
CDK7 NM_001799.2  
CDKN1A NM_000389.2 CDKN1, P21, CIP1, WAF1, 
SDI1, CAP20, p21CIP1, 
p21Cip1/Waf1 
CDKN1B NM_004064.2  
CDKN2A NM_000077.3 CDKN2, MLM, CDK4I, p16, 
INK4a, MTS1, CMM2, ARF, 
p19, p14, INK4, p16INK4a, 
p19Arf 
CDKN2C NM_001262.2  
CHEK1 NM_001114121.1  
CHEK2 NM_007194.3 RAD53, CDS1, CHK2, 
HuCds1, PP1425, bA444G7 
CREBBP NM_001079846.1 RSTS, RTS, CBP, KAT3A 
CRY1 NM_004075.3  
DDB1 NM_001923.3  
DDB2 NM_000107.1  
DNA2 NM_001080449.2 DNA2L, KIAA0083 
EGFR NM_201282.1 ERBB, ERBB1 
ERCC1 NM_001983.3  
ERCC2 NM_000400.2 XPD, MAG, EM9, 
MGC102762, MGC126218, 
MGC126219 
ERCC3 NM_000122.1  
ERCC4 NM_005236.2 XPF, RAD1, FANCQ 
ERCC5 NM_000123.2  
ERCC6 NM_000124.2 CKN2, CSB, RAD26, ARMD5 
ERCC8 NM_000082.3 CKN1, CSA 
EXO1 NM_006027.3  
FAN1 NM_001146094.1  
FANCA NM_000135.2 FACA, FANCH, FAA, FA-H, 
FAH 
FANCB NM_152633.2  
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FANCC NM_000136.2 FACC, FAC, FA3 
FANCD2 NM_033084.3 FACD, FANCD, FAD, FA-D2 
FANCE NM_021922.2 FACE, FAE 
FANCF NM_022725.2  
FANCG NM_004629.1 XRCC9, FAG 
FANCI NM_001113378.1 KIAA1794, FLJ10719 
FANCL NM_001114636.1 PHF9, FLJ10335, FAAP43, 
Pog 
FANCM NM_020937.2 KIAA1596, FAAP250 
FEN1 NM_004111.4 RAD2, FEN-1, MF1 
GEN1 NM_182625.3  
GTF2H3 NM_001516.3  
H2AFX NM_002105.2  
HDAC1 NM_004964.2 RPD3L1, HD1, GON-10 
HDAC2 NM_001527.1  
HLTF NM_139048.2 SNF2L3, SMARCA3, 
HIP116A, HLTF1, RNF80 
HUS1 NM_004507.2  
KRAS NM_004985.3 KRAS2, KRAS1 
LIG1 NM_000234.1  
LIG3 NM_002311.3  
LIG4 NM_002312.3  
MAD2L2 NM_001127325.1  
MDC1 NM_014641.2  
MGMT NM_002412.3  
MLH1 NM_000249.2 COCA2, HNPCC, FCC2, 
HNPCC2 
MLH3 NM_014381.2  
MNAT1 NM_002431.2  
MPG NM_001015052.1  
MRE11A NM_005591.3 MRE11, ATLD 
MSH2 NM_000251.1 COCA1, HNPCC, HNPCC1 
MSH3 NM_002439.2  
MSH4 NM_002440.3  
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MSH5 NM_172165.2  
MSH6 NM_000179.1  
MUTYH NM_012222.2  
MYC NM_002467.3  
MYD88 NM_002468.3  
NBN NM_001024688.1 NBS, NBS1, ATV, AT-V2, AT-
V1 
NEIL1 NM_024608.2  
NEIL2 NM_145043.2  
NEIL3 NM_018248.2  
NFKB1 NM_003998.2  
NKX3-1 NR_046072.1 NKX3A, NKX3.1, BAPX2 
NLRP2 NM_017852.1 NALP2, FLJ20510, PYPAF2, 
NBS1, PAN1, CLR19.9 
NTHL1 NM_002528.5  
OGG1 NM_002542.5  
PARP1 NM_001618.3 PPOL, ADPRT, PARP 
PARP2 NM_005484.3  
PARP3 NM_005485.4 ADPRTL3, ADPRT3, IRT1, 
hPARP-3, pADPRT-3 
PARP4 NM_006437.3 ADPRTL1, VAULT3, p193, 
VPARP, VWA5C 
PCNA NM_002592.2  
PIK3CA NM_006218.2  
PIK3CB NM_006219.1  
PIK3R1 NM_181504.2  
PMS1 NM_000534.4  
PMS2 NM_000535.5 PMSL2, H_DJ0042M02.9, 
HNPCC4 
PNKP NM_007254.2  
POLB NM_002690.1  
POLD1 NM_002691.2 POLD, CDC2 
POLD3 NM_006591.2  
POLD4 NM_021173.2  
POLE NM_006231.3  
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POLE2 NM_002692.2  
POLE4 NM_019896.2  
POLI NM_007195.2  
POLK NM_016218.2 DINB1, POLQ, DINP 
POLL NM_001174085.1  
POLM NM_013284.3  
POLQ NM_199420.3  
POLR2D NM_004805.3  
POLR2H NM_001278698.1  
POLR2J NM_006234.4  
PRKACB NM_182948.2  
PRKDC NM_006904.6 HYRC, HYRC1, DNPK1, 
p350, DNAPK, XRCC7, 
DNA-PKcs 
PRKX NM_005044.1  
PTEN NM_000314.4 BZS, MHAM, MMAC1, TEP1, 
PTEN1 
RAD1 NM_133377.2  
RAD17 NM_133338.1  
RAD18 NM_020165.2  
RAD21 NM_006265.2  
RAD23A NM_005053.2  
RAD23B NM_002874.3  
RAD50 NM_005732.2  
RAD51 NM_133487.2 RAD51A, RECA, HsRad51, 
HsT16930, BRCC5 
RAD51B NM_002877.5 RAD51L1, REC2, hREC2, 
R51H2 
RAD51C NM_002876.2  
RAD51D NM_002878.3 RAD51L3, R51H3, Trad, 
HsTRAD 
RAD52 NM_134424.2  
RAD54L NM_003579.2  
RAD9A NM_004584.2  
RB1 NM_000321.1 OSRC, RB 
RECQL NM_032941.2  
 253 
 
RECQL5 NM_004259.6  
REV1 NM_016316.2  
RFC1 NM_001204747.1  
RFC3 NM_002915.3  
RFC4 NM_181573.2  
RMI1 NM_024945.2 C9orf76, FLJ12888, BLAP75 
RMI2 NM_152308.1 C16orf75, MGC24665, 
BLAP18 
RPA1 NM_002945.3  
RPA3 NM_002947.3  
RPS27A NM_002954.5  
RRM2B NM_015713.3  
SIRT1 NM_012238.4  
SLFN11 NM_001104587.1  
SLK NM_014720.2  
SLX4 NM_032444.2 BTBD12, KIAA1784, 
KIAA1987, FANCP 
SMAD4 NM_005359.3 MADH4, DPC4 
SMARCA4 NM_003072.3 SNF2L4, hSNF2b, BRG1, 
BAF190, SNF2, SWI2, SNF2-
BETA, SNF2LB, FLJ39786 
SMC1A NM_006306.2 SMC1L1, DXS423E, 
KIAA0178, SB1.8, Smcb 
SMC3 NM_005445.3 CSPG6, HCAP, BAM, 
SMC3L1, bamacan 
SMUG1 NM_001243789.1  
SUMO3 NM_006936.2 SMT3H1, SMT3A 
TDG NM_003211.4  
TIPIN NM_017858.2  
TOP3A NM_004618.3  
TOP3B NM_003935.4  
TP53 NM_000546.2  
TP53BP1 NM_001141980.1  
TREX1 NM_016381.3 AGS1, DRN3 
UBB NM_018955.2  
UBE2T NM_014176.3  
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UNG NM_003362.3 DGU, UDG, UNG1, UNG2, 
HIGM4 
USP1 NM_003368.4  
WEE1 NM_003390.3  
WRN NM_000553.4  
XPA NM_000380.3  
XPC NM_004628.3  
XRCC1 NM_006297.2  
XRCC2 NM_005431.1  
XRCC3 NM_001100119.1  
XRCC4 NM_003401.3  
XRCC5 NM_021141.3  
XRCC6 NM_001469.3 G22P1, D22S731, D22S671, 
KU70, ML8 
Internal Reference Genes    
CC2D1B NM_032449.2   
COG7 NM_153603.3   
EDC3 NM_001142443.1 YJDC, LSM16, FLJ21128, 
hYjeF_N2-15q23, YJEFN2 
GPATCH3 NM_022078.2 GPATC3, FLJ12455 
HDAC3 NM_003883.2   
MTMR14 NM_022485.3 C3orf29, FLJ22405, 
FLJ90311, hJumpy, hEDTP 
NUBP1 NM_001278506.1 NBP1, NBP35 
PRPF38A NM_032864.3   
SAP130 NM_024545.3   
SF3A3 NM_006802.2   
TLK2 NM_006852.2   
ZC3H14 NM_001160103.1   
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1.3 Matlab script for normalisation 
Matlab script for normalisation steps of intensity measurements after laser 
microirradiation.  
 
%% Created by Sophie Cowman University of Liverpool 
  
%%Before you run this make sure you re-name the file output names 
correctly to not overwrite data 
  
  
%%This section deals with raw data - normalisation steps happen - 
for each 
% for each individual cell a graph is plotted 
% calculations have been tested in excel 
  
clearvars 
clc 
  
  
% change this to 1 if want to plot interim graphs to check quality 
of data 
plot_all_graphs = 0; 
  
FileNames = dir('cell *.xlsx'); 
% function to delete any old final_data files (allows you to run 
this 
% script on the same folder multiple times 
for i=1:length(FileNames) 
    filename = FileNames(i).name; 
    if ~isempty(regexp(filename,'.*_final_data', 'once')); 
       delete(filename); 
    end 
end 
  
FileNames = dir('cell *.xlsx'); 
  
for i=1:length(FileNames) 
    % get the file name: 
   filename = FileNames(i).name; 
   disp(filename); 
    
   data = xlsread(FileNames(i).name); 
  
   [pathstr,name,ext] = fileparts(filename); 
  
   % naming each column 
    DAM = data (:,1); 
    NONDAM = data (:,2); 
    BG = data (:,3); 
     
     b = size(data,1); 
    Total_time = 0:b-1; 
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    Total_time = Total_time(:); 
    Total_time =  15*Total_time; 
  
    if plot_all_graphs > 0 
        Fig_a = figure('Color',[1 1 1]); 
        plot (Total_time, DAM, 'MarkerEdgeColor', 'b') 
        hold on 
        plot (Total_time, NONDAM, 'MarkerEdgeColor', 'r') 
        hold on 
        plot (Total_time, BG, 'MarkerEdgeColor', 'g') 
        hold off 
        title (['BGS data ',name]) 
    end 
  
     
    % background subtraction 
    meanBG = mean(BG); 
    BGS_DAM = DAM-meanBG; 
    BGS_NUC = NONDAM-meanBG; 
  
    b = size(data,1); 
    Total_time = 0:b-1; 
    Total_time = Total_time(:); 
    Total_time =  15*Total_time; 
  
    % plotting BGS data 
     
    if plot_all_graphs > 0 
        Fig_a = figure('Color',[1 1 1]); 
        plot (Total_time, BGS_DAM, 'MarkerEdgeColor', 'b') 
        hold on 
        plot (Total_time, BGS_NUC, 'MarkerEdgeColor', 'r') 
        hold off 
        title (['BGS data ',name]) 
  
        Fig_b = figure('Color',[1 1 1]); 
        plot (Total_time, BGS_NUC, 'MarkerEdgeColor', 'r') 
        title ([' BGS UN-DAM REGION', name]) 
    end 
  
% need to determine how many pre-bleach values 
% prompt = 'How many pre-bleach values?'; 
% PBV = input(prompt); 
  
% if know how many pre-bleach values comment out last part and 
uncomment 
% next 
  
    PBV = 2; 
  
    % averaging pre-damage values 
    AVPDDAM = mean(BGS_DAM(1:PBV)); 
    AVPDNUC = mean(BGS_NUC(1:PBV)); 
  
    % normalising to pre-bleach values 
    new_DAM = BGS_DAM/AVPDDAM; 
    new_NONDAM = BGS_NUC/AVPDNUC; 
  
    if plot_all_graphs > 0 
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        Fig_c = figure('Color',[1 1 1]);     
        plot (Total_time, new_DAM, 'MarkerEdgeColor', 'b') 
        hold on 
        plot (Total_time, new_NONDAM, 'MarkerEdgeColor', 'r') 
        hold off 
        title (['Norm to predam ', name]) 
    end 
  
  
    % normalising for photobleaching 
    norm_DAM = new_DAM./new_NONDAM;   
  
  
    % Determing first pre-bleach value 
    % PB = norm_DAM(PBV+1); 
  
    % Determining max value 
    % highest = max(norm_DAM); 
  
    % scaling pre-bleach to 0 and highest to 1 
    % part1 = (norm_DAM - PB); 
    % part2 = (highest-PB); 
    % Final_data = part1./part2; 
  
    %% Re-organisng data into a new matrix 
  
    % Trimming down the data to remove pre-damage values 
  
    % Final_data = Final_data(PBV+1:end,:); 
  
    Final_data = norm_DAM(PBV+1:end,:); 
  
  
    % Plotting out all of the data 
    b = size(Final_data,1); 
    Total_time = 0:b-1; 
    Total_time = Total_time(:); 
    Total_time =  15*Total_time; 
  
    All_data = [Total_time, Final_data]; 
    Time = All_data(:,1); 
    Intensity = All_data(:,2); 
  
%     Fig_01 = figure('Color',[1 1 1]); 
%  
% %-- Set the figure position and size to prevent the figure being 
too low resolution (X pos, Y Pos, Width, Height) 
%     set(gcf,'position',[100 100 800 600]) 
% %-- Do this to make sure that the figure isn't cut off (or 
including other windows) when exporting 
%     movegui(gcf,'center')  
%  
% % '-x' means plot x for all data points 
%     plot(Time,Intensity, 'b-x', 'MarkerSize', 3, 
'MarkerEdgeColor', [0 .0 .0])  
%     axis auto 
%     xlabel ('Time (s)', 'FontSize', 12, 'FontName', 'Ariel', 
'FontWeight', 'bold') 
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%     ylabel ('Intensity (a.u)', 'FontSize', 14, 'FontName', 
'Ariel', 'FontWeight', 'bold') 
%     grid off 
%     title ([name,' Normalised data']) 
%     set(gca,'FontSize',12, 'FontName','Ariel', 'Box', 'off', 
'TickDir', 'out') 
  
%-- saving as png 
%     saveas(Fig_01,strrep(filename,'.xlsx',' 
normalised_data.png')); 
  
    [pathstr,name,ext] = fileparts(filename);  
  
    final_data_file = [name, '_final_data.xlsx']; 
    header = {'Time(s)','Normalised_Intensity'}; 
    xlswrite(final_data_file, header, 'Sheet1')  
    xlswrite(final_data_file, All_data,'Sheet1', 'A2'); 
     
%     smoothed_data=smooth(normalised_data,5) 
     
end; 
%% Compiling data together 
% Tested calcultions on excel - works perfectly  
  
% Inputting data and creating a new matrix 
  
clearvars 
clc 
  
FileNames = dir('*_final_data.xlsx'); 
%this gets all the file names in current directory that have 
extension 
%.xlsx, as a structure 
  
  
for i=1:length(FileNames); 
    % get the file name: 
   filename = FileNames(i).name; 
   %disp(filename); 
   data = xlsread(FileNames(i).name);   
   empty_matrix(:,i) = data(:,2); 
end 
  
compiled_data = empty_matrix; 
  
  
b = size(compiled_data,1); 
Total_time = 0:b-1; 
Total_time = Total_time(:); 
Total_time =  15*Total_time; 
  
xlswrite('Compiled_data.xlsx',compiled_data,'Compiled_data'); 
  
  
Fig_02 = figure('Color',[1 1 1]); 
set(gcf,'position',[100 100 800 600]) 
movegui(gcf,'center')  
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plot(Total_time,compiled_data, 'LineWidth', 2)  
ylim ([0 7]) 
xlabel ('Time (s)', 'FontSize', 20, 'FontName', 'Ariel', 
'FontWeight', 'bold') 
ylabel ('Intensity (a.u)', 'FontSize', 20, 'FontName', 'Ariel', 
'FontWeight', 'bold') 
grid off 
title ('') 
set(gca,'FontSize',20, 'FontName','Ariel', 'Box', 'off', 'TickDir', 
'out', 'LineWidth', 3) 
legend ('off') 
  
saveas(Fig_02,'All_cells_plotted.png'); 
  
  
  
%% using data in matrix to calculate mean and SEM 
   
average = mean(compiled_data.'); 
average = average(:); 
  
SEM = std(compiled_data.')/sqrt(size(compiled_data,2)); 
SEM = SEM(:); 
  
upperint = average+SEM; 
lowerint = average-SEM; 
  
final_data = [Total_time,average,SEM, upperint, lowerint]; 
  
Time = final_data (:,1); 
Meanint = final_data (:,2); 
SEM = final_data (:,3);                        
upperint = final_data (:,4); 
lowerint = final_data (:,5); 
  
header = {'Time(s)','Mean','SEM','Upperint','LowerInt'}; 
%averaged_data_file = [name, 'data.xlsx']; 
xlswrite('compiled_data.xlsx', header, 'averaged_data') 
xlswrite('compiled_data.xlsx',final_data, 'averaged_data', 'A2') 
  
%% plotting out final figure with mean and SEM 
  
Fig_01 = figure('Color',[1 1 1]); 
  
%-- Set the figure position and size to prevent the figure being too 
low resolution (X pos, Y Pos, Width, Height) 
set(gcf,'position',[100 100 800 600]) 
%-- Do this to make sure that the figure isn't cut off (or including 
other windows) when exporting 
movegui(gcf,'center') 
  
% '-x' means plot x for all data points 
% smooth() smooth data based on moving averages - this can be 
changed 
paleblue = 1/255*[115,164,255]; 
palered = 1/255*[255,131,153]; 
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plot (Time, upperint,'Color',paleblue) 
x2 = [Time; flipud(Time)]; 
inBetween = [lowerint; flipud(upperint)]; 
f = fill(x2, inBetween, paleblue); 
set(f,'EdgeColor','none'); 
hold on 
  
plot(Time,Meanint, 'k-x','Color',[0 .0 .0],'LineWidth', 1, 
'MarkerSize', 2, 'MarkerEdgeColor', [0 .0 .0] ) 
hold on 
  
plot (Time, lowerint, 'Color',paleblue) 
  
hold off 
% axis([0 inf 0 inf]) 
xlabel ('Time (s)', 'FontSize', 12, 'FontName', 'Ariel', 
'FontWeight', 'bold') 
ylabel ('Intensity (a.u)', 'FontSize', 14, 'FontName', 'Ariel', 
'FontWeight', 'bold') 
grid off 
title ('') 
set(gca,'FontSize',12, 'FontName','Ariel', 'Box', 'off', 'TickDir', 
'out') 
  
saveas(Fig_01,'Averaged_data.png') 
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1.4 Matlab script for curve fitting  
Matlab script for curve fitting and calculating parameters, created by David 
Mason, University of Liverpool 
clear all;close all; 
%-- get the user to find the MAT file which should contain two 
variables data_norm and data_hypo 
[inFile,inPath]=uigetfile('*.mat'); 
%-- load the workspace 
load([inPath,inFile]); 
  
%-- do you want to produce plots for quality control? creates a 
subplot 
makeFig=0; %-- [0,1] 
  
%-- Loop both conditions 
for condition=1:2 
  
    %-- load in the relevant dataset 
    if condition==1 
        data=data_norm; 
    else 
        data=data_hypo; 
    end 
  
    %-- If requested create an output figure 
    if makeFig==1 
        %-- figure out the dimensions of the subplot 
        nPlots=size(data,2)-1; 
        sub_cols=floor(sqrt(nPlots)); 
        sub_rows=ceil(nPlots/sub_cols); 
        %-- create the figure 
        figure(); 
        set(gcf, 'Position', get(0, 'Screensize')); 
    end 
    %-- pull the time data from the first column 
    pT=data(:,1); 
  
    %-- loop all traces to produce OUTPUT variable one row per trace 
with the following columns 
    %1   trace number 
    %2   Raw Data Maximum 
    %3   Raw Data Index 
    %4   Smoothed Maximum 
    %5   Smoothed Index 
    %6   Smoothed Index Time (sec) 
    %7   R squared for off time exp fit 
    %8   Intercept for off time exp fit 
    %9   Slope for off time exp fit (/sec) 
    %10  Calculated t 1/2 for off time exp fit FROM EXPERIMENT START 
(sec) 
    %11  Calculated t 1/2 for off time exp fit FROM SMOOTHED PEAK 
(sec) 
    %12  R squared for on time exp fit 
    %13  tau value for on time exp fit 
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    %14  Half time for recruitment (sec) 
  
    for trace=2:size(data,2) 
         
        pI=data(:,trace); 
        output(trace-1,1)=trace-1; 
        [maxVal_Raw,maxPos_Raw]=max(pI); 
        output(trace-1,2:3)=[maxVal_Raw maxPos_Raw]; 
  
        %-- find smoothed maximum 
        
[maxVal_smo,maxPos_smo]=max(smooth(pI,floor(size(pI,1)*0.3))); 
        output(trace-1,4:6)=[maxVal_smo,maxPos_smo,pT(maxPos_smo)]; 
  
        %-- check there are sufficient off points (some traces peak 
at final point) 
        if size(pI,1)-maxPos_smo>5 
            %-- fit everything past the max point (plus a bit) to an 
exponential decay curve 
            
[fitVals,fitAlg,fitGOF]=fit(pT(maxPos_smo+5:end),pI(maxPos_smo+5:end
),'exp1'); 
  
            if makeFig==1  
                %--select which plot to use 
                subplot(sub_rows,sub_cols,trace-1) 
                %-- plot the original 
                plot(pT,pI,'b.') 
                hold on 
                %-- Plot smoothed maxima 
                plot([pT(1),pT(end)],[output(trace-
1,4),output(trace-1,4)],'-','Color',[0.3 0.3 0.3]) 
                %-- highlight the points used for decay plot 
                plot(pT(maxPos_smo+5:end),pI(maxPos_smo+5:end),'go') 
                %-- plot the decay fit                 
                plot(fitVals,'r--') 
                %-- get rid of the legend 
                legend 'off' 
                title(['C',num2str(condition),' Trace 
',sprintf('%03d',trace-1)]); 
            end 
  
    %-- calculate the 50% (between peak and first value) off time 
(you can select just good fits here or include everything 
            if fitAlg.rsquare>0 
                output(trace-
1,7:10)=[fitAlg.rsquare,fitVals.a,fitVals.b,(log((((maxVal_smo-
1)/2)+1)/fitVals.a))/fitVals.b]; 
                output(trace-1,11)=output(trace-1,10)-output(trace-
1,6); 
                if makeFig==1 
                    plot([output(trace-1,10),output(trace-
1,10)],ylim,'m-'); 
                end 
            end 
  
            %-------------------------------------------------------
------------------------------------- 
            %-- Try to fit the on-rate from start to maxPos_smo 
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            %-------------------------------------------------------
------------------------------------- 
            %-- pull the on data 
            pT_on=pT(1:maxPos_smo); 
            pI_on=pI(1:maxPos_smo); 
             
            %-- two approaches either normalise the data or 
incorporate the processing into the fit 
            %-- both come out with the same value for tau 
             
            %-- option 1 
            if (0) 
                %-- unity normalise the Y data to fit the equation 
from XXX 
                pI_on_norm=(pI_on-1)./(maxVal_smo-1); 
                         
                custExp='1-exp(-x/tau)'; 
                %-- fit the data using 100 (s) as the start point 
for the tau paramater 
                
[fitVals_on,fitAlg_on,fitGOF_on]=fit(pT_on,pI_on_norm,custExp,'Start
Point',100); 
            end 
             
            %-- option 2 
            if (1) 
            %custExp='1+(1-exp(-x/tau))*(maxVal_smo-1)'; 
            custExp=['1+(1-exp(-x/tau))*',sprintf('%.2f',maxVal_smo-
1)]; 
             
            %-- fit the data using 100 (s) as the start point for 
the tau paramater 
            
[fitVals_on,fitAlg_on,fitGOF_on]=fit(pT_on,pI_on,custExp,'StartPoint
',100); 
            end 
             
            %-- record the rsquare for the exp fit 
            output(trace-1,12)=fitAlg_on.rsquare; 
             
            if fitAlg_on.rsquare>0 
                 
                %-- record the tau value 
                output(trace-1,13)=fitVals_on.tau; 
                 
                %-- record the half time 
                tmp_halfY=(((maxVal_smo-1)/2)+1); 
                output(trace-1,14)= -log(1-   (( tmp_halfY -1) / 
(maxVal_smo-1)) )  *fitVals_on.tau; 
                 
                if makeFig==1 
                    %-- plot the curve 
                    plot(fitVals_on,'r--'); 
                    %-- get rid of the legend (again) 
                    legend 'off' 
                    %-- plot the half time 
                    plot([output(trace-1,14),output(trace-
1,14)],[0,tmp_halfY*1.1],'g-'); 
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                    plot([0,output(trace-
1,14)*1.5],[tmp_halfY,tmp_halfY],'g-'); 
                end 
            end 
  
             
        else 
            %-- NaN empty values 
            output(trace-1,7:11)=nan(1,5); 
        end %-- loop sufficient off time 
  
    end %-- loop traces 
  
  
    disp(['Condition ',num2str(condition),' : Mean time to peak:  
',sprintf('%.f',mean(output(:,6),'omitnan')),' sec (SD: 
',sprintf('%.f',std(output(:,6),'omitnan')),' sec)']) 
    disp(['Condition ',num2str(condition),' : Mean off time:  
',sprintf('%.f',mean(output(:,11),'omitnan')),' sec (SD: 
',sprintf('%.f',std(output(:,11),'omitnan')),' sec)']) 
  
%-- rename the output file per condition 
    if condition==1 
        output_norm=output; 
    else 
        output_hypo=output; 
    end 
    clearvars output; 
end %-- loop condition 
  
%clearvars -except output*; 
  
if (0) 
    xVals=randn(size(output_norm,1),1)+5; 
    plot(xVals,output_norm(:,11),'bo') 
    hold on 
    xVals=randn(size(output_hypo,1),1)+10; 
    plot(xVals,output_hypo(:,11),'ro') 
    xlim([-5 20]) 
end 
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1.5 ATM activation in U251-MG and D566-MG under severe hypoxia 
 
ATM and ATMSer1981 levels in U251-MG and D566-MG incubated in 
moderate hypoxia. (A) U251-MG and (B) D566-MG cells were incubated in 
in 1% or 21% O2 for 5 days before treatment with 50 µM etoposide for 4 h. 
Protein was extracted and a western blot performed for ATM and 
ATMSer1981. At least three independent experiments were conducted. 
Densitometry was performed on a single representative blot using Image J.  
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1.6 ATM activation in U251-MG and D566-MG under severe hypoxia 
 
ATM and ATMSer1981 levels in U251-MG and D566-MG incubated in severe 
hypoxia. (A) U251-MG and (B) D566-MG cells were incubated in in 0.1% or 
21% O2 for 5 days before treatment with 50 µM etoposide for 4 h. Protein 
was extracted and a western blot performed for ATM and ATMSer1981. At 
least three independent experiments were conducted. Densitometry was 
performed on a single representative blot using Image J.  
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1.7 DNA Ligase IV western blot 
 
DNA ligase western blot example using Abcam Ab26039 antibody. 30 µg of 
protein was loaded per well from D566-MG whole cell lysate. Antibody was 
used at 1 in 1000. Actin was used as a loading control. No bands were 
observed for DNA ligase IV.  
1.8 PARP1 and PMS2 expression time course  
PARP1 and PMS2 are downregulated by acute and chronic hypoxia  
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PARP1 and PMS2 are downregulated after chronic and acute hypoxic 
exposure. D566-MG cells were incubated in 1% O2 for 1-5 days, as well as 
21% O2. After incubation, RNA was extracted and converted to cDNA for 
RT-PCR experiments, probing for PARP1 and PMS1. Data is represented as 
log2 fold change in mRNA levels with respect to level for the 21% O2 
samples. Data are the mean of at least three independent experiments, with 
error bars showing S.E.M. * denotes significant data where p<0.05 indicated 
by one-way student t-test. 
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1.9 PARP1, PMS2 and WRN expression after HIF inhibition 
HIF inhibition does not restore PARP1, PMS2 or WRN expression 
 
HIF inhibition does not restore PARP1, PMS2 or WRN mRNA levels in 
hypoxia. (A) D566-MG and (B) U87-MG cells were incubated in 21% and 1% 
O2 for 24 h with and without 5 µM Acriflavin. After incubation, RNA was 
extracted and converted to cDNA for RT-PCR experiments. Data is 
represented as log2 fold change in mRNA levels with respect to level for the 
21% O2 samples. Data are the mean of at least three independent 
experiments, with error bars showing S.E.M. 
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1.10 Digoxin does not affect HIF-1α levels or HIF transcriptional 
activity. 
 
Digoxin does not affect HIF-1α levels or HIF transcriptional activity. 
D566-MG cells were treated for 8 h with digoxin before incubating in 1% O2 
for 24 h. (A) Western blot of HIF-1α after 0 – 100 nM digoxin treatment. 
Control represents untreated cells incubated at 21% O2. (B) RT-PCR of 
GLUT1 levels after treatment with 0 – 100 nM digoxin. Data is represented 
as fold change with respect to 21% O2. Figure represents data from a single 
experiment.  
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1.11 MRE11 and NBN localisation 
 
MRE11 and NBN localisation after drug treatment. HeLa cells were treated 
with 50 µg/ml phleomycin or 50 µM etoposide for 4 h fixing and performing 
immunocytochemistry for γH2AX, MRE11 and NBN. Imaged on a Zeiss 
axiovert Epifluorescence microscope using Zeiss 38 HE filter set (GFP) with 
100x objective.  
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1.13 Time to maximal intensity measurements 
 
Time to maximal intensity. D566-MG cells transfected with XRCC4-EGFP 
were subjected to laser micro-irradiation. Signal intensity was measured for 
each individual cell. Normalised signal intensity was used to determine the 
time at which maximal intensity is observed as depicted by the schematic in 
(A). B) The mean time to maximum intensity for normoxic (n = 22) and 
hypoxic (n = 27) cells was determined, with error bars representing S.E.M. 
C) The distribution of time to maximal intensity for each hypoxic and 
normoxic cell. Line represents the median. * denotes significant data where 
p<0.05 indicated by student t-test. 
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